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Amongst the more promising non-viral DNA vehicles are liposomes, with those derived from cationic 
lipids showing significant potential, despite moderate transfection levels in vivo. 
This study has investigated the effect of liposome-anchored ionophore crown ethers on lipoplex-mediated 
gene transfer in vitro and in vivo. Several liposomes were constructed to include the cytofectin 3β[N(N’,N’-
dimethylaminopropane)-carbamoyl] cholesterol (Chol-T), the co-lipid dioleoylphosphatidylethanolamine (DOPE), 
and 5% (mole/mole) of the cholesteryl crown ethers RUI-128 (aza-18-crown-6) or RUI-129 (aza-15-
crown-5). Liposome size and lamellarity were established by transmission electron microscopy. All 
liposome preparations were shown to bind, condense and protect DNA avidly in the respective band shift, 
ethidium displacement and nuclease protection assays.  
Lipoplex targeting to hepatocytes may be achieved via the asialoglycoprotein receptor (ASGP-R), which 
is abundantly expressed on the human hepatoblastoma cell line HepG2. Therefore six additional 
liposomes were formulated to include 5% (mole/mole) of the cholesteryl galactosyl RUI-90 (Gal) and 
cholesteryl glucosyl RUI-92 (Glu) ligands. Their hepatotropic gene delivery was examined in the HepG2 
cell line using the pCMV-luc plasmid. Transfection studies in the human embryonic kidney cell line 
HEK293 (ASGP-R-negative) revealed an increase in transgene activity in lipoplexes displaying the RUI-
129 cholesteryl derivative. No ionophore-mediated enhancement of transfection activity was observed in 
HepG2 cells although Chol-T:DOPE, Chol-T:DOPE:RUI-128 and Chol-T:DOPE:RUI-129 liposomes 
achieved very high transfection levels, exceeding those of their hepatocyte targeted counterparts. 
Liposome-anchored crown ethers have been shown to potentiate in vitro transfection activity of 
lipoplexes in the HEK293 cell line. The novel cholesteryl glycosyl derivatives were, however, unable to 
enhance the targeted entry of lipoplexes into HepG2 cells. 
The three most effective preparations from in vitro studies were taken forward for in vivo assessment in 
NMRI mice at the University of the Witwatersrand Molecular Medicine and Haematology unit. Three 
groups of mice were employed for the evaluation of Chol-T:DOPE, Chol-T:DOPE:RUI-129 and Chol-
T:DOPE:RUI-129-Gal lipoplexes with the Psi-CHECK plasmid. Mice treated with hydrodynamic 
injection and untreated animals made up two control groups. Luciferase activity was determined on 
examination of the harvested liver homogenates.  All liposomes showed modest, but significant 
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1.  INTRODUCTION 
1.1.  THE NEED FOR GENE THERAPY: THE EARLY YEARS AND BEYOND 
Of all non-communicable diseases cancer has been implicated as the foremost cause of mortality, 
accounting for approximately 7.1 million global deaths annually. Over half of these have been observed 
in developing countries with cancer also being identified as the primary cause of death in high income or 
industrialized countries (Morille et al., 2008).  
Application of conventional cancer treatments is often insufficient in the face of aggressive, resistant, 
invasive tumours which have complex mechanisms of propagation. This obstinacy to conventional 
therapies of chemotherapy, radiotherapy or even hormonal therapy makes cancer an ideal model for 
therapeutic treatment at the molecular level (Morille et al., 2008). Consequently new approaches are 
being sought with particular focus given to the investigation of genes involved in cancer development. 
Our current and extensive knowledge of the genetic basis of many human diseases has provided the 
impetus for molecular manipulation of disease through the employment of recombinant DNA 
methodologies. The chief goal for cancer therapy is to bring about treatment through exploitation of 
therapeutic information encoded in the DNA sequence (Lim, 1999; Rozema, 2008). Besides this, many of 
the systemic diseases facing us presently are as a consequence of deficiencies in enzymes or factors 
resulting from defects or the absence of specific genes (Sharma and Sharma, 1997; Rozema, 2008). 
Treatment at the source of infection has thus made gene therapy an invaluable commodity for tumour 
eradication (Morille et al., 2008).  
Gene therapy that involves the introduction of exogenous DNA into somatic cells needs vectors with 
specific requirements that allow, reasonably effective transfection, a controllable period of expression as 
well as cell or spatial specificity in addition to the minimization of safety concerns (Holladay et al., 
2009). Morille and collaborators (2008) showed that cancer gene therapy in particular requires specific 
vector types such as those in Table 1.1, which can meet the four specific criteria listed: 
i. Deactivation of oncogene expression, 
ii. Enhancement of tumour suppressor expression to promote cancer cell apoptosis, 
iii. Inhibition of neo-angiogenesis, and 
iv. Immune system stimulation against the neoplasm. 
2 
 
Table 1.1. Gene delivery vector systems for cancer gene therapy (Adapted from Lim, 1999; Mountain, 
2000; Zuckerbraun and Tzeng, 2002). 




Very high transfection efficiency ex vivo and in vivo 
Transfects both dividing and non-dividing cells 
Substantial clinical experience 
Efficient retargeted transfection demonstrated 
Large capacity 
Repeat dosing infective owing to strong immune responses 
Transgene  size limit of 7.5 kb 




Long  term stability  for  prolonged expression 
High transfection efficiency ex vivo 
Substantial clinical experience 
Low immunogenicity 
Chromosomal integration 
Transient delivery and low transfection efficiency in vivo 
Transgene size limit of 8 kb 
Transfects only dividing cells 
Random DNA insertion 




Efficiently transfects a wide variety of cells in vivo 
Very prolonged expression in vivo 
Low immunogenicity and non-pathogenic in humans 
Easily manipulated 
Stable integration  
Transgene limit of 4.5 kb 
Manufacture in large quantities is very difficult 
Little clinical experience 
Safety concern of mutagenesis 
Repeat dosing affected by neutralizing antibodies 
Naked DNA 
Manufacture, storage are simple and safe 
Very low immunogenicity 
Very good safety profile 
Clinical efficacy demonstrated in critical limb ischemia 
Very short duration of expression in most tissues 
Very inefficient transfection in vivo 




Relatively simple manufacture and storage 
Efficient transfection ex vivo and in vitro 
Low immunogenicity 
Transfects all cell types 
Inefficient transfection in vivo 
Short duration of expression 
Little clinical experience 
Retargeting transfection difficult 
Cationic 
polymers 
Relatively simple manufacture and storage 
Efficient transfection ex vivo 
Relatively non-pathogenic 
Retargeted transfection demonstrated 
Inefficient transfection in vivo 
Very short duration of expression 




Pathologically, cancer has been found capable of averting its own destruction through the variety of 
inherent mechanisms. Medical intervention in this regard has resulted most often only in prolonging a 
patient’s life from months to possibly years. Presently surgery involving the bulk removal of primary 
tumours is useful for the treatment of certain types of metastases (Dass and Choong, 2006). Cancer gene 
therapy can be classified into two completely distinct therapeutic strategies for gene delivery into targeted 
cells, i.e., corrective and cytoreductive gene therapy. Corrective gene therapy looks at the reversal or 
inhibition of the pathophysiology of cancer via the introduction of wild-type genes into pre-neoplastic or 
neoplastic cells. Cytoreductive gene therapy alternatively involves the augmentation of a tumour specific 
immune response to stimulate malignant cell death or the in vivo transfer of genes in the same way as 
cytotoxic drug introduction (Lim, 1999).  
In predominantly healthy tissue a single cancerous cell may develop after a sufficient number of mutation 
events. Thereafter by drawing on the available nutrient resources the cancerous cell may ensure its rapid 
growth. Tumour cells require oxygen, glucose and amino acids for their replication, and if presented with 
sufficient nutrients will metastasize and replace the remaining healthy tissue. The effectiveness of cancer 
gene therapies is reliant on the ability of the applied treatment to kill neoplastic cells while minimally 
affecting normal tissue (Brannon-Peppas and Blanchette, 2004). Comprehensive investigations have 
revealed that the arrested development in cancerous growth-related effects may be achieved through 
carrier induction of growth inhibitory or pro-apoptotic genes to the targeted tumour (Mäkelä, 2008). This 
and other findings have further fueled investigations for future cancer therapeutics, however, irrespective 
of the therapuetic strategy employed, successful delivery systems which are safe and effective are still 
elusive and remain a primary goal of gene therapy.  
Faith in gene therapy as a true therapy of the 21st century stems from its primary role, to purge disease at 
its cause rather than most available drug systems which only afford symptomatic relief. The ability to 
correct genetic abnormalities in the relatively simplistic treatment of either heritable or acquired diseases 
has cemented the indispensability of gene therapy to medicinal applications. Originally gene therapy was 
applied to the treatment of inherited disorders of adenosine deaminase deficiency, cystic fibrosis, 
Gaucher’s disease, familial hypercholesterolemia, hemophilia and Duchenne muscular dystrophy. More 
recently though it has also been applied to the treatment of acquired diseases such as the acquired 
immunodeficiency virus, cancers, heart disease, arthritis and neurodegenerative disorders such as 
Parkinson’s and Alzheimer’s upon identification of the genetic basis in each case (Nishikawa and Huang, 
2001). As with most potential therapeutics there are disadvantages which need to be overcome to allow 
development. Some notable disadvantages are linked to patient specificity, cell immunogenicity and cost 
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considerations due to greater difficulty in cell manipulation, manufacturing and quality control 
(Mountain, 2000; Chaudhuri, 2002). 
Simply put, gene therapy involves the introduction of genetic material into cells for the purpose of 
altering the course of a medical condition or disease at the molecular level. Some of the nucleic acids 
investigated for their therapeutic potential as disease modifying agents in cancer gene therapy include, 
plasmid DNA (pDNA), synthetic nucleic acids or antisense oligonucleotides, aptamers, small interfering 
RNA (siRNA), or other double stranded RNA’s like poly inosine-cytosine (pIC). Plasmid DNA vectors 
are predominantly employed to produce a ‘gain in gene function’ via the simple replacement or 
substitution of specific genetic function in the targeted cell through intra-nuclear delivery and can result 
in an amended diseased state. For successful application to human diseases gene therapy must tackle a 
few challenges for instance the relevent therapeutic gene needs to be identified together with the promoter 
and regulatory sequences that will drive transgene expression as well as efficient target site delivery of 
therapeutic genes (Russ and Wagner, 2007; Uddin, 2007; Rao, 2010). In addition the characteristics of the 
chosen vector determine the efficiency and specificity of transfection and transduction, the time taken for 
expression of the transgene and the immune response of the host to the vector. The treatment and 
successful execution of present antiviral therapy in many liver diseases is inadequate despite biomedical 
progress (Uddin, 2007). 
As with gene delivery, many difficulties face the dose and target specific distribution of therapeutic drugs 
in attempts to halt disease progression through alteration of disease pathology. Success has been achieved 
with many patients using the conventional therapies; however, much research is still required to 
understand what causes the initiation of the cancer and ultimately its metastasis. Further insight is 
required to enhance the delivery mechanisms of therapeutics to tumours in vivo (Dass and Choong, 2006).  
The liver has maintainted its status as an ideal target for gene transfer partly due to its level of 
accessability and partly because it is the site of a variety of well characterized diseases. Despite efforts 
employing both viral and non-viral systems for nucleic acid delivery, success in liver gene delivery 
systems for the treatment of genetic disorders is still hampered by the absence of an ‘ideal’ vector system. 
Some of the goals of liver directed gene delivery systems are replacement of absent genes, normal gene 
overexpression, interference of gene expression or the repair of a genetic defect (Richardson et al., 2002).  
The therapeutic prospects of nucleic acid therapy are constantly expanding due to recent discoveries such 
as that of RNA interference (RNAi), which is thought, at least in principle, to enable selective gene 
silencing. The number of obstacles facing effective gene therapies have been made more apparent by their 
inability to bring about specific gene transfer to their targets, such as non-germ cell tissue in sufficient 
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quantities to result in correction of the disease (Kay et al., 1997). Ever since the initiation of gene therapy 
in clinical trials it has brought with it a plethora of information on the genetic basis of a multitude of 
diseases (Naik et al., 2009). 
 
1.2. CARRIER SYSTEMS FOR GENE THERAPY 
The basic principles behind gene therapy provide a relatively straightforward manner of evaluating gene 
and protein function and regulation from the in vitro to in vivo stage. The drawback to the application of 
gene therapy is not the administered nucleic acid, but rather the vehicle employed. The vehicles employed 
for gene therapy are classified as either biological or non-biological. These systems of gene delivery will 
be examined in further detail. 
 
1.2.1. Viral Systems As Gene Therapy Vectors 
The production of a viral vectors involves the separation of coding genes and cis-acting sequences into 
distinct nucleic acid molecules so as to prevent their reconstitution into active viral particles via 
recombination. The combination of these cis-acting sequences with the therapeutic gene can then be 
introduced into the same cells producing replication-defective particles capable of specific transduction of 
novel genetic material into targeted cells. For the therapy to be successful an adequate quantity of  the 
therapeutic gene needs to be delivered to the target tissue without substantial toxicity (Kay et al., 2001). 
However, in spite of, numerous manipulations to eradicate toxicity, many limitations including 
immunogenicity, endogenous viral recombination, oncogenic effects and their restricted capacity to 
convey transgenic materials still occur. A general advantage associated with viral systems is that the 
transfection  machinery enables the DNA to effectively access the cytosol, while DNA conveyed by non-
viral vectors requires an event that will allow escape into the cytoplasm of the cell prior to reaching the 
lysosome (Wattiaux et al., 2000). 
Viral-based vectors (retroviruses, adenoviruses, herpesviruses, lentiviruses, and hybrid/ 
retroadenoviruses, etc) have been successfully used in gene delivery systems. Most earlier applications of 
gene therapy have drawn in the use of retroviral vectors due to their capacity for stable gene intergration 
associated with efficient cellular entry. Of their limitations two concerns in particular have lead to their 
limited use in clinical trials. The first relates to the potential for the generation of an infectious wild type 
virus after a recombination event and the second to random target cell integration of the viral sequence 
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leading to a tumourigenic or cytotoxic event. Some other associated problems limiting viral vector use are 
the requirement of a helper virus, limited host range, cytotoxicity, immunogenicity and other known 
safety issues (Thierry et al., 1997). Even if improbable, insertional mutagenesis has the potential to 
modulate the expression of vital genes including tumour suppressors and cell-cycle mediators and is 
therefore highly significant in terms of its application (Richardson et al., 2002).  
The essential strategy involved with the application of viruses, which are considered natural vehicles for 
gene delivery, is the removal of a few significant viral genes and their replacement with the therapeutic 
gene of interest. In doing so a replication-defective particle or viral vector is produced which is 
advantageous in efforts to overcome the undesired toxic effects of viral-based vectors. The identification 
of an optimal or ideal viral vector for either transient or permanent gene expression is an essential 
consideration for therapeutic gene delivery (Eming et al., 2007). Viruses, being structurally and 
symetrically highly complex due to millions of years of evolution, require their intrinsic properties to be 
altered so as to regulate their safety, effectiveness  and  stability as vectors for human therapeutics 
(Mäkelä, 2008).  
Of these vectors the retro- and adeno viruses have been the foremost viral vector systems employed thus 
far. Retroviruses undergo efficient random intergration into the host genome upon cellular entry thus 
facilitating stable expression and mainentance of the transgene. Even though these vectors may produce 
lasting in vivo transgene expression, some systems have also been identified to display transient 
expression of the gene of interest. A major advantage of using these vectors is their capacity for large 
inserts of foreign DNA effective transient transduction of quiescent as well as proliferating cells. In 
addition  they are capable of producing high titres. Adenoviral vectors pose a lower risk for mutagenesis 
since there is no host integration of the viral DNA. The recombinant adenoviral vectors have also 
revealed the capability for the highest levels of gene delivery in vivo. Alternatively, lentiviral vectors are 
reliant on active nuclear transport to enable transduction of non-dividing cells. Some viral systems rely on 
co-infection with an unrelated helper virus to produce infection. One such vector is the adeno-associated 
virus which belong to the Parvoviridae family of the genus Dependovirus. Due to their non-
pathogenicity, stability, low immunogenicity, and potential for site specific integration they have become 
leading vectors in gene therapy. In addition to these, other vectors derived from the herpesviruses, 
alphaviruses and poxviruses have been and still are utilized in a variety of gene therapeutic applications 
(Mäkelä, 2008).  
Of the viral vectors used for clincal trials the recombinant retroviruses based on the Mouse Moloney 
Leukemia virus have been utilized most frequently. These vectors contain viral regulating sequences with 
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all viral genes removed which results in only dividing cells being transduced. Since the cells in vivo are 
predominantly in the quiescent state these vectors are less effective unless the cells are stimulated in the 
target organ (Kay et al., 1997). Further clinical evaluations have shown non-viral vectors to be the safer 
alternative for future gene transfer processes, unfortunately no single vector is ideal for all types of gene 
transfer experiments. Although cationic lipids have been empirically established as producing higher 
levels of transfection, further research is required for identification of both potential barriers and solutions 
for the enhancement of transfection (Uddin, 2007). 
 
1.2.2. Non-Viral Sysytems As Gene Therapy Vectors 
It is possible to transfer genes directly into mammalian cells without the use of viral systems. In this 
regard the gene of interest may be incorporated into bacterial plasmid DNA together with a mammalian 
promoter, enhancer, and other sequences that ensure gene expression. This plasmid DNA may then be 
incorporated into lipid vesicles such as liposomes, complexed with proteins for tissue specific targeting, 
or complexed with polymers including poly(L-lysine) and polyethyleneimine. Besides these chemical 
methods of introducing the DNA into the mammalian cells for expression of the desired gene, many 
physical techniques have been applied over the years (Rozema, 2008). 
Although non-viral systems produce lower transduction efficiency and a reduced duration of transgene 
expression compared with their viral counterparts, they show the following advantages: 
 Safety, 
 Simplicity of preparation,  and  
 High capacity for gene encapsulation. 
The immense promise of gene theapy will not achieve its full potential until the development of a safe and 
efficient gene delivery vector has been resolved (Chen et al., 2007). Despite the numerous advantages of 
non-viral vectors promoting their extensive investigation over the use of the naturally evolved viral 
vectors, their most significant disadvantage is their diminished capacity for genomic intergration 
(Richardson et al., 2002). These systems are typically transient, resulting in the relatively short-lived 
expression of transgenes which is ineffective for the treatment of diseases where prolonged expression is 
advantageous (Jo and Tabata, 2008). 
Over the past 40 years non-viral methodologies have been establised as popular research tools, not only 
for the treatment of disease, but also for the elucidation of gene structure, regulation and function. Pivotal 
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to the success of DNA delivery in this regard is their transfection capabilities. Despite efforts to improve 
transgene expression through the implementation of strong promoters and enhancers, significant 
enhancement of transfer is difficult to realize due to the limited number of DNA molecules that eventually 
reach the nucleus (Luo and Saltzman, 2000). 
Non-viral or synthetic vector research has increased in response to severe set backs associated with the 
highly efficient engineered viruses (Ewert, et al., 2006; Eming et al., 2007).  The techniques used for non-
viral vector mediated gene delivery have been classified into two groups: (i.) Physical methods of naked 
DNA delivery and (ii.) Chemical carrier mediated delivery. Although both these methods enable effective 
and target specific delivery of genes with little or no toxicity, the chemical techniques are considered the 
more desirable (Suda et al., 2009).  
 
1.2.3. Naked DNA Delivery and the Physical Methods Employed 
To achieve nucleic acid delivery to a specific site, physical targeting involving a series of physical 
techniques that produce localized action may be employed (Russ and Wagner, 2007). The use of physical 
stimulus can enhance plasmid DNA delivery into cells by transporting the DNA into close proximity to 
the cell membrane or through the temporary permeabilization of the membrane (Jo and Tabata, 2008). 
One of the earliest, although relatively ineffective methods of producing significant levels of transfection 
is the use of calcium phosphate co-precipitation (Lim H., 1999).  
Nucleic acids are in general large molecules displaying a multitude of negative charges resulting in 
ineffective and non-specific cellular uptake together with meager bioavailabiilty due to their highly 
hydrophilic nature, size and interactions with serum proteins once in the cytoplasm (Gao et al., 2007). 
These limitations have hindered their use as therapeutic agents. Modifications have been applied to 
nucleic acids in an effort to overcome these limitations by imparting on the nucleic acid various novel 
properties including improved nuclease resistance and better penetration through plasma membranes (Yan 
and Tram, 2007).  
The use of naked DNA in the absence of a carrier vector is the simplest and safest means of systemic 
DNA administration. Plasmids were initially identified for the transfer of antibiotic resistance genes 
between markers and can be identified as circular DNA molecules. The replacement of these regions of 
antibiotic resistance with recombinant genes enables their use in the preparation of a number of proteins 
for use in pharmacological situations (Zuckerbraun and Tzeng, 2002). Some sites for direct plasmid DNA 
injection have included tumours, skin, skeletal muscle, thyroid, heart muscle, liver and urological organs. 
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Although a convenient method of administration the area and level of expression post injection are 
limited due to rapid serum nuclease degradation and clearance via the mononuclear phagocyte system.  
This system of direct plasmid injection is one of the most practical for the introduction of DNA into 
targeted tissues. Furthermore support of this approach has come in the form of a novel and elegant 
technique known as ‘puncture-mediated’ or ‘micro-seeding’ where multiple perforations are produced 
through the use of oscillating solid micro-needles. This technique was determined to be more efficacious 
than that using the single dermal injection (Ciernik et al., 1996 and Eriksson et al., 1998; cited in Eming 
et al., 2007). 
Many of the physical manipulations shown in Figure 1.1 and listed below have been applied to increase 
the efficacy of gene transfer although these technologies and are known to induce transient injuries or 
defects on cell membranes to allow diffusion of DNA into the cells (Gao et al., 2007).  
 
Figure 1.1: An outline of some non-viral gene delivery technologies and the different routes of naked 
DNA injection (Niidome and Huang, 2002). 
 
1.2.3.1. Electroporation: 
Since the first application of electroporative mechanisms in cultured cells in 1982 they have achieved 
extended application to in vivo plasmid DNA delivery.  This mechanical technique initiates the reversible 
permeabilization of cell membranes through the use of a controlled electric field thus allowing DNA to 
move along a gradient and gain cellular entry. This process has proved advantageous through evasion of 
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the endocytic pathway. It is also considered a safe, simple and inexpensive method which has been 
applied efficiently for DNA translocation in vitro. Gene expression attained by injection of naked DNA in 
conjunction with electroporation has shown increases up to 1000 fold compared with the injection alone 
(Nishikawa and Huang, 2001; Russ and Wagner, 2007). Its use allows for both improved post injection 
gene uptake as well as enduring expression in numerous tissues with muscle tissue being one of the best 
candidates for its application.  
The use of short intense electric pulses has improved the efficacy of non-permeable drug uptake 
(Nishikawa and Huang, 2001). Hellar and colleagues (2000) demonstrated the use electroporation in the 
mediation of DNA delivery to hepatocellular carcinomas which although rare in Western countries are 
common in Africa and Asia and are often associated with chronic viral hepatitis (Russ and Wagner, 
2007). 
Several types of electrodes have been developed for in vivo administration. Needle electrodes for deep 
tissues, surface electrodes, and electroporation catheters which are applied for hollow organs such as 
blood vessels (Kawakami et al., 2008). The use of the syringe electrode has recently been reported to 
produce comparable levels of transfection to those achieved by conventional electrodes while using far 
lower electric field strengths which therefore minimizes tissue damage (Russ and Wagner, 2007). 
Although considered to be the most effective of gene transfer methodologies it is unfortunately 
constrained by high levels of cellular mortality as a result of the cellular exposure to high voltage as well 
as difficulties encountered in optimization (Luo and Saltzman, 2000). The amount and distribution of 
DNA within the treated tissue prior to electroporation has an important impact on in vivo transfection 
efficiency. One of the first drawbacks found with the in vivo application of electroporation is the 
restricted range between electrodes of approximately 1 cm which makes transfection of a large area rather 
difficult. The fact that the process requires surgical intervention to introduce the electrodes deep into the 
internal organs is a further problem. Finally irreversible damage to tissue could result from thermal 
heating brought about by the application of high voltage or the influx of calcium ions in response to cell 
membrane disruption (Gao et al., 2007).  
1.2.3.2. Gene gun:  
This process is also termed biolistic particle delivery and can achieve the simultaneous introduction of 
DNA into a large number of cells (Luo and Saltzman, 2000). This method proves highly efficient in its 
ability to bring about direct penetration of tissues or cells. The process involves gold particles coated with 
the DNA destined for delivery being shot and consequently directly passing through the cell membrane 
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entering the cytoplasm or even nucleus.  The particles utilized for this biological and ballistic delivery 
need to be non-toxic, non-reactive and smaller than the diameter of the target cell.  
This form of administration like electroporation provides the advantage of evading the endosomal 
compartment; however, an associated disadvantage is the shallow level of tissue penetration that is 
achieved (Niidome and Huang, 2002). By altering the pressure of the high-pressure helium propellant, the 
loaded particles can be directed to the individual epidermal layers. This proves advantageous for 
achieving optimal gene expression, as it results in an accumulation of the gold particles in the basal 
epidermal cell layer (Eming et al., 2007). 
After surgical exposure, the skin, liver and muscle have been successfully transfected. In vivo gene gun 
application predictably has revealed low levels of expression that persist for only a short period 
(Nishikawa and Huang, 2001). Nevertheless other reports have identified the liver and brain as target sites 
for in vivo application (Kawakami et al., 2008). Particle bombardment has been employed widely for 
DNA vaccination in which the local administration of DNA is sufficient to achieve an immune response 
(Luo and Saltzman, 2000). 
1.2.3.3. Ultrasound:  
This technique can be used to manipulate the cell membrane, increasing permeability to plasmid DNA 
and other macromolecules. Ultrasound induced cell permeability as introduced in the mid 1990s is in 
clinical application for both therapeutic and diagnostic objectives. To date this physical manipulation has 
been applied to vascular cells, muscle and foetal mice. Irradiation of the injected tissue with ultrasonic 
waves has been shown to improve observed gene expression. Its flexibility and safety makes this a 
valuable method of gene delivery for clinical use (Niidome and Huang, 2002). This technique has been 
successfully applied to both the in vitro and in vivo situations. 
The application of naked DNA in combination with ultrasound systemically has proved inefficient. This 
could potentially be ascribed to serum nuclease digestion of the DNA as well as low concentrations of the 
DNA within the environment of sonoporated cells. Furthermore the use of combinations of ultrasound 
together with transfection agents with the capacity for high levels of expression, have been revealed as a 
pathway full of potential for the future of ultrasound enhanced liposomal gene targeting (Huang., 2008). 
Ultrasound has also been used in conjunction with ultrasound contrast agents or microbubbles that lower 
the cavitation threshold through ultrasound energy and together can produce further increases in the level 
of gene expression achieved (Niidome and Huang, 2002). 
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Acoustic cavitations in this process are known to induce non-thermal effects, where cavitation is a 
consequence of the gaseous inclusion and ultrasonic wave interaction producing cavitation bubbles. This 
results in cell membrane damage and increased reversible permeability to macromolecules and cell 
survival. This method of gene delivery is referred to as sonoporation and has so far achieved good 
expression in the muscle, carotid artery and solid neoplasms (Kawakami et al., 2008).  
The efficiency of this technique is determined by the frequency, its output strength, the duration of the 
treatment as well as the quantity of plasmid DNA to be introduced, and can be improved by enhanced 
membrane fluidity (Gao et al., 2007).  
1.2.3.4. Magnetofection: 
This process has indicated potential for both in vitro and in vivo gene targeting. For nucleic acid delivery, 
this technique involves the reversible attachment of nucleic acids to super-paramagnetic nanoparticles. 
These particles are then focused via a high-energy magnetic field to the target site. This process is known 
to encourage swift transfection with high levels of gene expression. The magnetic field in this technique 
does not affect the uptake of lipoplexes or polyplexes which are physically associated with paramagnetic 
particles. The magnetic forces are, however, suggested to produce an accelerated accumulation of 
complexes at the surface of the cell without inducing cell traction.  The external application of a strong 
magnetic field to an experimental animal model in the region of the liver has achieved improved liver 
targeting in recent studies (Russ and Wagner, 2007). 
1.2.3.5. Hydrodynamic injection:  
This injection of plasmid DNA in the absence of a carrier system results in the transient overflow of a 
DNA solution at the inferior vena cava which exceeds the cardiac output. The subsequent flow of solution 
in retrograde to the liver creates a significant increase in intra-hepatic pressure, expansion of the liver as 
well as the reversible disruption of the fenestrae. This delivery strategy has broad applicability to any 
water-soluble compound, small colloidal particles, or viral particles due to its non-specific nature. This 
method circumvents the need for delivery via an endocytotic pathway; however, a key challenge remains 
its translation to the human model (Gao et al., 2007). 
Practically it involves the rapid tail vein injection of naked DNA- saline solution at high volume. Tail 
vein injection of naked DNA into investigated mouse models has shown little to no gene expression 
produced in the major organs by virtue of the prompt nuclease digestion and  RES (reticuloendothelial 
system) clearance together with low extravasation in vivo (Nishikawa et al., 2001). Due to flexibility and 
large volume capacity, the liver has been proposed as the primary site for accumulation of injected DNA. 
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An additional mechanism proposed for efficient liver expression is the rupture of the endothelial barrier 
due to the force of pressure (Niidome and Huang, 2002).  
1.2.3.6. Photochemical internalization: 
This technology improves gene delivery to specific light-exposed target sites. Upon endocytosis of gene 
carrier systems acidic amphiphilic photo-sensitizers position themselves in the endosome forming 
associations with the gene carrier. At this point they produce illumination leading to chemical damage and 
tearing of the endosomal membrane allowing the release of the carrier complexes into the cytoplasm, this 
together with other investigations in vitro have revealed the potential of this method for taking gene 
therapy to the next level (Russ and Wagner, 2007). 
1.2.3.7. Occlusion:  
Restriction of blood flow at the vena cava, hepatic artery or portal vein can be used to induce high levels 
of liver gene expression upon receptor or non-receptor mediated internalization of DNA into hepatic sites. 
Gene transfer may further be affected by the time that the plasmid DNA is retained. Weak binding of 
DNA at the hepatic cell surface allows blood flow to easily wash away injected DNA. The interruption of 
blood flow permits the stable binding and cellular internalization of DNA (Niidome and Huang, 2002). 
Trangene expression has been shown to date to be decisively increased in mouse liver by the transient 
occlusion of blood flow swiftly after the peripheral intravenous injection of plasmid DNA-saline solution 
(Nishikawa and Huang, 2001). 
1.2.3.8. Hyperthermia: 
A controlled elevation of temperature to the target area has been applied to treatment of tumours and is 
already in clinical use (Russ and Wagner, 2007). The application has been employed to eliminate tumour 
growth and inhibit the progression of cancer disease. Hyperthermia generally is applied as one of three 
different strategies: local hyperthermia, regional hyperthermia or whole body hyperthermia. Local 
hyperthermia limits the application of heat to the tumour site, while regional hyperthermia may be applied 
to an entire organ or limb and the final strategy involves the application of heat to the entire body. The 
system makes use of microwaves, high frequency radiowaves, special radiant heat systems and even the 
application  of high energy magnets over the area of tumour. There are unfortunately major risks to the 
host tissue therefore the restricted application of heat to the volume of the tumour is a potential solution to 
maximize the toxic effect to the areas of malignancy and not the normal cells (Campbell, 2007). Some 
associated side effects observed have been direct cytotoxicity, immunomodulatory effects in addition to 
radiation and chemotherapy sensitizing effects (Russ and Wagner, 2007). 
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1.2.3.9. Laser irradiation: 
This technique involves a laser beam focused onto target cells through the use of a lens. This process 
results in the formation of relatively large pores in the cell membrane which re-seal and repair themselves 
fairly swiftly. The formation of these pores allows for the entry of DNA while the cell membranes 
capability to repair and re-seal allows for its retention. The mechanism employed by this process to 
improve gene expression in vivo is still unclear. This, however, is not often applied due to its expensive 
nature, the physical size of the laser and difficulties encountered in attempts to control an appropriate 
environmental temperature (Kawakami et al., 2008). 
 
1.2.4. Gene Delivery Via Chemical Carriers 
Chemical derived gene transfer vectors can be manipulated for specific function and may be grouped as 
follows: 
i. DNA complex forming carriers that condense and protect DNA against digestion; 
ii. Carriers designed for targeted cell specific DNA delivery; 
iii. Cytosol or nucleus delivery enhancing carriers; 
iv. Carriers designed for cytosolic dissociation; and 
v. Carriers that facilitate continuous and controlled expression in tissues 
The earliest method applied for the chemical introduction of DNA involved the use of a high salt 
concentration with polycationic proteins for improved cellular entry of nucleic acids. From that point 
many other chemicals have been introduced such as DEAE-dextran (Warden and Thorne, 1968) and 
calcium phosphate which interact and form complexes with DNA that become deposited on the cell 
surface for internalization (Luo and Saltzman, 2000). Of the many novel carriers designed lipids and 
polymers have garnered the most attention in gene delivery. 
 
1.2.4.1. Polymer for gene therapy:   
Cationic polymer-based gene delivery systems are effective DNA condensing agents and may thus 
provide more protection to the DNA cargo when compared to the lipid based systems discussed later (Li 
and Huang, 2000). There are two essential types of cationic polymers employed in nucleic acid delivery, 
natural polymers such as chitosan and atelocollagen  and synthetic polymers such as poly(L-lysine) 
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(PLL), poly(ethyleneimine) (PEI) and dendrimers. In general the natural polymers are non-toxic and 
display adequate mucoadhesive, biocompatibility and biodegradability in contrast to synthetic polymers 
which provide flexibility and offer the ability for tailoring to fit the size and topology of plasmid DNA 
(Kawakami et al., 2008). These carriers upon complexation with DNA form a polyplex (Felgner et al., 
1997) capable of cell directed gene transfer. Of these the most extensively evaluated are poly(L-lysine) 
and poly(ethyleneimine) (El-Aneed, 2004).  
PEI is highly versatile, being produced as either a branched or linear polymer of varying chain lengths. Its 
versatility together with its capacity for increased transgene expression in a diverse range of cell lines has 
placed it above most other non-viral gene delivery systems. Once involved in the endocytic pathway PEI-
DNA complexes are presented with a decrease in the pH of their environment from neutral to pH 5.0 
whereupon they are destabilized. Polyethylenimine is considered to act as an internal buffer within 
endosomes due to its ‘proton sponge’ nature (Chen et al., 2007). This buffering capacity at any 
encountered pH has been attributed to this branched polymer having every third amino nitrogen 
protonated (El-Aneed, 2004). Despite this PEI polymers exhibit high levels of  toxicity due to their 
polycationic nature and their non-biodegradability in vivo (Morille et al., 2008).  
Poly(L-lysine) (PLL) due to its peptide structure and associated biodegradability has proved advantageous 
in vivo. This cationic polymer was the first employed for gene transfer and until only the past decade was 
one of the most utilized. The low molecular weight poly-L-lysines, however, possess a reduced ability to 
form stable complexes resulting in the need for implementation of high molecular PLL for systemic gene 
delivery. Although these cationic polymers enter the cell via the same mechanism as PEI polyplexes their 
transfection efficiency is not comaparable (Morille et al., 2008). Co-application of lysosomotropic agents 
such as chloroquine can reduce lysosomal degradation. Due to their apparent low levels of transfection 
these polymers are rarely applied alone or in the absence of some form of chemical alteration. One 
commonly employed modification is the introduction of PEG to increase the circulation half-life and 
consequently the efficacy of transfection (El-Aneed, 2004). For in vivo gene delivery polyethylene glycol-
poly-L-lysine (PEG-PLL) micelles that form self-assembling particles with DNA have been developed 
(Niidome and Huang, 2002). DNA delivery using the polycation poly(L-lysine) can be linked to 
asialoorosomucoid for hepatocyte targeting or transferrin for direction to dividing cells.   
Some poly-L-lysine derivatives have been identified in recent reports to be water soluble and 
biodegradable and capable of releasing condensed DNA on hydrolysis. A few of these reported 
derivatives have shown higher-level efficiency of gene transfection in vitro accompanied by lower 
cytotoxicity than that found with poly-L-lysine. Temperature fluctuations have been reported to initiate 
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swelling or de-swelling of hydrated polymers. Consequently thermosensitive polymers have been 
produced to control the release of entrapped DNA (Niidome and Huang, 2002). 
Dendrimers are highly branched, spherical polymers of which the most commonly used are polyamines, 
polyamides. The most abundant dendimer found is the polyamidoamine (PAMAM) due its capacity for 
high level transfection. Dendrimers possess primary amines on their surface which are involved in DNA 
binding and compaction promoting cellular uptake while the tertiary amines present inside act as proton 
sponges enabling endosomolysis. Their properties of size, modifiable surface functionality, multivalency, 
water solubility and their internal cavity that is available makes them attractive for drug delivery (Cho et 
al., 2008).  
In an effort to overcome some of the drawbacks faced in applying dendrimers to gene therapy, Holladay 
and others (2009) proposed a system of partially degraded dendrimers capable of condesing DNA 
forming complexes which may then be entrapped within a three-dimensional collagen matrix. The 
supposition put forward was that the collagen matrix can serve as a reservoir for the complexes and thus 
produce a slower rate of transfection together with prolonged transgene expression. Those cells 
transfected most significantly were the highly migratory and rapidly dividing cells while those cells that 
show slower rates of proliferation produced lower levels of transfection activity (Holladay et al., 2009).  
1.2.4.2. Peptide for gene therapy: 
The amphiphilic peptides employed here are capable of undergoing conformational changes when 
presented with an acidic environment to thus enable endosomal or lysosomal escape. The presence of 
positively charged amino acids, such as histidine, lysine, arginine allow for effective condensation of 
DNA. The incorporation of cysteine residues into the backbone of the peptide can increase the release of 
DNA into the cytoplasm due to the formation of reducible disulphide bonds within the complex (El-
Aneed, 2004). Those carriers containing incorporated redox-sensitive thiols condense DNA in an 
exceedingly stable complex and are capable of strong in vitro transfection activity due to the spontaneous 
oxidation of the thiol group. Amplification of expression without affecting DNA uptake has been 
achieved in this system via peptide cross-linking inferring the reduction of the disulphide bond as a key 
trigger for intracellular release. Stealth activity peptides such as polyethylene glycol and glycopeptides 
containing sulfhydryl cross-linking for in vivo gene targeting have previously been synthesized (Niidome 
and Huang, 2002).  
There are four basic requirements for peptide-based local gene delivery systems namely, DNA binding, 
condensation, nuclear transfer of DNA and release of active DNA for the nucleus. An appropriate balance 
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needs to be maintained between the size and stability of peptide DNA complexes as their large size and 
potent charge can result in cytotoxicity, antigenicity and insolubility (Trentin et al., 2005).  
Protamine is an arginine rich peptide that condenses DNA prior to cationic lipid complexation. Liposome-
protamine-DNA (LPD) complexes can facilitate endocytosis and enhance the circulating half-life in vivo 
as a result of their small size. Asialofetuin is a liver targeting ligand that used to coat Liposome-
protamine-DNA and other cationic DNA complexes for the targeting of liver parenchymal cells (HepG2) 
allowing increased uptake of entrapped DNA (Uddin, 2007). 
1.2.4.3. Lipid for gene therapy:  
Since the unveiling of liposomes in 1987 as potential carriers for gene delivery, lipid-mediated gene 
transfer has maintained its position as the foremost technique for cellular gene delivery. A wealth of 
cationic lipids including cationic derivatives of cholesterol and diacylglycerol, and quaternary ammonium 
detergents, additionally polyamine lipid derivatives have been reported (Niidome and Huang, 2002). 
A variety of lipofection agents or cytofectins have been developed and evaluated in cell culture, animal 
models and clinical trials. The term cytofectin is used in reference to positively charged lipid molecules 
that have the ability to promote the functional entry of  macromolecules, polynucleotides as well as small 
molecules into dividing cells while being able to evade degradation by the lysosome (Felgner et al., 
1994). These systems afford the user the advantages of simplicity and efficiency of formulation, 
commercial availability and the capacity for specific tailoring. The presence of the cationic head group is 
essential for binding the negatively charged phosphate groups on the DNA backbone (Gao et al., 2007). 
Differentiation of these lipids as outlined below and in Figure 1.2 is based on the number of postive 
charges in their head group as well as the structure of  their hydrophobic moiety: 
 Monovalent aliphatic groups that posses a single amine function present in the head group, e.g. 
DOTMA, DMRIE and DOTAP, 
 Multivalent aliphatic lipids with polar headgroups having various amine functions including the 
spermine group, e.g. DOGS – a class of cationic amphiphile that possesses a cationic spermine group 
connected to a double chain lipophilic group through an amidoglycyl spacer arm.  





Figure 1.2: Structures of some cationic lipids currently applied in gene therapy and the helper lipid 
DOPE ( Adapted from Morille et al., 2008).  
 
DOTMA and DOGS and their various derivatives have been widely applied in the delivery of DNA to 
eukaryotic cells. Through their head group containing one to a possible four positive charges these lipids 
introduce hydrophobic aliphatic groups to the DNA (Cotton and Wagner, 1993). DOPE assumed to 
posses a weak surface hydration when combined with the lipopolyamine DOGS, may produce a stable 
bilayer structure due to the inverted cone shape adopted by the  molecules (Thierry et al., 1997).  
Cationic lipids are chiefly produced from two distinct hydrophobic segments, DOTMA for example, 
consists of two long hydrocarbon chains that make up its hydrophobic anchor, while DC-Chol and Chol-T 
employ a cholesterol backbone. Modification at the molecular level is important to the transfection and 
DNA complexing capability of the cationic lipid. Tang and Hughes (1999) showed in their work that a 
single tailed cationic lipid could also be used in a carrier system for DNA transfer. An additional 
structural parameter for consideration is the head group-anchor linker, as it plays a vital part in effecting 
gene transfer. In this regard the ether linkage as found in DOTMA was shown to be more effective in vivo 
than the ester link used in DOTAP. The ether linkage was also shown to be favourable when linking a 
cationic ammonium head group with a cholesteryl backbone. The  same components appended by either 
an ester or urethane linker proved to be less effective (Dileep et al., 2001; Bajaj et al., 2008). However, 
the introduction of an ester bond within the alkyl chain has been found to minimize the toxicity associated 
with cationic lipids. 
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Helper lipids such as dioleoylphosphatidylethanolamine (DOPE) or cholesterol are known to introduce 
additional stability and/or fusogenicity to the cationic carrier (Kawakami et al., 2008). 
Phosphatidylethanolamine has been applied to many cytofectin liposome formulations for optimal 
activity. The phosphatidylethanolamine is believed to elicit its effect due to an ability to undergo 
transition from a bilayer or lamellar phase to the inverted hexagonal phase. DOPE in particular has 
displayed this effect through promotion of membrane fusion and destabilization in cationic lipid-mediated 
nucleic acid transfer. A number of other lipids such as DOTAP, DOTMA and polymers have also shown 
the ability to promote DNA complex-cell or endosomal membrane fusion (Resina et al., 2009). 
Zwitterionic lipid DOPE alone is reported to be ineffective for transfection, possibly due to its difficulty 
to form a union with the nucleic acid molecule. At neutral pH DOPE cannot produce stable uniform 
formulations, yet when combined with cytofectins stable liposomes are formed. Vesicles that possess 
DOPE are known to experience a drop in net positive charge as the pH is increased from 7.0 – 9.0 
(Felgner et al., 1994). 
Moreover DOPE is known to assist in membrane destabilization of the either cell or endosome. In this 
regard the amine group of DOPE may prefer the cationic lipid interaction with the negative phosphate 
groups on the DNA. This association can thus interfere with the existing interactions between the DNA 
and cationic amphiphile. Therefore formulations consisting of phosphatidylethanolamine are suggested to 
be more susceptible to cellular factors promoting disassembly (Zuhorn et al., 2002).  
Liposomes have been described as vesicles consisting of an entirely enclosed aqueous inner core 
surrounded by the natural membrane resembling phospholipid bilayer membrane. In general these 
vesicles have been applied to formulations of poorly soluble therapeutic agents for either parenteral or 
oral administration (Schnyder and Huwyler, 2005). Being the most studied nanoparticles, liposomes are 
also able to improve the pharmacokinetics and pharmacodynamics of associated drugs (Wang et al., 
2008). The cationic lipids DC-Chol and DOTAP are generally employed in liposome formulations 
because of their ability to form stable lipoplexes on electrostatic interaction with DNA or oligonucleotide 
(ODN) molecules (Naik et al., 2009).  To become more widely useful as transfection agents the efficiency 
of the cationic liposome – DNA complexes needs to be improved, which requires increased understanding 
of the transfection mechanism as well as the chemical and physical parameters that influence it (Ewert et 
al., 2006). 
Neutral liposome formulations provide an alternative to the use of cationic liposome – DNA complexes 
where they are capable of entrapping the DNA within the vesicles. This system may also be coupled to 
targeting vectors or coated with PEG and can as a result be characterized by high levels of DNA stability 
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under the physiological conditions in addition to an extended half life (Schnyder and Huwyler, 2005). 
Liposomal half-life can be improved through coupling with gangliosides or polyethylene glycol (PEG) 
derivatized lipids. The conventional liposomes coated with PEG, an inert and biocompatible polymer, 
form sterically stablized liposomes that display a limited affinity for cells in vitro and the non-diseased 
tissues in vivo making it a safe alternative for drug delivery systems (Schnyder and Huwyler, 2005).  
A further strategy is the utilization of pH-sensitive liposomes which assist in the release of liposomal 
drugs or nucleic acids within the cytoplasm as these liposomes are associated with the spontaneous 
discharge of their contents upon encountering a decrease in pH. These liposomes are in general 
formulated in conjunction with DOPE or ionizable anionic lipids such as CHEMS 
(cholesterolhemisuccinate) and can be applied to the conventional as well as long-circulating, sterically 
stabilized liposomes (Schnyder and Huwyler, 2005). 
1.2.4.3.1. Additional applications of liposomes 
A number of drugs, chemotherapeutic agents in particular, have a small therapeutic window, limited 
clinical application and are compromised by a dose limiting toxic effect. Consequently the therapeutic 
effectiveness of these drugs requires their formulation in a beneficial manner. Vesicular systems as 
pharmaceutical carriers are typically extremely well ordered assemblies consisting of one or more 
concentric lipid bilayers resembling biological membranes which are ubiquitous structures that 
encapsulate and organize cells and organelles (Sharma and Sharma, 1997; Biju et al., 2006).  
Drugs entrapped in liposomes at either the phospholipid bilayer or in the aqueous internal core, are 
expected to be transported without undesired degradation or pronounced side effects to the recipient. The 
positional entrapment of the drug is believed to be dependent on the lipophilicity of the therapeutic drug 
or agent (Sharma and Sharma, 1997; Goyal et al., 2005).  
The successful development liposome-drug delivery systems (Kozubek et al., 2000) for the treatment of a 
significant number of diseases in both animal and human models underscores the future potential of these 
systems for clincal and veternary applications. Both unilamellar and multilamellar liposomes ranging in 
size from 50 – 700 nm have been approved as vehicles for the safe and effective delivery of drugs such as 
doxorubicin, an anthracycline antibiotic drug used in cancer chemotherapy. Moreover they have been 
applied as molecular imaging agents for both ultrasound and magnetic resonance imaging (MRI) 
(Wickline et al., 2006).  
Liposomes have been applied to topical ocular drug delivery as well as for the oral administration of 
insulin (Biju et al., 2006). Besides being applied as drug carriers for topical treatments liposomes have 
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also been used as active ingredients in skin care products. As such they may either improve penetration of 
the active component or function through the diffusion of their lipidic ingredients into the skin 
(Hatziantoniou et al., 2007). 
Liposomes have matured into sophisticated models for use as not only cosmeticeuticals, but more 
importantly pharmaceutical products.  The primary aim of liposomal application is to obtain selective 
localization brought about by either passive or active targeting of the drug molecule at the site of disease 
be it tumour or inflammation. For the liposomes to be completely effective they must conform to four 
general requirements:  
i. Stable and sufficient drug or agent loading  
ii. Prolonged cytoplasmic circulation. 
iii. Extravasation at the point of infection or disease. 
iv. Target cell translocation of active drugs. 
Passive targeting is known to exploit the innate ability of specific cells such as Kupffer cells and 
macrophages to phagocytose foreign particles such as liposomes while active liposomal drug targeting 
may be achieved through the attachment of certain antibodies to the vesicles producing 
immunoliposomes. Active targeting has the ability to enhance target site affinity of the carrier system in 
contrast to the effect of passive targeting which is known to minimize the non-specific associations with 
non-targeted sites through the reticuloendothelial system (RES) (Hattori and Maintani, 2005). For the 
active targeting of a tumour site, ligands corresponding to over-expressed growth factors and surface 
receptors can be coupled to the nucleic acid delivery systems. The serum glycoprotein transferrin is one 
ligand applied for targeted delivery to the transferrin receptor. Expression within the tumour is found to 
occur primarily at sites in close proximity to structures resembling primitive blood vessels (Russ and 
Wagner, 2007).  
Since liposomes that display extravascular leakage will result in poor therapeutic effect at the specific site 
of disease, the liposomal system must be designed such that stability is retained through storage and in 
vivo plasma circulation, but is in part lost upon interaction with the targeted site of action (Barenholz, 
2001). Neoplasms have unique physiological attributes that may be exploited for enhanced nucleic acid or 
drug delivery. In fact recent works have revealed the propensity of cationic liposomes to accumulate or 
concentrate within the tumour vessels. Consequently cationic liposome-mediated gene delivery can be 
considered a valuable pathway for the delivery of antiangiogenic and antivascular drugs to tumour 
endothelial cells. It has been suggested that cationic liposomes achieve significantly higher levels of 
localization at tumour sites compared to normal vascular networks.  A potential explanation is that the 
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erratic and lethargic blood flow within the tumour may promote increased association of cationic 
liposomes with the angiogenic anionic sites (Campbell et al., 2002). 
Drug-targeting strategies have been categorized as either ‘prodrug’ or ‘carrier mediated’ systems. 
Prodrugs once at their site of action become converted from being drug-related precursors to their active 
form. Carrier systems on the other hand entails either covalent or non-covalent association of the drug 
molecules with the targeting moiety thus enabling cellular targeted drug transfer. With the primary 
application of drug targeting being for therapeutic and diagnostic uses they aim to induce the distribution 
of drugs throughout the body (Russ and Wagner, 2007). 
In their role as carrier vesicles liposomes are able to convey many pharmaceutically active molecules 
such as chelating agents, anti-neoplastic and antimicrobial drugs, vaccines, steroids and genetic material 
(Sharma and Sharma, 1997). Many attempts have been undertaken to introduce targetable characteristics 
to the liposome including their non-covalent association with cell specific antibodies, coating with heat 
aggregated immunoglobulins, covalent coupling of poly- or monoclonal antibodies, glycoprotein bearing 
liposomes as well as those containing glycolipids (Goyal et al., 2005). In targeted lung transfection, 
cationic liposome carriers have primarily been used for the treatment of cystic fibrosis both in vitro and in 
vivo. Despite their moderate levels of in vivo gene expression off-setting their advantages, the continued 
production of a wide variety of cytofectins for lipoplex-mediated gene delivery, indicates that the 
suitability of cytofectins varies with their application (Wheeler et al., 1996; Ferrari et al., 2001).  
Since the first application of liposomes as immunological adjuvants to elevate the immune response to the 
diphtheria toxoid, they have been employed as non-toxic adjuvants with bacterial, viral, protozoan, 
neoplastic and other antigens which can be introduced into the aqueous volume or bilayer depending on 
their lipophilicity. In the early days of liposomal therapeutics, the liposome vesicles containing 
inactivated hepatitis A virions were successfully applied as a vaccine for human use.  Their limitations 
include stability, reproducibility of batch formulations, control of particle size, substantial batch 
production sizes and stunted circulation half life of vesicles (Sharma and Sharma, 1997).  
Besides their potential to be applied as drug, antigen and gene delivery carriers for transfer to specific 
cells, liposomes have been developed to contain the ultrasound imaging gas perfluoropropane. These 
liposome-based technologies are referred to as novel liposome bubbles. The use of these bubble 
liposomes in conjunction with ultrasound could produce minimally invasive and specific tumour targeted 
gene delivery (Suzuki et al., 2008). Moreover they have also found application capability in antimicrobial 
therapy where the simple in vitro administration of liposomes coupled with a specific antibiotic could be 
active against the bacterial infection. This application is in response to the need presented by antibiotics 
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which can only act against intracellular infections if they are able to penetrate phagocytic cells and since 
liposomes are reknowned for their localization in organs where many microorganisms exist such as the 
liver and spleen. They are highly effective at directing the antibiotics to these organs. In addition to their 
imperative role in gene therapy, liposome formulations have achieved success in the potentiation of DNA 
mediated vaccination (Goyal et al., 2005).  
Recently developed liposome-protamine-DNA complexes have shown superiority over conventional 
lipoplexes providing a possibility for the production of future conjugates of modified cationic lipids 
capable of DNA compaction and cell penetration (Uddin, 2007). 
1.2.4.4. Crown ethers and their cationic amphiphile associations 
One of the barriers to cellular transport of drugs, chemicals or nucleic acids is the membrane of the cell. 
This ubiquitous membrane protects the cell contents from invasion by inappropriate chemicals or foreign 
molecules and furthermore limits potential leakage of cellular components. Moreover the plasma 
membrane must also maintain the equilibration of closely related ions and their concentrations. In this 
regard the sodium cation must be maintained at a concentration of 150 mM outside and 10 mM inside the 
cell, while the potassium ion must be kept at 5 mM outside and 150 mM inside the cell. In most instances 
these cations, in addition to some organic species such as sugars are transported via the assistance of 
complex channel-forming proteins. In contrast to channel-forming compounds that produce pores in the 
cell membrane through which cations and water align, cation carriers complex with the cation and ferry it 
across the membrane (Gokel and Mukhopadhyay, 2001).  
Since their conception by Charles Pederson in the late 1960’s, crown ethers have received recogniton for 
their role as ionophore antimicrobial agents. This is significant as interruption of the Na+/K+ balance is 
potentially fatal to the cell, furthermore the use of an ionophore to transport ions that are hydrophilic in 
nature through the hydrophobic membrane can result in bacterial death (Hardinger, 2003). In 
investigations of crown ether based transport of alkali metal cations across membranes it was revealed 
that in almost all cases a carrier mechanism was involved (Gokel and Mukhopadhyay, 2001).  
Crown ethers have shown a preferance for binding at the basic sites within a peptide. This complexation 
with peptides occurs at varying amounts resulting in peptides of all sizes and charged states. Thus 
peptides that were originally similar could be distinguished on the basis of their size, charge and mobility 
(Hilderbrand et al., 2006). 
Several substituted macrocyclic polyethers have been synthesized with varying ring sizes and functional 
groups producing diverse levels of enhanced cation binding and rates of transport without affecting the 
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flexibility of the molecule. Of these the triaza crown ethers have displayed impressive affinity for 
protonated amines in comparison to oxo-, mono- and diaza crown ethers which show greater affinity for 
potassium (Vogel and Wengel, 2002). Many of these amphiphilic polyaza crown ethers when grafted at 
opposite ends of an oligonucleotide backbone can produce significant levels of DNA duplex stablization. 
Much of the research into the introduction of cation-transporting capability into bilayer membranes has 
involved the large unilamellar vesicles  and naturally occuring ionophores. The mechanism of cation 
transport has been established to be different when measured across a lipid bilayer and when investigated 
across a model liquid membrane. Due to their low water solubility monoaza-crown ethers with amide 
linked-lipophilic side arms cannot be introduced into liposomal membranes after the liposomes have been 
synthesized (Xie et al., 1994).  These azacrown ethers are in general prepared with tosyl or 
toluenesuphonyl groups to protect the nitrogen atoms from further substitution (Gokel et al., 2004). 
The introduction of an aza-group allows for control of the crown ether function by means of a figurative 
on-off switch, where the open cavity enables greater ion affinity. By means of this simple action of 
switching a light source on or off the selective removal of ions from solution can be regulated (Kim et al., 
2008). Crown ethers as larger fused ring structures are only capable of partial freezing of the ribose 
pseudo-rotational cycle, however, if this effect is retained, these compounds could potentially impart 
antimicrobial, antifungal or even antiviral activity. This so-called ‘freezing’ refers to the restriction of the 
ribose-like moiety in a receptor- preferred conformation for an improved pharmacological profile 
(Coppola et al., 2008). The most commonly used substituents in crown ethers are benzene rings which 
where discovered by Pedersen in his identifiction of dibenzo-18-crown-6 ( (Pedersen, 1967; Gokel et al., 
2004). 
Structurally crown ethers consist of an electron rich cavity made up of oxygen lone pairs that enable 
binding with cations and they have an external hydrophobic ‘blanket’. The crown ethers may be named 
based on size of the ring, shape and the number of oxygens, for example the 15-crown-5 and 18-crown-6 
ether compounds. The size of the crown ether cavity is considered to be proportional to the size of the 
ring. Consequently selectivity of ion complexation may be reliant on the size of the cavity and the ion to 
be bound such as the sodium ion that has a radius of approximately 1.94 Å and the potassium ion having a 
radius of 2.66 Å. Conflict exists between earlier reports of 15-crown-5 cavity size and more recent 
evaluations, which reveal a cavity diameter of 1.7 – 2.2 Å and consequently stongest binding of the 
sodium ion. The potassium ion on the other hand is firmly bound by the 18-crown-6 with a cavity 
diameter of 2.6 – 3.2 Å. The crown ether – cation complex can attain stability when the ratio of crown 
cavity size to cation diameter is at approximately 1 with ratios under 0.7 producing low levels of stability 
(Darwish and Uchegbu, 1997; Hardinger, 2003). Under suitable conditions the 15-crown-5 and 18-crown-
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6 ether compounds are capable of binding Ca2+ having an ionic diameter of 2.7 Å. Additionally, an 
increase of sodium ions can induce an increase in the intracellular levels of the calcium ion released by 
the sarcoplasmic reticulum. This elevation of calcium has been implicated as part of the ROS system of 
crown ethers, allowing physiological function (Boojar and Goodarzi, 2006). 
The cation selectivity and binding ability of crown ethers is assumed to be dependent on the following 
parameters: 
 Cavity size – cation diameter relationship; 
 The number of donor atoms; 
 Crown ether conformation, either rigid or flexible; and  
 Crown ether lipophilicity. 
Some factors that determine the extent of their ability for metal cation binding are the size of the crown 
ether cavity, the nature of the heteroatoms (oxygen, nitrogen or sulphur), the substituents present in the 
macrocycle and the solvent employed. One of the most accepted methods of determining the cation 
complexing ability of crown ethers is by using solvent extraction techniques. Comparative investigations 
of the relationship between the size of the crown ether cavity and the cation or ‘Hole Size relationship’, 
have shown optimal binding if both are of the same size.  In this area of research two concepts of 
molecular switching and sensing have evolved. With molecular switching alterations occur which can 
either allow or inhibit cation binding in host systems that may or may not have had the ability. Earlier 
investigations have revealed that the position of crown ether attachment has the ability to influence its 
preference of complexation (Izumi et al., 1986).   
Being capable of complexing alkali metal ions, crown ethers, cyclams and cyclenes have been applied as 
metal carriers in research in analytical chemistry and radiomedicine. Another potential use of crown 
ethers that has drawn them further into the spotlight is their antitumour activity (Muzzalupo et al., 2007).  
Crown ethers in their simplest form are cyclic polyethers resembling polyethylene glycols composed of 
alternating ethyleneoxy (-CH2CH2O-) units and heteroatoms, typically ether oxygens. Two ethyleneoxy 
units afford dioxane, while six repeating units give 18-crown-6. Macrocycles repeating this unit more 
than four times are general referred to as crown ethers rather than by their systematic names because of 
their ability to complex cations (Gokel et al., 2004). The grafting of a lipophilic long-chain alkyl group to 
a crown ether results in the production of a crown ether surfactant known as a bolaform which is capable 
of forming micelles that are similar to those of traditional nonionic surfactants in aqueous solution (Turro 
and Kuo, 1987). Bola amphiphiles produced from two aza-15-crown-5 or aza-18-crown-6 headgroups 
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separated by a 12 carbon spacer were shown by DeWall and co-workers (1997) to generate lipid 
monolayers of a stable nature. Upon dispersion and sonication in aqueous solution, these molecules self-
assemble into unilamellar vesicles that express prolonged stability in the face of various temperatures and 
changes in ionic strength (Muzzalupo et al., 2007).  
In general these macrocycles are toxic and severe irritants to tissues being absorbed through the skin, 
respiratory and intestinal tracts. These compounds are also able to expand their reactivity range by their 
characteristic solubilization of inorganic molecules in the presence of organic solvents (Pedersen, 1967). 
The dibenzo- and dicyclohexyl-crown ethers are the most broadly applied, however, others in this group 
include the ‘azacrowns’ and ‘thia crowns’ where one or more oxygen atoms may be replaced by an NH or 
S group respectively. Still others that exist and are in use are the cryptands and lariat ethers. Crown ethers 
are also known to complex protonated amino acids (DeWall et al., 1997). 
In terms of their toxicity, crown ethers are expected to increase in toxicity with increasing ring size, also 
the unsubstituted crown ethers show only moderate toxicity. Chelators such as crown ethers are 
considered polydentate ligands that can fill more than one point in the co-ordination sphere of the ion, in 
particular the metal ions, primary amines and single protons (Rozema, 2008). Although widely 
acknowledged as toxic compounds, many studies have shown crown ethers not to interfere with the 
integrity of the genetic material in mammalian cells. It was demonstrated using biomarkers that exposure 
of the rat lung to crown ethers could produce oxidative stress in which the local production of oxidative 
free radicals is significant. This oxidative stress can give rise to high levels of reactive oxygen species 
(ROS) which attack the cellular membrane lipids or DNA in tissues and can potentially cause oxidative 
injury leading to a number of disorders. This effect can be enhanced by the movement of crown ethers 
across the cell membrane producing structural alterations to the membrane (Boojar and Goodarzi, 2006). 
The introduction of crown ethers into molecules or vehicles capable of biological activity has potential to 
afford the novel tools of labelling and structural probing of biomolecules (Ossowski et al., 2005). In this 
regard their strong association with protonated primary amines and binding of lysine and arginine side 
arms has been exploited in a group of receptors called ‘molecular mouse traps’. It has further been 
reported that the aza-18-crown-6 molecule displayed greater protein affinity than the 18-crown-6 
molecule (Gokel et al., 2004). 
Amphotropic compounds are capable of producing thermotropic liquid crystals which may coalesce into 
ordered supramolecular assemblies including micelles, monolayers, liposomes and lyotropic liquid 
crystalline phases. Crown ethers have received more interest for application in ionoselective membranes 
due to their capability to form monolayer and bilayer membranes. However, stable and well ordered 
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membranes produced in this manner have not yet been established (Qian et al., 1996). The cation-crown 
ether complexation in general occurs in the solvent from which the two-dimensional complex may 
crystallize. The rate of complexation and release of cations by the crown ethers is notably faster in polar 
solvents (Gokel et al., 2004). In water the aza-crown ether amphiphiles self assemble to produce micelles 
or niosomes even in the absence of nitrogen donor atoms (Hardinger, 2003). When prepared with 
cholesterol, aza-15-crown-5 produced a solid state structure upon crystallization. Moreover the presence 
of a hydrophobic tail and polar head groups allow for the development  of stable vesicles on sonication, 
which, being rigid, suggests a high level of bilayer organization. A wide variety of crown ethers have 
been shown to produce aggregates commonly or more specifically they form liposomes.  
Colloidal drug delivery systems have received a great deal of attention with regard to micellar solutions, 
vesicle, liquid crystal dispersions and nanoparticles. Alternatives to phospholipid based vesicles are being 
investigated for potential exploitation due to the large number of non-ionic surfactants currently available 
and capable of entrapping or complexing both hydrophobic and hydrophilic solutes. The main reason 
behind this is the associated improved costing, fewer problems with storage and better stability of these 
systems (Muzzalupo et al., 2007). Furthermore the presence of a hydrophobic exterior and hydrophilic 
interior results in the crown ether being able to enhance the solubility of large molecules (Bauer et al., 
2004). 
The in vivo use of liposome vector systems requires the application of lipoplexes or liposome-DNA 
complexes which are large and in general possess an excess of positive charge. These characteristics 
under the in vivo conditions could lead to significant disruption of the cellular ionic equilibrium which has 
potential to inactivate protein structures and surface lectins inhibiting their optimal functionality. Since 
there is no way of maintaining control of the amount of metal salts on the surface of complexes consisting 
of neutral liposomes and DNA, it is possible that the net charge at the surface cannot be controlled. To 
circumvent this, work has been carried out to introduce crown ethers at the head of the amphipathic lipids 
so as to exploit their ability to coordinate metal ions. In these investigations the crown ethers were 
assumed to bring about interactions with the metal cations of suitable strength so as to afford the lipoplex 
the required stability to reach the target cells, but still lose the cation and retard DNA release upon 
cytoplasmic entry until it reaches the nucleus (Bruni et al., 2009).  
The aza crown ethers have also been applied to polymers as ring opening reagents (Nakaya and Li, 1999). 
Besides their regular application in chemistry, crown ethers have also been applied to regulate enzymes, 




1.3.  CELLULAR ENTRY MECHANISMS, BARRIERS AND SOLUTIONS 
The cellular membrane is a relatively lipophilic deliminating structure that restricts the entry of large, 
hydrophilic or charged molecules such as non-viral gene vectors. Yan and Tram (2007) noted that the 
delivery methodologies for nucleic acid therapeutics require three concepts to be addressed namely: total 
uptake, kinetics of uptake and subcellular distribution, since the phospholipid bilayer poses a potent 
obstacle to the movement of ions. Nucleic acid internalization via this membrane is, in general, inefficient 
by virtue of the charge repulsion that exists between the negative charges on the nucleic acid and the cell 
surface. This ineffective and slow rate of their internalization poses a further barrier as their prolonged 
exposure to physiological conditions creates the potential for enhanced nuclease degradation.  
Endocytosis proposed for the entry of most non-viral agents is considered a mechanism for cellular 
internalization of macromolecules and solutes through the employment of membrane-bound vesicles. 
There are a number of endocytic pathways of internalization that have been proposed each of which pose 
their own obstacles to gene therapy (Figure 1.3). In terms of the kinetics of the mechanism three modes 
have been identified, namely: fluid phase refering to the bulk uptake of solutes in proportion to their 
extracellular concentration and is a non specific and low efficiency process; adsorptive endocytosis and 
lastly, receptor mediated endocytosis which involves macromolecules being concentrated and bound to 




Figure 1.3: Schematic representation of the different hurdles encountered by a gene delivery system 
through the various internalization pathways into a tumor cell (Morille et al., 2008). 
 
Two broad classes that have been established for endocytosis are phagocytosis and pinocytosis (Khalil et 
al., 2006). Mechanistically endocytosis encompasses diverse and highly regulated pathways. Where 
phagocytosis is restricted to specialized mammalian cells and is responsible for the regulation of cellular 
entry of large particles, pinocytosis entails fluid and solid internalization in all types of cells  (Mäkelä, 
2008). The latter of the two has been further divided  into the four morphologically distinct pathways 
listed below:  
1.3.1. Clathrin Mediated Endocytosis 
Clathrin mediated endocytosis (CME) is the major and best characterized of the pathways and is known to 
take place constitutively in mammalian cells. The process involves the continous uptake of essential 




This receptor recognition, binding and internalization forms the first port of call for the clathrin mediated 
pathway of endocytosis. The first step in this process is the binding of a ligand to a specific cell surface 
receptors. Two of the most common ligands taken up by this pathway are the cholesterol laden low desity 
lipoprotein (LDL) and the iron laden transferrin (Tf) which are recognized by their specific receptors. The 
occurrence of the internalization signal within the cytoplasmic tail of the receptor together with clathrin 
assembly on the plasma membrane’s cytoplasmic face, results in the production of the clathrin coated 
pits. Thereafter ligand-receptor complexes accumulate in the coated pits which develop into intracellular 
vesicles upon invagination and pinching off from the plasma membrane. The GTPase dynamin has been 
implicated as the responsible factor for mediation of invagination and pinching off of the maturing vesicle 
from the cell membrane  (Mäkelä, 2008).  These clathrin coated vesicles thus convey the complexes into 
the cell (Khalil et al., 2006).  
In this endocytic mechanism the depolymerization or uncoating of the vesicles’ clathrin coat produces an 
early endosome which goes on to fuse with endosomes already existing thus forming a late endosome 
which finally fuses with lysosomes. This is a highly regulated and energy dependent process where 
assembly of the polygonal clathrin lattice having a proposed diameter of 120 nm (Mäkelä, 2008) on the 
plasma membrane is imperative for intracellular vesicle formation and detachment (Khalil et al., 2006). 
Clathrin independent pathways such as caveolae-mediated endocytosis have also been proposed where 
caveolae are static invaginations of the plasma membrane which delineate cholesterol and sphingolipid 
rich microdomains. In comparison to CME this is a slow process that also has relatively low capacity 
(Mäkelä, 2008). The use of several inhibitors has been exploited to establish that lipoplex mediated 
transfection is achieved through clathrin-mediated endocytosis (Hoekstra et al., 2007). 
1.3.2. Caveolae Mediated Endocytosis 
The Caveolae mediated endocytotic pathway uses Caveolae which are regarded as small flask, tubular, 
flat or detached vesicle structures that form hydrophobic membrane microdomains primarily composed of 
cholesterol and glucosphingolipids. Functionally the caveolae are involved in a number of celluar 
processes such as cholesterol regulation and transport of glycosphingolipids. They are found therefore in 
a diverse range of cell types, but are predominantly located in endothelial cells. Cholesterol is considered 
essential to internalization via caveolae therefore drugs that bind specifically to cholesterol may disrupt 
this internalization. The exploitation of this pathway may prove to be fruitful as it is not known to involve 
lysosomes and by extension any potential lysosomal degradation of the molecule being conveyed (Khalil 




The formation of large vesicles of variable morphology produced through an actin derived invagination of 
the plasma membrane is referred to as macropinocytosis which accompanies cell surface ruffling. Since 
the endocytic vesicles are distinctly large they can provide an efficient pathway for the non-selective 
endocytosis of solute macromolecules. Furthermore it shows the advantage of having an inherently leaky 
constitution allowing easy escape from micropinosomes and the capability of circumventing lysosomal 
degradation (Khalil et al., 2006).  
1.3.4. Phagocytosis 
Phagocytosis has been known to be conducted predominantly by specialized cells such as macrophages, 
monocytes, dendritic cells and neutrophiles in mammalian cells where they are responsible for the 
imperative removal of relatively large pathogens or debris from sites of tissue damage or inflammation 
(Mäkelä, 2008). Internalization via this active process involves various sequential and complicated steps. 
This may be initiated by an interaction between the phagocyte specific receptors and ligands present on 
the particle to be taken up, which triggers actin assembly and the production of cell surface extensions. 
These projections then engulf the particle forming phagosomes which become part of an endocytic 
pathway that result in an ultimate mature phagolysosome where the particles may be degraded (Khalil et 
al., 2006; Mäkelä, 2008).  
1.3.5. Receptor Mediated Endocytosis 
Despite receptor internalization taking place primarily via clathrin mediated endocytosis some other 
pinocytic routes are available for selective receptor-mediated endocytosis. Receptor mediated transfer of 
genetic material is considered an advantageous and promising mode of disease treatment (Khalil et al., 
2006). A wide variety of ligand grafted cationic vectors have consequently been synthesized and 
investigated for the intracellular presentation of plasmid DNA. However, transgene expression at sites 
other than sites of disease is unfavourable when the plasmid DNA is constructed using viral promoters 
such as those from the cytomegalovirus or SV40 which are known to produce inflated levels of gene 
expression (Ahearn and Malone, 1999). Subsequently specific promoters including that for the α-
fetoprotein gene have been applied to cell-specific gene transfer systems (Aramaki et al., 2003).  
Lectins are receptor proteins which specifically recognize and bind carbohydrates which may be a sugar 
or glycan moiety of glycosylated proteins or lipids. These lectins have been revealed to actively direct 
their specifically bound ligand to either the endosome, lysosome or Golgi apparatus. Two strategies have 
been put forward for receptor-mediated drug delivery. The first proposes a potential lectin-drug molecule 
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association that could target cell surface glycoproteins or glycolipids followed by interaction with the 
glyco-protein or lipid allowing drug internalization. A second possibility invovles the drug molecules 
being associated with a specific glycan moiety which is then recognized by surface lectins. Endocytosis of 
the lectins is dependent upon their structure and sugar binding specificity (Yan and Tram, 2007). 
Ashwell and Morell (1974, cited in Tozawa et al., 2001) were responsible for the discovery of the 
asialoglycoprotein receptors which are found abundantly expressed on the sinusoidal surface of liver 
parenchymal cells or hepatocytes. This hepatic receptor was shown to be capable of mediating the swift 
clearance of glycoproteins displaying desialylated galactose or acetylgalactosamine hexoses as well as 
lipoproteins and apoptotic cells from circulation (Tozawa et al., 2001; Wu et al., 2002). 
The human asialoglycoprotein receptors (ASGP-R) are hetero-oligomeric complexes consisting of two 
homologous subunits called hepatic lectin (HL) 1 and 2 to enable high affinty-binding. The two subunits 
are both composed of an N-terminal cytoplasmic domain, a transmembrane segment, a stalk domain and 
finally a C-terminal domain for carbohydrate recognition. The hepatic lectin 1 is the major subunit 
exclusively containing the signal for endocytosis and being seven times more abundant than the second 
subunit. The HL2 subunit on the other hand, is a significant element for basolateral (sinusoidal) 
organization of hetero-oligomeric receptor molecules (Tozawa et al., 2001).  
A wide array of physiological roles have been proposed for this pathway in the past, one such postulation 
is the clearance of lipoproteins and chylomicron remnants through the low density lipoprotein (LDL) 
receptor. In their potential role in host defence, the receptor may also be involved in vertebrate protection 
against pathogenic organisms that exploit the neuraminidase for host invasion. It is believed that the 
action of C-type lectin ASGP-R may have originally evolved for protection against viral and bacterial 
manipulation. Patients with liver cirrhosis notoriously display an accumulation of serum 
asialoglycoproteins in conjunction with a decrease in receptor expression (Tozawa et al., 2001; Pathak et 
al., 2008).  
Of the ligands exploited for cell selective expression of the transgene both in vitro and in vivo the 
galactose has been the most investigated (Pathak et al., 2008). The asialoglycoprotein receptor displays a 
prerequisite for calcium ions (Ca2+) and the presence of three conserved disulphide bonds within the 
extracellular galactose binding domain. Consequently these hepatic lectins are able to bind non-reducing 
galactose and N-acetylgalactosamine residues of desialylated tri- or tetra-antennary N-linked glycans. The 
non-reducing terminal of oligosaccharide moieties present on glycoproteins are usally capped by sialic 
acid residues with neuraminidases removing the terminally positioned residues. The remaining galactose 
residues will be exposed and thus recognized by the asialoglycoprotein receptors. The specific hydrogen 
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bonding of the 3 and 4-hydroxyl groups with the carboxylate and amide side chains of key amino acids 
allows for receptor specificity to the D-galactose ad D-mannose residues (Wu et al., 2002).  
This binding and recognition is dependent on receptor structural organization on the cell membrane as 
this has not been observed for isolated receptors. This has thus been referred to as the ‘cluster effect’ by 
some reseachers. In addition the recognition of the synthetic glycosides is also dependent on the length of 
the sugar residues’ spacer being maintained at a minimum of 15Å. Moreover in addition to 
asialoglycoprotein receptors, hepatocytes have been identified to express the major facilitative glucose 
transporter isoform, GLUT2. This glucose transporter affinity has been employed for targeting carriers to 
the liver (Russ and Wagner, 2007). Asialofetuin and galactosylated albumin have often been employed 
for the evaluation of hepatocyte-targeting effect through the asialoglycoprotein receptor both in vitro and 
in vivo. The presence of asialofetuin or galactosylated albumins has the ability to inhibit the effect of 
hepatocyte-targeting as well as the capability to decrease the efficiency of transfection (Zhang et al., 
2007). 
1.3.5.1. The cellular internalization and trafficking barrier 
Endocytosis is considered a multistep pathway comprising cellular internalization, endosome formation 
and fusion with lysosomes and finally lysis. The low pH and presence of enzymes within endosomes and 
lysosomes will bring about the destruction of the DNA and associated particles. The DNA that survives 
this must then dissociate from their complexes for nuclear entry. The relatively poor delivery of DNA 
generally identified for carrier mediated endocytosis is relative to this multistep process where the number 
of DNA molecules for expression is reduced at each step during its translocation to the nucleus (Luo and 
Saltzman, 2000; Wattiaux et al., 2000). DNA – carrier dissociation has been evaluated to be a significant 
factor in the efficacy of nuclear delivery, moreover the precise quantification of delivered DNA and the 
ultimate efficiency of transfection are essential for a thorough understanding of the hurdles to gene 
therapy technologies (Hoekstra et al., 2007).  
The mechanism involved in cytoplasmic trafficking to the nucleus is relatively unknown, however, a 
potential prospect for future synthetic systems is the exploitation of those used by viral vectors and 
bacterial pathogens. These particles are able to traverse the periphery of the cytoplasm to reach the 
nucleus by means of an intracellular transport system composed of a network of actin or tubulin filaments 
(Klink et al., 2004). Serum is assumed to exhibit its inhibitory effect either through interfering in the 
lipoplex-cell membrane interaction or by the presence and association of serum proteins with the 
complexes thus limiting their ability to effectively deliver the transgene for expression. Of these the 
lipoproteins have been identified as the predominant component responsible for this effect of serum 
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(Nchinda et al., 2002). Ineffectual binding and cellular internalization is a major limiting parameter in 
liposomal mediated gene therapy (Chaudhuri, 2002).  
1.3.5.2. The endosomal barrier 
The endosome is produced by the pinching off of invaginated plasma membrane consisting of anionic 
phospholipids. The endosome thus presents an environment that comprises anionic lipids and low pH of 
approximately 6.2 (Mäkelä, 2008). The positive charge of the cationic amphiphile-DNA carriers is 
neutralized by mixing with the anionic lipids thus displacing the DNA. Lipid mixing may also prove 
beneficial, enabling membrane fusion and release of DNA into the cytoplasm for nuclear transport. The 
lipid phase present in the liposome – DNA complexes has been identified as crucial for escape of DNA 
from the endosome (Hirashima et al., 2007). It is also believed that the mechanism of escape from the 
endocytic vesicle will rely on membrane destabilization or endosomolysis (Chaudhuri, 2002). 
Endosomes are considered accountable for the separation of internalized cargo to either the recycling 
pathway where it is sent back to the surface of the plasma membrane or transferred to the late endosome. 
Following this some pathogens and downregulated receptors are transported to lysosomes where they are 
degraded by acid hydrolases. Late endosomes are known to have a lower luminal pH of 5.5 – 5.0, discrete 
protein composition, as well as cisternal and vesicular regions (Mäkelä, 2008).  
A few gene carriers like polyethyleneimine have displayed an inherent buffering capacity that produces 
osmotic swelling in the endosomal cavity. The vector or cationic polymer becomes protonated at low pH 
triggering an influx of chloride ions together with protons. This leads to an influx of water with ultimately 
swelling and perturbation of the endosomal membrane together with the concomittant release of the 
entrapped vectors for nuclear targeting. This phenomenon is referred to as the ‘proton sponge effect’ and 
was initially proposed by Behr and co-workers (Behr et al., 1997; Khalil et al., 2006; Shigeta et al., 
2007). Lysosomotropic subtances that can accumulate in the lysosome and bring about destabilization of 
the membrane may also be utilised. The entry of these agents via the endocytic pathway can bring about 
an osmotic imbalance and consequent swelling resulting from an influx of water (Wattiaux et al., 2000).  
Anionic lipids such as cardiolipin present in mitochondria have also been identified to be located mainly 
in endosomal membranes and the cytoplasmic-facing monolayer of the plasma membrane. A potential 
trigger for the initiation of membrane destabilization is the presence of phosphatidylethanolamine in lipid 
structures having high curvature. Since bilayer destabilization leads to accumulation of anionic lipids at 
the interaction point, the process of fusion once initiated is deemed autocatalytic (Xu and Szoka, 1996).  
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Another theory involves the release of compacted DNA within the endosome from the cationic lipid 
producing osmotic stress which may rupture the endosomal membrane and allow cytosolic release of 
DNA (Gershon et al., 1993). Release of DNA at the cell surface, in comparison may not be able to 
produce sufficient membrane stress required to induce rupture (Xu and Szoka, 1996). 
1.3.5.3. Nuclear localization and entry 
DNA translocation to the nucleus is important for expression of the therapeutic protein through the 
transcription machinery. Two methods that could aid in this situation are nuclear pore trafficking or 
nuclear breakdown via mitotic activity (Chaudhuri, 2002). 
Since 1962 it has been understood that both active and passive transport either into or out of the nucleus 
occurs via nuclear envelope embedded pores. These embedded nucleopore complexes are made up of 
three distinct domains, a central domain forming an aqueous channel through the nuclear envelope, a 
nuclear domain of nuclear filaments forming a basket-like structure joined to a nuclear ring and a 
cytoplasmic ring comprising an estimated 50 different nucleoporin proteins and attached to long 
cytoplasmic filaments.  
Pouton and colleagues (2007) looked at the two categories of nuclear localizing signals, i.e. classical and 
non-classical sequences for carrier-cargo complex nuclear direction. Classical nuclear pore sequences 
exist as short stretches of basic amino acids, the most well examined of these are those resembling the 
SV40 large tumour antigen. The non-classical variety do not possess these stretches of basic amino acids 
and the most established example is the primarily hydrophobic 38-residue M9 sequence of the human 
mRNA-binding protein, hnRNP A1. The two primary physical constraints for the delivery of cargo to the 
nucleus are passage through the cytoplasm and passage through the nuclear membrame. This is as a result 
of the molecular sieving effect experienced in both cases restricting the size of the cargo able to gain 
entry. The larger molecules must consequently form an association with those molecules forming a part of 
the sieve so as to overcome this physical impediment.  
A simpler alternative for the nuclear entry of DNA is via certain cellular mechanisms. During mitosis 
some cellular mechanisms activate the separation of chromosomal DNA into two nascent daughter nuclei 
upon nuclear envelope breakdown. This nuclear breakdone thus presents an opportunity for 





1.3.6. Lipoplex Endocytosis 
 
Of the numerous methods of gene transfection available, lipofection or cationic liposomal gene 
transfection has been determined to be a promising means of foreign gene delivery to target cells. Thus a 
variety of cationic liposomes have been developed (Hirashima et al., 2007). Despite little knowledge 
pertaining to their mechanism of action, cationic liposomes have been employed for DNA transfection 
both in cell culture and animal models (Xu and Szoka, 1996).  
Barriers to be encountered in liposome-mediated gene transfection may be classified into two groups of 
systemic and cellular barriers. Biological barriers interfere with the specific localization to the affected 
sites after administration of lipoplexes. Lipoplexes associated with an excess of positive charges are 
implicated in non-specific interactions promoting promiscuous attachment to both biological surfaces and 
systemic molecules which in vitro may be advantageous for gene expression and internalization. Once 
applied to in vivo conditions, however, these non-specific electrostatic interactions may potentiate 
reduced stability and targeting ability of lipoplexes (Chaudhuri, 2002).  
Cationic lipoplex mediated gene deivery is controlled by factors determined by the cationic liposome 
formulation, thermodynamic state as well as the cellular properties (Uddin, 2007). To navigate 
intracellular barriers systemic gene therapy requires that vectors be designed to: 
 Safely and efficiently convey extracellular DNA to the cell nucleus, 
 Overcome physiological obstacles to internalization, 
 Escape the endosomal vesicle, 
 Transfer the nucleic acid from the cell cytosol to the nucleus. 
Cellular internalization of the lipid-DNA complexes may take place via either of two possible pathways, 
direct fusion and endocytosis. Firstly unless a specific cell surface receptor targeted compound exists on 
the lipoplex transfection will involve electrostatic interaction driven lipoplex-cell surface association. 
Only approximately 2% of the cell population are thought to potentially take part in this internalization 
via direct fusion (Zhdanov et al., 2002). To preclude any non-specific interactions at the cell surface a 
diminution of the charge ratio is essential (Wasungu and Hoekstra, 2006).  
Inspite of earlier suppositions, Clancy and Sorscher (1999) showed that the second pathway of 
endocytosis was in fact the required path of internalization for the majority of complexes. This process 
ends in either destruction of the endosome or the transported complex (Zhdanov et al., 2002). Of the 
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various endocytic pathways, clathrin-mediated endocytosis has been reported for a few cationic lipids 
with application to diverse cell types (Wasungu and Hoekstra, 2006).  
At the point of DNA complex endosomal entrapment, a fraction of the bound nucleic acid dissociates 
from the cationic amphiphile and manages to free itself from the early endosome to enter the cytoplasm. 
Depending on the nucleic acid cargo different functions can be undertaken. For the expression process, 
transcription, mRNA export, translation and proper protein folding is essential. While nuclear trafficking 
is required for DNA, mRNA will perform its function directly in the cytoplasm (Murray et al., 2001). 
Once nuclear entry has been attained, the ultimate event in the transfection process is the expression of 
the gene (Ahearn and Malone, 1999). 
It is in general understood that the transfection of anionic and neutral liposomes is not impressively 
effective, since they achieve moderate activity in vitro and relatively poor expression in vivo. The 
complexes prepared on the basis of neutral phospholipids are able to avoid, in part, a few of the 
drawbacks associated with the application of cationic liposomes. One of these is their extensive and tight 
binding of DNA limiting its release and further transport to the nucleus (Zhdanov et al., 2002). 
An important aspect in the evaluation of the mechanisms involved in cationic liposome-DNA complexes 
(lipoplexes) is to determine the proteins and other molecules involved with lipoplex internalization that 
are present at the cell surface. Proteoglycans present at the cell surface are responsible for an assortment 
of functions ranging from the production of the extracellular matrix to cell to cell contact and 
communication. Furthermore they have shown the ability to mediate mechanisms of gene delivery into 
cultured cells that involve polylysine or cationic liposomes, which implies their potential role in lipoplex 
uptake in vivo. Despite this supposition the use of heparin sulphate in vitro has proved capable of 
releasing DNA from these complexes indicating that the glycosaminoglycan-bearing proteoglycans 
present in the biological milieu may prevent the uptake of these complexes. Sialic acid is another 
significant anionic surface molecule that when exhausted produces a similar effect to that produced by the 
depletion of proteoglycans, which results in the inhibition of in vivo lipoplex internalization. However, in 
contrast to the depletion of proteoglycans in vitro which prevents internalization, sialic acid depletion in 
this environment may enhance the transfection (Mounkes et al., 1998).  
1.3.6.1. Liposome-receptor targeting 
By definition targeting incorporates any strategy to bring about improved specificity of delivery and 
expression of the gene at the site of the tumour. Past targeting strategies employed have included targeted 
delivery of nucleic acids as well as transductional and transcriptional targeting to the intracellular site of 
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tumour cells. Transductional targeting includes all systems for improving intracellular release and 
transport of genes to the target cell nucleus. Upon gaining nuclear entry, only the presence of adequate 
promoter and/or enhancer elements in the expression cassette will allow gene expression (Russ and 
Wagner, 2007).  
Ever since glycotargeting was first demonstrated in the early 1970’s as a prospective method for directing 
therapeutic genes to protein receptors found at the site of localization, the  potential of the application of 
carbohydrate ligand targeted drug delivery systems has been well established. The chief biological 
mechanism exploited for glycotargeting is receptor-mediated endocytosis (RME). The application of 
glycoconjugates also termed sugar-macromolecule conjugates may be classified into two types, the first in 
which the macromolecule is itself the drug or therapeutic agent and the second where the macromolecule 
has an essential part in assisting the drug or therapeutic agents delivery. Multivalent glycans are generally 
necessary for efficient functioning of glycotargeting since the mono- and bivalent ligands do not have a 
high enough binding affinity (Yan and Tram, 2007). 
A large amount of high affinity cell surface receptors are exclusivley expressed on liver parenchymal 
cells for binding and internalization of asialoglycoproteins. Over the  years there have been a number of 
attempts to manipulate liposomes and other carrier systems to display ASGP-R sepcific ligands. 
Moreover it was revealed that a few synthetic galactose polymer ligands were more effective at ASGP-R 
complexation than its natural asialofetuin ligand. Additionally specific strategies have been employed in 
the design and development of these receptor-specific ligand bound vectors, involving the covalent 
coupling of a neoglycoprotein to the vectors’ surface resulting in conjugates with extended sugar epitopes 
and multisaccharides at their surface (Wu et al., 2002).  Collections of triantennary β-galactoside arranged 
on cholesteryl esters have proved stable and capable of producing high levels of ASGP-R-mediated 
uptake together with reduced glycolipid exchange with other lipid compartments (Singh and Ariatti, 
2003). A critical pitfall in the application of glycotargeting is the potential overloading of the sugar 
density upon which a higher proportion of cellular uptake will take place non-specifically probably via 
the Kupffer cell receptors (Davis and Robinson, 2002).  
Wu and others in the late 1980’s demonstrated successful liver gene transfer in in vivo investigations upon 
administration of poly-L-lysine (PLL)-asialoorosomucoid linked complexes. Galactose presenting 
complexes may avoid serum protein interaction due to their electric neutrality. The galactosylation of 
cationic liposomes thus appears to be an effective mechanism to achieve effective hepatocyte targeting 
(Kawakami et al., 2008). A variety of galactose and lactose terminated compounds including 
asialoorosomucoid, galactosylated poly-L-glutamic acid, asialofetuin glycopeptide, lactosylceramide and 
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others which have been applied as ligands for liver targeting liposomes, polymers and nanoparticles 
(Zhang et al., 2007).  While the reductive amination of galactose with lactose results in the production of 
galactosyl residue, the reductive amination of galactose with galactose results in an acyclic modification 
which lectins find difficult to recognise (Davis and Robinson, 2002). 
Further modifications, this time, in the length of the spacer between the sugar and the backbone of  the 
polymer can increase the uptake of these molecules and their contents (Davis and Robinson, 2002). This 
improvement in transfection has been observed with an increase in the length of the spacer that links the 
cholesterol and galactosyl moieties together. Furthermore the affinity of ASGP-R binding appears to 
show significant dependence on the galactose and N-acetylgalactosamine residues in addition to the space 
between the respective galactose residues (Singh and Ariatti, 2003).  Shigeta and co workers (2007) 
developed a carrier Gal-C4-Chol that was modified to contain an imino group for electrostatic binding of 
plasmid DNA as well as a galactose residue for specific recognition by asialoglycoprotein receptors 
exclusively expressed on mammalian hepatocytes.  
Glycosylated liposomes have also been developed and their effect determined for liver targeting whereby 
the use of cationic lipoplexes composed of glycosylated cholesterol were capable of producing a 10 fold 
enhancment in liver gene expression. Liver cancer is another significant target for gene therapy with 
hepatocellular carcinoma being attributed as a leading cause of deaths across the world (El-Aneed, 2003). 
Other potential ligands for drug delivery that act as enhancers of penetration and drug adsorption are bile 
salts and glycyrrhizin as  a result of their specific affinities for hepatocytes (Kawano et al., 2002).  
It is interesting to note that in addition to the effect of the physiochemical properties of the carrier vector, 
the structure of the ligand grafted to the carrier also plays an influential role in determining the amount 
delivered through systemic administration to the receptor positive cells. For receptor mediated cellular 
internalization of carbohydrates both receptor recognition and cell surface accessibility play a major role. 
Hashida and co-workers (2001) explained that for effective hepatocyte targeting the size of 
galactosylated-cationic liposome-DNA complexes must be condensed to a diameter of 150 nm. Since 
charge is also a siginificant determining factor for cationic liposome based gene delivery, the positive 
charge that is displayed should not be too elevated as this will enhance non-specific interactions. The in 
vitro and in vivo transfection efficiencies are also influenced by the lipidic composition of theses 
complexes. Control of these parameters consequently are essential to the in vivo gene transfer mediated 
by glycosylated liposome carriers. The Gal-C4-Chol cationic lipoplexes have been found to be efficiently 
recognized and internalized by the HepG2 asialoglycoprotein receptors leading to expression of the 
transgene (Hashida et al., 2001).  
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1.4.  IN VIVO STUDIES AND REQUIREMENTS 
The liver makes up approximately one-fiftieth of the total adult body weight and recieves about 25% of 
cardiac output. The liver system consists of both biliary and blood circulation systems. The biliary system  
is responsible for connecting the apical surface of all hepatocytes to the duodenum via the canals of 
Hering. The sinusoid is the terminus for all blood vessels in the liver and is known to possess a 
discontinous endothelium. Furthermore the absence of a basement membrane permits improved 
permeability and translocation of molecules less than 100 nm in size to the basolateral surface of the cells. 
Thus the liver is one of the most amenable organs to gene delivery, as it assumes a pivotal role in a 
number of acquired and genetic disorders (Hara et al., 1997; Suda et al., 2009).  
The liver acts as a protein factory for serum circulating polypeptides and numerous enzymes. It comprises 
different cell types such as hepatocytes (liver parenchymal cells) which are the predominant cell type, 
sinusoidal endothelial cells and Kupffer cells resident in the macrophages of the liver. An estimated 80% 
of the liver mass is composed of hepatocytes which are the main targets for gene transfer in the treatment 
of several genetic disorders. These cells are round in shape and contain a nucleus and a significant amount 
of cellular organelles associated with metabolic and secretory functions. To provide support for the 
metabolic functions there exists an abundance of mitochondria acting as an energy supply. Since the liver 
is involved in the circulation of blood, this makes the liver parenchymal cells the attractive prospects that 
they are for the treatment of a multitude of liver associated diseases through the application of gene 
therapy (Pathak et al., 2008).  
Liver transplantation has been established as a successful treatment for hepatic failure caused by acute or 
chronic liver disease. As a treatment modality, liver transplantation, is instigated by a shortage of donor 
tissue thus alternative approaches must be developed (Kren et al., 2002). For the successful treatment 
prolonged expression of the transgene is essential, however, this has been most successfully achieved 
using retroviral vectors in reimplantation and partial hepatectomy (Hara et al., 1997). 
The first liposome systems applied to liver targeted gene delivery were anionic liposomes which only 
achieved low level transfection and transient gene expression. However, they showed that intravenous 
administration of liposomes for liver specific gene transfer could be realized (Heller et al., 1996). 
Cationic liposomes were thus applied for this purpose and have been successful in vitro while evaluations 
for successful in vivo application are ongoing. After the success achieved with DC-Chol numerous 
cationic cholesterol derivatives were synthesized and investigated. From this it became clear that the 
linker and cationic head group of these amphiphilic molecules are critical to their ability to produce 
expression of the transgene and toxicity. Due to the need for repetitive dosing as a result of their limited 
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period of gene expression, complexes containing a carbamate ester linker are generally recommended. 
Ding and colleagues (2008) provided both in vitro and in vivo confirmation that lipoplexes displaying a 
slight excess positive charge were in fact more effective than the negatively charged or almost neutral 
lipoplexes in producing higher levels of gene expression within tumour tissues. 
The use of large-scale screening of available liposome carriers for in vivo gene transfer has enabled the 
elucidation of a vast array of highly active compounds. DMRIE for example has achieved successful 
transfer of therapeutic and reporter genes to solid tumours in both preclincal and clinical trials while 
several lipids including DOTMA have been reported to elicit potent reporter gene signals in a variety of 
tissues. Consequently much screening and empirical testing is needed for the development of cationic 
liposomes specific for particular in vivo applications. These cationic lipids may also be introduced into 
synthetic artificial viruses to enable non-viral vector targeting (Clancy and Sorscher, 1999). 
It has been suggested that the use of highly stabilized lipoplex structures can produce elevated levels of 
transfection in vivo. Furthermore those possessing a spaghetti like structure at optimal transfection 
concentrations and diameters ressembling that of the nuclear pore may potentially be the ideal cationic 
lipoplex for active transfection in vivo. This potential arises from the similarity of the spaghetti structures 
to the microvilli where they are highly curved with small radii, thus allowing for effortless adherence and 
fusion to flat cells. Additionally the excess of positive charge at their surface promotes fusion with both 
the cell and nuclear membranes thus enabling DNA transfer through the cytosol and to the nucleus (Ma et 
al., 2007). It has been reported previously that the salt concentration can play a significant role in the 
stability of galactosylated lipoplexes for enhanced in vivo hepatocye specific gene expression, where the 
presence of an essential quantity of sodium chloride for the prepartion of lipoplexes could stablize their 
final form in accordance with the surface charge regulation theory (Pathak et al., 2008).  
The introduction of genes into experimental animal models and in human trials which produces either 
general or tissue specific expression may permit the specific manipulation of biological processes in vivo 
with the intention of treating disease and protection against pathogens through induced immune response. 
The administered lipoplex is thought to also undergo alterations with regard to its physical properties, the 
extent of which is based on the level of interaction with the biological fluids. Some routes investigated by 
radiologists for therapeutic gene delivery to the liver are direct percutaneous injection, and transcatheter 
intra-arterial or intraportal administration (Choi et al., 2002).  
Kawakami and colleagues (2008) identified that a lower charge ratio of the lipoplex is favoured for 
intraportal administration of galactosylated DNA lipoplexes for ASGP-R targeting. This is due to the 
interaction with the biological mileu which has posed significant issues to both in vivo and in vitro 
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conditions. Moreover the association of both polyplexes and lipoplexes with erythrocytes results in an 
accumulation in the lung for expression (Kawakami et al., 2008). In contrast intratumoural injection 
involves little interaction with the biological fluids and there are few or no changes to the physical 
properties of the lipoplex. Intravenous administration comparatively results in altered size, structure and 
net charge of the lipoplex prior to reaching the target cell (Li and Huang, 2000). Cationic formulations 
composed of Gal-C4-Chol were shown to produce improved transgene expression in liver parenchymal 
cells exclusively on portal vein administration (Wu et al., 2002). It has been reported that the tail vein 
injection of 25 μg of plasmid DNA with the luciferase reporter into rodents could produce nanogram 
levels of the gene product per milligram of protein in the tissue extract (Kay et al., 1997).  
Viral or synthetic carrier mediated gene transfer mechanisms can take place either by ex vivo or in vivo 
methods of cellular entry. Ex vivo refers to the incubation and transfection of the vectors with human cells 
derived directly form the patient which are then returned to bring about a therapeutic event. The in vivo 
model (Figure 1.4) on the other hand involves systemic delivery either by general administration or local 
injection directly into the tumour (Safinya et al., 2006). In general both viral and non-viral vectors are not 
liver specific, although the exceptions of recombinant adenoviruses and some targeted vectors do exist. 
Consequently these vectors must be injected into the liver peritoneal cavity; infused into the portal or 
hepatic vein; or instilled into the bile duct, if they are to realize effective delivery. Despite the intravenous 
administration, liposomes show an innate affinity for the liver, without the presence of a targeting ligand 





Figure 1.4: In vivo gene therapy performed by targeting the gene delivery system to the desired cell type 
in the patient using either physical tissue injection (brain tumour) or biolistics (dermal DNA 
vaccination), or potentially using systemic infusion of cell-specific receptor-mediated DNA 
carriers (reconstructed liposomes or viruses) (Miesfeld, 2001). 
 
The in vivo requirements for efficient transfection, in the most part, differs from that achieved in cell 
culture and consequently some of the more effective complexes for in vivo studies are lost at the level of 
in vitro cell culture analyses (Nchinda et al., 2002). An inherent problem with in vivo gene targeting, is 
the low transfection levels which are difficult to detect and analyze. Hence, there is a need for an accurate 
and sensitive measurement system for these low level systems (Ino et al., 2005).  
Targeting to the hepatocytes is not only attractive, but also a practical consideration as they express an 
abundance of hepatic lectins on their sinusoidal plasma membrane domain facing the capillaries. They 
display in particular the asialoglycoprotein receptor presented at an approximate 105 – 5x105 binding sites 
per cell (Pathak et al., 2008). In addition, their physicochemical properties play a determining factor for 
the amount transferred to the target site upon systemic administration. The establishment of delivery 
systems with biological and physicochemical properties necessary for site directed delivery of plasmid 
DNA, is important for in vivo expression. Stablility in vivo of the DNA-carrier complexes is reliant on the 
size of both nucleic acids and polycationic carriers. For effective recognition by asialoglycoprotein 
receptors, the carriers employed should contain a significant amount of galactose residues in their 
structures. Despite the grafting of the sugar moiety to the carrier vector, Nishikawa and co workers (1998) 
44 
 
showed that successful delivery of the plasmid DNA could not be realized as the cationic complexes may 
distribute to various cell types upon systemic administration. For administration to mice the complexes 
were designed to possess a weak negative charge which could emphasize the specific hepatocyte uptake 
via receptor-mediated endocytosis. During receptor-mediated endocytosis the larger sized particles rarely 
reach the hepatocytes as the number of fenestrae having a diameter of larger than 200 nm in the liver 
sinusoid is very few (Nishikawa et al., 1998).  
Both extracellular and intracellular problems to gene delivery exist in vivo (Finsinger et al., 2000). To 
maintain stability of the liver, it is typically protected against foreign genetic material via the existence of 
intra- and extracellular barriers. One barrier to both viral and non-viral systems upon administration to the 
lung is the apical membrane of the intact epithelial airways, as this is the most fortified boundary 
providing protection from the hostile environment (Klink et al., 2004). The lung poses as the first obstacle 
facing liver targeted gene therapy, however, the promise of gene therapy may yet be achieved through the 
use of gene therapy to the lung for the successful treatment of cystic fibrosis nad lung neoplastic disease 
(Ding et al., 2008). 
A further concern with systemic gene therapy is direct tumour targeted delivery (Wolschek et al., 2002). 
In addition to its regular degradative effect, serum may penetrate into the lipoplex structure interfering 
with the packaging of the DNA. This results in nucleic acid unfolding with subsequent protrusion at the 
lipoplex surface thus causing interference with further cell surface interactions down the line (Wasungu 
and Hoekstra, 2006). Lipoplex association with negatively charged blood components causes the 
production of large aggregates which have the potential to be adsorbed onto the surface of circulating 
blood cells, trapped in a thick mucous layer or embolized in microvasculature thus inhibiting their 
localization at their intended target (Gao et al., 2007). 
Non-viral vectors that produce effective gene transfer in vivo have yet to be realized. To produce systems 
for broad range applicability transgene expression must be extended. The generally transient expression 
produced by non-viral vectors may be attributed to their inability for either intergration or 







1.5.  THESIS OUTLINE 
 
Amongst its many potential applications, gene therapy is also being investigated for the treatment of both 
benign and malignant tumours. Thus the development of novel vectors that are safe and effective for both 
the in vitro and in vivo application is receiving much attention.The requisite high titre administration of 
some viral vectors is known to produce severe hepatic inflammation while others pose challenges of 
random chromosomal DNA intergration. Non-viral transfer of nucleic acids has proven safe and nontoxic 
in the treatment of human melanoma. Of the different vector systems, cationic liposomes have been 
revealed to be effective therapeutically in benign and malignant diseases in tested animal models (Hui et 
al., 1997 cited in Mohr et al., 2001).  
 
In this thesis the delivery of plasmid DNA using various cationic liposome formulations both in vitro and 
in vivo has been evaluated. Cationic liposomes were produced with a cationic cholesterol derivative Chol-
T in association with the neutral lipid DOPE. Furthermore macrocyclic crown ethers were incorporated 
with the cytofectin and DOPE to produce liposomes. A distinct obstacle encountered by approaches to 
gene therapy is the ability to achieve effective delivery of functional therapeutic genes into the target cells 
(Hwang et al., 2001). In order to assist in this regard both targeted and untargeted liposomes were 
synthesized by incorporation of unprotected glucosyl and galactosyl moeities. These were prepared with 
the primary aim of specifically targeting the asialoglycoprotein receptors present on the liver hepatocytes. 
 
The first step in the investigation is the formulation of the above mentioned liposomes and the 
characterization of their structure, size and distribution assessed by transmission electron microscopy 
using a negative staining – vitrification protocol. The liposome – DNA complexes were analyzed in much 
the same manner, however, the interaction between the liposome and DNA was also assessed by agarose 
gel electrophoretic retardation and ethidium bromide displacement assays. Thereafter the in vitro 
trasfection efficiency of plasmid DNA complexes with cationic cytofectin and crown ether containing 
liposomes at different mixing ratios were empirically examined in the human hepatocellular carcinoma 
cell line HepG2 (ASGP-R positive) and the human embryonic kidney cell line HEK293 (ASGP-R 
negative) in terms of their physiochemical properties. The transfection activity and growth inhibition of 
these cationic liposomes were determined using the luciferase reporter gene assay with the pCMV-Luc 
plasmid and crystal violet growth inhibition assay respectively. This was also assessed in vivo in NMRI 




The primary goal of this investigation was to produce cationic liposomes capable of high transfection 
activity in vitro that could be successfully applied to the in vivo situation, in the hope of overcoming the 
descrepancies often found to exist between the two models. Improvement in liver targeting through the 
application of receptor specific ligands as well as a better understanding of the effects of the crown ether 








2. LIPOSOMES SYNTHESIS AND STRUCTURAL CHARACTERIZATION 
2.1. INTRODUCTION 
The principal mechanism of intracellular liposomal drug delivery has shown a strong dependence on 
liposomal composition. This and other factors provide a means for liposomal classification into five 
catergories listed below and of which four are represented in Figure 2.1: 
i. Conventional liposomes; 
ii. pH sensitive liposomes; 
iii. Cationic liposomes; 
iv. Immunoliposomes; and  
v. Long-circulating or stealth liposomes. 
 




During their formative years liposomes were prepared from a variety of lipids which were analogous to 
those in biological membranes (Kozubek et al., 2000). This innate correlation with natural cell 
membranes has made liposome vectors the favoured biocompatible drug delivery system (Figure 2.2). 
Liposomes are established as microscopic vesicles composed of single or multiple bilayers encasing a 
watery or aqueous interior (Sharma and Sharma, 1997; Chaudhuri, 2002).  Liposomes that comprise lipid 
layers with an internal water phase have the capacity to encapsulate both water soluble and lipophilic 
drugs; and their behavior in vivo may be controlled through surface modification (Maitani et al., 2001). 
 
Figure 2.2:  Showing acceptance of the liposome into the cell and the membrane similarity between both 
the liposome and cell (Adair, 2005). 
Liposomes have been placed into three categories of classification, viz: 
i. Multilamellar vesicles (MLV) (0.1 – 0.5 µm); 
ii. Large unilamellar vesicles (LUV) (> 0.06 μm); and  
iii. Small unilamellar vesicles (SUV) (0.02 - 0.05 μm). 
Description of liposome preparations traditionally involve the parameters of size and lamellarity rather 
than method of preparation whether they be described as reverse-phase evaporation (REV), French press 
vesicles (FPV) or ether injection vesicles (EIV) (Vemuri and Rhodes, 1995). The production of these 




Figure 2.3:  Stepwise mechanism and processing for the generation of various types of vesicles (Patel, 
2006).  
Thin film rehydration is one of the most commonly applied methods of preparation involving the 
hydration of a thin film of lipids with an aqueous buffer above the lipid transition temperature. This 
procedure results in heterogeneous populations having diameters between 1 – 5 μm. Although widely 
used and simple to apply, an associated disadvantage is the relatively poor encapsulation of hydrophilic 
drugs. Liposomes can be prepared to display high levels of entrapment through the freeze-drying of pre-
formed SUV and dispersion in an aqueous solution containing the drug under investigation. Furthermore 
by performing liposome hydration using a buffer in the presence of an organic solvent, the efficiency of 
encapsulation achieved by these liposomes can be improved (Sharma and Sharma, 1997).  
A variety of techniques are available for the production of these large vesicles such as solvent injection 
using ether or ethanol, detergent dialysis, calcium induced fusion as well reverse phase evaporation 
(Batzri and Korn, 1975; Skoza and Papahadjopoulos, 1978; Sharma and Sharma, 1997). In comparison to 
multilamellar vesicles unilamellar liposomes have the capacity to carry large volumes of solution in their 
cavity. Additional advantages of unilamellar liposomes include a reduction in the amount of lipid 
employed resulting from the larger capacity for drug encapsulation as well as reproducible rates of drug 
discharge (Vemuri and Rhodes, 1995).  
In general large unilamellar liposomes may experience reduced physical stability in the presence of a 
deficiency of surface charge leading to self aggregation. Neutral liposomes due to the anionic nature of 
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the cellular surface cannot associate successfully necessitating cellular drug entry through extracellular 
release from the liposome. The size of liposomes is an important factor in determining the proportion that 
is cleared by RES where small liposomes are opsonized to a lesser degree than the larger liposomes. 
Accumulation of liposomes in the tumour tissues has been attributed to a reduction in liposomal size and 
partly to the enhanced half life of circulating small liposomes. Many techniques have been employed to 
bring about size reduction of MLV or LUVs including sonication (bath or probe type), extrusion or 
micro-fluidization (Sharma and Sharma, 1997). The bath sonicator has shown numerous advantages of 
use including temperature control and product processing in an aseptic environment. Previous attempts at 
sonication of MLVs to produce the small unilamellar vesicles were performed under the effects of 
nitrogen or argon, alternatively injection of ether or ethanol can be used in their preparation (Vemuri and 
Rhodes, 1995). 
Cationic liposomes have, since their introduction into the world of gene therapy established themselves as 
the foremost synthetic vectors available (Lin et al., 2003). The unilamellar liposomal vesicles are 
produced through a variety of different methods including; sonication, detergent removal or through 
membrane extrusion to provide uniform liposomes (Dass and Choong, 2006; Uddin, 2007). The head 
group of cationic amphiphiles, typically consist of primary, secondary, tertiary amines or quaternary 
ammonium salts. However, some studies have also explored the potential of incorporating imidazole or 
guanidino groups (Lv et al., 2006; Kim et al., 2009). The presence of the cationic charge on the 
amphiphilic lipid distinguishes it from its natural phospholipid structural analogue which may be negative 
charged or neutral depending on the pH of the environment (Rao, 2010).  
Cholesterol and its derivatives have also often been introduced into liposome formulations to improve 
bilayer stability. Their inclusion has improved membrane fluidity and stability in the presence of blood, 
plasma or other biological fluids, and minimized permeability to water soluble molecules (Vemuri and 
Rhodes, 1995).  Owing to its stable association with the liposomal membrane, cholesterol is often chosen 
as the hydrophobic anchor in liposome formulations (Hashida et al., 2001).  
Despite the wide array of techniques available for liposome formulation only a handful may afford a large 
enough capacity for water-soluble drugs (Vemuri and Rhodes, 1995). The preparations of liposomes 
involves the dissolution of the respective components in an organic solvent followed by subsequent 
drying to produce a thin film. Thereafter a liposome suspension can be obtained through the dispersion of 
the film in an aqueous solution at a critical hydrating temperature which should be above the phase 
transition temperature of the employed phospholipid (Biju et al., 2006).  
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In the case of lipid mixtures prepared in the presence of organic solvents, both the lipid mixture and 
contaminants present in the solvent are concentrated on solvent evaporation. Liposomal stability is of 
primary importance at all points of their preparation, from initial processing, storage and administration. 
In this regard the fusion and breakage during storage results in the undesired vesicular drug leakage. The 
pH, buffer used, solvent system and ionic strength play a siginificant part in influencing the stability of 
liposome formulations. and liposome shelf-life. Some organic solvents employed for the facilitation of 
uniform lipidic dispersion are freon, methylene chloride, methanol, ethanol and chloroform and their 
combinations. When determining the solvent for use, factors such as safety, solubility and purity need to 
be considered. Chloroform although efficient for lipid dispersion, contains the carcinogen, carbon 
tetrachloride. Therefore when intended for human applications it is of the utmost importance to ensure 
complete removal of the solvent (Vemuri and Rhodes, 1995).  
Liposomal formulations may have short shelf lives, due to the level of chemical and physical stability 
which is dependent on the liposomal composition. This can be explained by the chemical oxidation of 
fatty acids in phospholipids which result in reaction products that may alter bilayer permeability. The 
storage stability of liposomes may be increased through preservation by lyophilization of the liposomes. 
To ensure suitable quality control liposomes need to undergo characterization promptly upon preparation 
as well as during storage. The size and size distribution of liposomes have been previously successfully 
examined using freeze-fracture electron microscopy and dynamic light scattering to monitor vesicle 
stability (Sharma and Sharma, 1997).  
This chapter involves the preparation of nine novel cationic liposomes and crown ether (CE) cationic 
liposomes with and without targeting moieties. All contain the cationic cholesterol derivative, 3 β [N-(N’, 
N’-dimethylaminopropane)-carbamoyl] cholesterol (Chol-T) and the neutral lipid 
dioleoylphosphatidylethanolamine (DOPE). Characterization of all liposome preparations was performed 









2.2. MATERIALS AND METHODS 
2.2.1. Materials 
Dioleoylphosphatidylethanolamine (DOPE) was purchased from the Sigma Chemical Company, St Louis, 
USA. Chol-T cationic lipid 3β[N-(N’,N’-dimethylaminopropane)-carbamoyl] cholesterol was synthesized 
at the University of KwaZulu-Natal Department of Biochemistry, Westville, South Africa. The aza-15-
crown-5, aza-18-crown-6 ether preparations crown ethers (CE) 1 and 2 respectively as well as the RUI-90 
and RUI-92 unprotected galactosyl and glucosyl targeting preparations were synthesized at the University 
of Witwatersrand, Johannesburg, Department of Chemistry. The 2-[4-(2-hydoxyethyl)-1–piperazinyl] 
ethanesulphonic acid (HEPES) was purchased from Merck, Darmstadt, Germany.  The Uranyl acetate 
(ACS) of molecular weight 425.15 Daltons, depleted of radioactivity was obtained from Ted Pella Inc. 
All other chemicals were of analytical grade. 
 
2.2.2. Methods 
2.2.2.1. Preparation of cationic liposomes 
The cationic liposomes were prepared in accordance with an adaptation of the protocol employed by Goa 
and Huang (1991). This was due to the cationic liposomes investigated displaying only a slight variation 
in chemical structure compared to that originally synthesized by Goa and Huang. The components used 
are presented in Table 2.1. The liposome preparations were made up to contain a total of 4 µmoles of lipid 
in 1 ml of HEPES buffered saline (HBS). All liposome preparations contained the cytofectin 3 β [N-(N’, 
N’- dimethylaminopropane)-carbamoyl] (Chol-T) that was originally synthesized in our laboratory from 
cholesteryl chloroformate according to the scheme presented in Figure 2.4. The structures for the crown 
ethers RUI-128 and RUI-129 as well as the targeting moieties RUI-90 and RUI-92 are shown in Figure 
2.5. The general method for the synthesis of CE 1(RUI-129) and CE 2 (RUI-128) are shown in Figure 
2.6. The 1,3-dipolar cyclo-addition reaction or Click reaction were performed by using Cu(II)SO4 in 
presence of sodium-ascorbate using dichloromethane:water (3:1) to afford the  novel triazole linked 
cholesterol derivatives. These were then deacetylated using K2CO3 in methanol (10 ml) to produce the 
unprotected targeted sugar moieties. This scheme is presented in Figure 2.7. 
The lipid mixtures were prepared in the presence of the chloroform. The liposome lipidic components 
were dissolved in chloroform, mixed and deposited as thin films in test tubes by rotary evaporation of 
solvent in vacuo (Büchii Rotavapor-R). Samples were dried under high vacuum in a drying pistol for 
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several hours. The thin film of the samples was then rehydrated in a total volume of 1 ml containing 
sterile HBS (20 mM HEPES and 150 mM NaCl, pH 7.5). All preparations were vortexed and hydrated 
over night. Following this, preparations were sonicated for 5minutes in a bath sonicator (Labotech 



































Chol-T 2 1.03 2 1.49 - - - - - - - - 
Chol-T-Gal 1.8 0.926 2 1.49 - - - - 0.2 0.135 - - 
Chol-T-Glu 1.8 0.926 2 1.49 - - - - - - 0.2 0.135 
Chol-T/RUI-
128 
2 1.03 1.8 1.34 0.2 0.135 - - - - - - 
Chol-T-RUI-
128-Gal 
1.8 0.926 1.8 1.34 0.2 0.135 - - 0.2 0.135 - - 
Chol-T-RUI-
128-Glu 
1.8 0.926 1.8 1.34 0.2 0.135 - - - - 0.2 0.135 
Chol-T-RUI-
129 
2 1.03 1.8 1.34 - - 0.2 0.126 - - - - 
Chol-T-RUI-
129-Gal 
1.8 0.926 1.8 1.34 - - 0.2 0.126 0.2 0.135 - - 
Chol-T-RUI-
129-Glu 
1.8 0.926 1.8 1.34 - - 0.2 0.126 - - 0.2 0.135 






    
 











Figure 2.4: Reaction scheme showing the preparation of the cationic cholesterol derivative Chol-T from 






Figure 2.5: Structures of crown ethers and targeting components used for the various liposome 
preparations: (a) Aza-18-crown-6 (RUI-128), (b) Aza-15-crown-5 (RUI-129), (c) 
cholesteryl galactosyl (RUI-90) and (d) cholesteryl glucosyl (RUI-92). (Compounds 
synthesized and provided by Islam, R.U., Professor C.B. de Koning, Professor W. Van 
Otterlo and Professor P. Arbuthnot). 
 
 
Figure 2.6: (a) Chemical synthesis scheme of the structural moieties (b) and (c) attached to (x) 
cholesterol derivatives. (b) = CE 1 (RUI-129) and (c) = CE 2 (RUI-128) (Adapted from Islam 




Figure 2.7: Schematic showing the click reaction for the production of the deacetylated sugar moieties 
conjugated to cholesterol derivatives. Showing the introduction of  Cu(II)SO4 (0.1mmol) and 
sodium-ascorbate (0.1mmol) to an alkyne (1mmol) and azide (1.2 mmol) solution in 
DCM:water (3:1). Upon drying with MgSO4 the crude solid was purified by column 
chromatography using 50% ethyl acetate: hexane. K2CO3 in methanol was used for 
deacetylation producing unprotected sugar moieties conjugated to cholesterol by a 
triazole linker. X = NH, Sugar moiety= Galactose and glucose (synthesis provided by Islam, 




2.2.2.4. Characterization of liposomes by transmission electron microscopy (TEM) 
Cationic liposome preparations were diluted 1:5 with HBS to promote fluidity of the samples.  Aliquots 
of 1 µl of each diluted sample were placed on Formvar coated grids with a 1 µl aliquot of a saturated 
solution of the uranyl acetate negative stain. The coated grids were then allowed to stand for 3 – 5 
minutes after which the excess liquid was removed with filter paper. For the crown ether liposome 
formulations the grids were coated with carbon prior to use. The samples were immediately vitrified by 
plunging into liquid nitrogen cooled propane gas, using a spring-loaded Leica CPC system.  Grids were 
then transferred to a Gatan cryotransfer system and viewed using a JEOL 1010 TEM without warming 
above -150ºC. The electron micrographs, obtained from this negative staining – vitrification 
methodology, were subjected to statistical analysis to assess the size and dimensions of the liposome 
formulations. 
 
2.2.2.5. Statistical analysis 
Particle sizes of the different liposome preparations were analyzed using a matched student t-test. 
P-values of less than 0.05 were considered to be of statistical significance. 
 
2.3.  RESULTS AND DISCUSSION 
2.3.1.  Preparation of Cationic Liposomes 
Cationic liposomes were prepared successfully using the method described in section 2.2.2.1. The two 
major ingredients in all liposome preparations were the cytofectin Chol-T and the neutral zwitterionic 
phospholipid dioleoylphosphatidylethanolamine (DOPE) which is employed as a helper or co-lipid.  The 
Chol-T was synthesized according to a procedure reported by Singh and co-workers (2001). Being 
described as cationic amphiphiles this implies the presence of both a hydrophobic and hydrophilic region 
within the lipid. The cationic amphiphile examined here has a cholesterol ring anchor, a carbamoyl linker 
bond and a monovalent dimethylamino head group (Wasungu and Hoekstra, 2006).  The incorporation of 
cationic lipids into liposomal membranes is known to adjust the vascular structure. Cholesterol 
derivatives such as this are in general unable to produce stable bilayers in liposome formulations unless 
they include neutral lipids such as DOPE or cholesterol in their preparation (Hattori and Maintani, 2005). 
Cholesterol, for example is responsible for controlling membrane fluidity and permeability (Obata et al., 
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2009). The use of DOPE or cholesterol for application of cationic lipids in transfection has been reported 
to induce the conversion of the lamellar lipoplex phase into the hexagonal conformation which enhances 
the effectiveness of transgene expression. The ratio of helper lipid to cationic lipid determines toxicity 
and transfection efficiency (Morille et al., 2008).  
Pedersen (1967) showed that of the solvents used for the solublization of crown ethers, formic acid, 
chloroform, ethylene dichloride and pyridine were the best, while ethers, methanol, water and other 
alcohols were moderate to very poor solvents for these compounds.  In our preparation of cationic 
liposomes with crown ether (CE) functionalities chloroform was used as the organic solvent resulting in 
complete dissolution of the crown ethers. Our preliminary investigations showed that the CE’s although 
known to form micellar structures, were unable to form liposomes in the absence of cationic lipids 
(results not shown). 
For the targeted liposome formulations RUI-90 and RUI-92 targeting moieties were employed in the 
liposomes.  The ligands were designed to specifically target the asialoglycoprotein receptors (ASGP-R) of 
liver hepatocytes.  In their synthesis the targeting moieties were prepared using click chemistry to bridge 
the sugar moiety to the cholesteryl anchors. In this study, the novel unprotected galactosyl and glucosyl 
cholesterol derivatives were formulated in cationic liposomes to specifically target the ASGP-R on the 
hepatocyte derived cell line HepG2 in culture.  
 
2.3.2. Characterization of Liposomes by Transmission Electron Microscopy 
Transmission electron microscopy using the negative staining-vitrification protocol (outlined in section 
2.2.2.4.) revealed the sizes and unilamellar structure of the different cationic liposome preparations 
(Figures 2.8 to 2.10).  Cationic liposomes showed a broad size range of 30 nm to 650 nm in diameter. The 
















Chol-T 68.40 39.31 
Chol-T-Gal 37.24 21.05 
Chol-T-Glu 64.75 30.62 
RUI-128 528.52 89.73 
RUI-128-Gal 96.20 19.8 
RUI-128-Glu 37.36 5.74 
RUI-129 124.28 23.98 
RUI-129-Gal 54.06 12.04 
RUI-129-Glu 80.71 3.80 
Note: Data presented as mean ± standard deviation (n = 5). 
From the results it is clear that those liposome preparations incorporating the galactosyl and glucosyl 
targeting ligands display a reduced diameter size. It can also be noted that the CE 2 formulation consisting 
of the aza-18-crown-6 ether moiety produced distinctly large liposomes. This may be attributed to the 
large crown ether (CE) cavity that it possesses, having an average cavity size of 2.6 – 3.2 Å. The Chol-T 
and CE 1 liposomes displayed liposome diameters that fall within the range of  30 – 530 nm. The 
relatively low standard deviations indicate only a slight divergence in particle size, while those displaying 
higher standard deviations show greater size variation within a liposome population. Preparations were 
not extruded through defined pore size membranes. 
A result may be considered statistically significant if the p-value is below the preset threshold of 0.05. In 
this regard both targeted preparations of Chol-T showed no significant size variation compared with the 
untargeted Chol-T liposome (p > 0.05). On the other hand all crown ether (CE) liposomes showed 
statistically significant differences in size between the targeted and untargeted preparations (p < 0.05). 
Moreover a comparison of the Chol-T liposome and both CE liposomes revealed statistically significant 
size variations between it and each of the crown ether liposomes. This provides us with comparative 
information of the different liposomes in terms of their size distribution. 
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All liposome preparations showed a generally spherical morphology, with some showing a deformed 
nature which could be attributed to manner in which the samples were frozen, rendering the liposomes 
immobilized and in some instances deflated. Artifacts seen in some of the liposome images are attributed 
to the cryo-TEM process. Moreover any stippling in the micrographs can be attributed to the propane 
employed in the above mentioned freezing protocol or the carbon coating used on Formvar grids 
employed for viewing the crown ether preparations. The carbon coating was essential for the examination 
of crown ether preparations as the ether present in the formulation was observed to corrode the delicate 
Formvar grids, making it impossible to view the micrographs. Although TEM provides a more than 
adequate preliminary examination of the size and relative distribution of liposomes in a given sample 
there are many techniques available that can provide more significant information on the distribution of 
the liposomal population.  Two such techniques are dynamic light scattering and zeta-sizing, which were 





Figure 2.8:  Transmission electron micrographs of cationic liposomes. (a) Chol-T, (b) Chol-T -Gal, (c) 







Figure 2.9: Transmission electron micrographs of cationic liposomes. (a) RUI-128, (b) RUI-128-Glu, (c) 





Figure 2.10: Transmission electron micrographs of cationic liposomes. (a) RUI-129, (b) RUI-129-Glu, 








3.  PREPARATION AND CHARACTERISATION OF LIPOSOME – DNA COMPLEXES 
OR LIPOPLEXES 
3.1. INTRODUCTION 
Plasmids are exciting polynucleotides that have been the primary focus of research and application in 
gene therapy due to the flexibility of their production which offers numerous advantageous prospects. 
Their capacity to be engineered to incorporate large DNA segments enables transfection of a large open 
reading frame or combinations of genes (Ahearn and Malone, 1999).  
The spontaneous association of cationic liposome head groups with plasmid DNA is the first step in the 
transfection process mediated by cationic lipid molecules and results in the formation of a heterogeneous 
lipoplex (Figure 3.1) (Reimer et al., 1997; Ferrari et al., 2001).  Monocationic lipids notwithstanding their 
need for a relatively high minimum positive charge, can achieve effective DNA binding through self 
assembly resulting from their hydrophobic tail alignment. These vectors can be regarded as multipurpose 
constructs as they provide a multivalent surface to which the plasmid DNA can bind electrostatically, thus 
offering protection and charge neutralization. This neutralization consequently leads to the collapse of the 
plasmid DNA structure producing small distinct particles that are compliant with the requirements of the 










Figure 3.1:  Illustration of the formation of cationic liposome-DNA complex showing electrostatic 
binding of positively charged liposome to negatively charged DNA. (Diagram not drawn to 
scale). 
 
Typically lipoplexes are prepared by combining DNA and liposome solutions at room temperature and 
have been drawing attention ever since Felgner and co workers (1997) described their potential use in 
gene therapy. Lipoplexes may be applied to in vitro and in vivo systems although endogenous DNAse 
digestion has been observed for DNA in lipoplexes tested in clinical trials (Obata et al., 2009). The 
specificity and structural requirements for effective transfection are determined by variation associated 
with liposomal arrangement and are dependent upon both the size and charge ratio of the lipoplex (Russ 
and Wagner, 2007). The final size of the complex produced is proportional to the mass of the nuleic acid 
compacted by the vector (Uddin, 2007). Although size is a critical factor to be considered particularly for 
in vivo studies a perfect complex size has not been agreed upon with earlier reports indicating sizes larger 
than 200 nm were effective and more recent efforts showing the opposite to be true (Rao, 2010). 
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A positive ratio of liposome to DNA results in positively charged complexes that will repel each other 
remaining as distinct entities. The DNA association may, however, be limited by the presence of half the 
positive charges on the interior of the bilayer, resulting in a higher liposome to DNA ratio (Singh and 
Ariatti, 2003). However, when the complexes are close to the isoelectric point or at lipid concentrations 
above 0.1 mM large aggregates will form on interaction due to van der Waals forces of attraction 
overcoming the weak electrostatic forces of repulsion (Lasic et al., 1997; Colosimo et al., 1999). 
Continuous aggregation of lipoplexes results in poor stability over time and necessitates their 
administration promptly on preparation. The stability of these complexes is influenced by the physical 
factors such as particle size, zeta potential, the DNA/liposome ratio and the ionic strength of the medium. 
These factors are assumed to have marked effects on complex formation and ultimately the efficiency of 
transfection (Wasungu and Hoekstra, 2006; Uddin, 2007).  
In order to develop and optimize cationic lipid formulations capable of effective transfer of therapeutic 
nucleic acids, many studies have concentrated on the structure-function relationship of cationic lipids and 
DNA (Zuhorn et al., 2002). DNA is known to carry 20 phosphate groups per helical pitch of 34.1 Å and 
on complete condensation will have its counter-ions released and replaced by the cationic lipid as 
illustrated in Figure 3.2 (Rädler et al., 1997; Wagner et al., 2000). This results in an increase in entropy 
that drives the reaction and compensates for changes in positive enthalpy that is known to occur upon 
interaction of pure cationic lipids with DNA (Barenholz, 2001; Pozharski and MacDonald, 2002; 
Goncalves et al., 2004). The formation of the liposome-DNA complex is a highly dynamic process 
involving two steps, the first of which is a fast exothermic process ascribed to the electrostatic binding of 
the DNA to the surface of the liposome. The second process involves a slow endothermic reaction which 
may potentially be attributed to the subsequent fusion of the two entities and the associated structural 





Figure 3.2: Diagram of cationic lipid-DNA complex formation, illustrating the presence of loosely bound 
counter-ions in the vicinity of both cationic liposomes and DNA. (A) Unilamellar cationic 
lipid vesicle. (B) Naked DNA. (C) Multilamellar complex. (D) DNA coated cationic lipid 
vesicle. (E) Released counter-ions resulting in a gain in entropy (Pozharski and MacDonald, 
2002).  
 
During lipoplex formation it is understood that the DNA molecule undergoes several changes on 
condensation and charge neutralization. In addition there is liposome restructuring and fusion producing 
large aggregates and involving release of its aqueous contents (Khalil et al., 2006;  Hoekstra et al.,, 2007). 
Liposomal restructuring was confirmed by electron microscopy presenting elongated rod-like structures 
together with globular particle aggregates (Gershon et al., 1993). After investigation of these aggregates 
using cryoelectron microscopy and small angle X-ray scattering studies it was found that an internal 
multilamellar structure existed, within which the hydrated DNA and lipid bilayers alternate (Lasic et al., 
1997; Radler et al., 1997; Goncalves et al., 2004). 
Despite being widely used for gene transfer, the physical and chemical characteristics of cationic 
liposome – DNA (CL – DNA) complexes are not well distinguished. A plethora of morphological 
structures have, however, been revealed using freeze fracture microscopy including beads on a string 
(Gershon et al., 1993) (Figure 3.3), spaghetti and meatball, multilamellar (LαC) and the inverted 
hexagonal (HIIC), in addition to the recently identified map-pin and sliding columnar phase structures (Ma 
et al., 2007). Questions pertaining to the relationship between the efficiency of delivery as well as the 
micro- and macroscopic structure of the complex together with the physical mechanisms of complex 
formation are still rife despite the great strides made in both their biomedical and biophysical studies 




Figure 3.3: Cartoon of a „beads-on-a-string‟ (i.e. cationic liposomes attached to a string of DNA) 
complex electrostatically bound to the anionic surface of an animal cell. The enlargement 
shows a Cationic liposome bound to a section of negatively charged DNA on one side and 
the plasma membrane with cell surface proteoglycans and negatively charged sulphated 
groups on the other side (Safinya, 2006).  
 
The “beads on a string” structure involving a strand of DNA distinctly decorated with attached liposomes 
was one of the first models described and was confirmed by electron microscopy (Gershon et al., 1993; 
Rädler et al., 1997). Thereafter „spaghetti and meatball‟ structures were proposed that are believed to 
comprise semi-fused liposomes connecting DNA and tube-like structures that may be representative of 
lipid coated DNA.  DNA stability in addition to the mechanism of nuclear delivery and expression may be 
affected by the strength of the ionic/hydrophobic interactions of the lipid with DNA. It may be necessary 
to develop lipid based carriers that yield complexes which are stable against circulating enzymes yet 
permit the dissociation of lipid from the DNA after entry into the cell through the maintenance of strong 
ionic/hydrophobic interactions (Reimer et al., 1997; Xu et al., 1999).  
The inverted hexagonal (HIIC) and the more abundant lamellar (LαC) liquid crystal phases (Figure 3.4) are 
equilibrium structures for the CLs – DNA complexes and although capable of comparative transfection, 
their mechanisms vary greatly as a consequence of their structures. Over and above the rigidity and 
membrane composition, the structure of the DNA complexes is determined by the molecular shape and 
preferred lipid curvature. Evidence for this can be seen in the tendency of DOPE to promote the HIIC 
phase, due to its cone-shaped molecular structure (Ewert et al., 2006). Whether or not the cationic 
liposome-DNA complex will take on its preferred morphology is known to be dependent on the chemical 
nature of the zwitterionic or helper lipid (Khalid et al., 2008). The DNA in this regard is identified in a 
transmembrane orientation to avoid exposure to the lipid tails, while interaction with the lipid headgroup 
results in the deformation of the bilayer in the vicinty to DNA. The presence of the neutral helper lipid 
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DOPE can cause looser binding of the cationic lipid with DNA as can be identified on ethidium bromide 
intercalation analyses (Wasungu and Hoekstra, 2006).  The lamellar form of lipoplexes results in a 
condensed globular structure containing DNA monolayers sandwiched between cationic bilayers and is 
characterized by uniform inter-helical spacing. Alternatively the inverted hexagonal phase comprises 
cationic lipid coated DNA monolayers on a two dimensional hexagonal lattice (Morille et al., 2008).  
 
Figure 3.4: Schematic representation of lamellar or inverted hexagonal phase structure in the formation 
of lipid-DNA complexes (lipoplexes) (Morille et al., 2008). 
 
Since zwitterionic and negatively charged liposomes are unable to effectively encapsulate DNA, the DNA 
must either be made more lipophilic or carried by cationic liposomes. The liposome –DNA association is 
believed to occur in one of two ways. The first involves the DNA being electrostatically adsorbed onto 
the cationic liposome surface and is referred to as the „external model‟, while the second termed the 
„internal model‟ suggests that the DNA is encased in a lipid envelope (Ma et al., 2007). It is thus 
generally accepted that cationic lipids will offer their DNA cargo more protection than the non-cationic 
lipids as enclosure within a liposome depends on a good entrapment efficiency to provide optimal 
protection (Legido and Abell, 1998).  
For our own investigations synthesized cationic liposomes were used mixed with plasmid DNA. The 
resulting lipoplexes were further characterized in respect to their size, shape, degree of condensation, 
binding and protection of DNA against serum nuclease digestion. Agarose gel electrophoresis was 
employed to examine the electrostatic interactions between the positive charge of cationic liposomes and 
the negatively charged anionic DNA molecules which lead to, binding and compaction of the nucleic acid 
into the lipoplex (Hasegawa et al., 2002). The level of DNA condensation within the lipoplexes was 
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estimated using the ethidium dye displacement protocol. Serum is considered to dramatically affect the 
biophysical and transfection properties of lipoplexes. It is assumed to lead to significant aggregation 
causing further associations and disintergration with the subsequent release and destruction of DNA (Li 
and Huang, 2000; Wattiaux et al., 2000). Cationic liposomes such as those investigated are known to 
afford DNA in lipoplexes protection against DNAse I digestion; however, upon complex dissociation this 
protection is lost (Xu and Szoka, 1996). Moreover, the presence and morphology of the lipoplexes was 
verified using transmission electron microscopy (TEM). 
 
3.2. MATERIALS AND METHODS 
3.2.1.  Materials 
Ultra pure DNA grade agarose was acquired from Bio-Rad Laboratories, Richmond, USA.  pBR322 
DNA was purchased from Roche Diagnostics, Mannheim, Germany. Ethidium bromide was obtained 
from Merck, Darmstadt, Germany.  All other chemicals were of analytical grade. 
3.2.2. Methods 
3.2.2.1.  Gel retardation assays 
In essence the agarose gel mobility shift assay is used to analyze this ability of  the positive charges 
present on liposome molecules to neutralize the negative charges of the DNA phosphate backbone 
producing electroneutral complexes that cannot migrate during electrophoresis (Huang et al., 1998). The 
charge ratio as can be determined through analysis of mobility shift assays as well as zeta potential are 
significant in understanding the interaction between the DNA and the cationic lipid within the complex as 
well as with the cell as a whole. When the charge ratio approaches 1 there is aggregation of the complex  
together with a reduction in zeta potential (Zhdanov et al., 2002). 
3.2.2.1.1. Gel retardation of:      
a) Chol-T : DNA,  
b) Chol-T-Gal: DNA and, 
c) Chol-T-Glu: DNA 
A 1% agarose gel was prepared by dissolving 0.2 g of agarose in 18 ml of 18 Mohm water. To this 
ethidium bromide was introduced at 1μg/ml. This was then left to set for a minimum of 45- 60 minutes. 
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A fixed amount of pBR322 DNA (0.5 µg) was added to increasing amounts of Chol-T cationic liposome 
(0, 1, 1.5, 2, 2.5, 3, 3.5, 4 µg), respectively.  This was made up to a final volume of 7 µl with HBS. 
Similar incubation mixtures were set up with the cationic RUI-90 and RUI-92 targeted liposomes at 
increasing amounts of (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg). Complexes were allowed to incubate for 30 
minutes at room temperature. Thereafter 2 µl of gel loading buffer (50% glycerol, 0.05% bromophenol 
blue, 0.05% xylene cyanol) was added to all samples.  The samples were subjected to electrophoresis on 
1%  agarose gels in a Bio-Rad electrophoresis tank containing electrophoresis buffer (36 mM Tris-HCl, 
30 mM sodium phosphate, 10 mM EDTA pH 7.5), for 90 minutes at 50 volts.  The gels were thereafter 
viewed under UV transillumination and images captured using the Vacutec Syngene G: Box gel 
documentation system.   
3.2.2.1.2. Gel retardation of:      
a) RUI-128 : DNA,  
b) RUI-128-Gal: DNA and, 
c) RUI-128-Glu: DNA 
The gel retardation of these liposomes was carried out using the procedure as outlined above in section 
3.2.2.1.1.  A constant amount of pBR322 DNA was introduced to each sample tube containing increasing 
amounts (0, 1, 1.5, 2, 2.5, 3, 3.5, 4 μg) of the crown ether cationic liposome RUI-128.  The same principle 
was applied to the two RUI-90 (Gal) and RUI-92 (Glu) targeted liposomes at the liposome amounts of (0, 
2, 2.5, 3, 3.5, 4, 4.5, 5 μg). These samples were then incubated at room temperature for 30 minutes.  
Thereafter samples were incubated and subjected to electrophoresis as described in 3.2.2.1.1.  
3.2.2.1.3. Gel retardation of:      
a) RUI-129 : DNA,  
b) RUI-129-Gal: DNA and, 
c) RUI-129-Glu: DNA 
The reaction mixtures were prepared according to section 3.2.2.1.1 where varying amounts of RUI-129 : 
DNA (0, 2, 2.5, 3, 3.5, 4, 4.5, 5 μg), RUI-129-Gal (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg) and RUI-129- Glu (0, 
1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg) were incubated with 0.5 μg of pBR322 plasmid DNA and incubated at room 





3.2.2.2. Nuclease protection assay 
Lipoplexes were preformed and analyzed to determine the protection offered by the different liposome 
preparations to the DNA against nuclease attack. Varying amounts of cationic liposomes (Table 3.1) were 
added to a constant amount of pBR322 DNA (1 µg).  This was made up to a final volume of 10 µl with 
HBS.  The samples were allowed to incubate for 30 minutes at room temperature.  Foetal bovine serum 
(FBS) was thereafter added to the complexes to a final concentration of 10%, based on published methods 
obtained from literature (Huang et al., 1998).  Two controls were employed, a negative control containing 
only pBR322 DNA and a positive control containing only pBR322 DNA and FBS.  The samples were 
then incubated for 4 hours at 37°C.  After the incubation period, the chelator ethylenediaminetetraacetic 
acid (EDTA) was added to the samples to a final concentration of 10 mM to stop the nuclease reaction 
and sodium dodecyl sulphate (SDS) to a final concentration of 0.5% (w/v), to liberate DNA for migration.  
The samples were thereafter incubated for a further 20 minutes at 55°C.  Thereafter the samples were 
subjected to electrophoresis on a 1% agarose gel (as per 3.2.2.1) for 120 minutes at 50 volts.  Following 
electrophoresis, the gel was stained with ethidium bromide (1 µg/ml) for 20 minutes, and images captured 














Table 3.1:  Nuclease protection assays. Component ratios of liposomes as indicated were incubated with 
pBR322  DNA (1 µg) and FBS (10%, v/v). 
 
3.2.2.3. Ethidium bromide intercalation assay 
In order to ascertain the ability of the liposomes to compact DNA an ethidium displacement or ethidium 
bromide intercalation assay was carried out using a Shimadzu RF – 551 Spectrofluorometric Detector 
which was set at an excitation wavelength of 520 nm and an emission wavelength of 600 nm. . Ethidium 
bromide, a widely used label for fluorescent detection of DNA, intercalates between base pairs of the 
DNA double helix producing an intense fluorescence (Xu and Szoka, 1996). The level of condensation is 
important particularly at the point of endosomal escape for delivery of DNA therapeutic drugs (Lasic et 
al., 1997).  
Initially 10 µl (1 µg) of an ethidium bromide stock solution (100 µg/ml) was added to 500 µl of HBS in a 
quartz microcuvette and measured to obtain a baseline relative fluorescence reading of zero.  The 100% 
relative fluorescence was set by introducing 24 µl (6 µg) of pBR322 DNA to the HBS-ethidium bromide 
mixture.  Thereafter 1 µl aliquots (approximately 2.5 µg) of liposome preparation were systematically 
LIPOSOME PREPARATION 
 
LIPOSOME AMOUNT (µg) DNA (µg) 
Chol-T 3 4 5 1 
Chol-T: Gal 5 6 7 1 
Chol-T: Glu 5 6 7 1 
RUI-128 6 7 8 1 
RUI-128: Gal 7 8 9 1 
RUI-128: Glu 9 10 11 1 
RUI-129 5 6 7 1 
RUI-129:Gal 3 4 5 1 
RUI-129: Glu 3 4 5 1 
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added to the mixture and readings taken until approximately 12 - 25 µg of each liposome preparation had 
been added or until a plateau in readings had been reached.  In order to ensure an accurate reading the 
solution was mixed to promote full dispersion of the liposome in the solution thereby encouraging 
complete compaction of the DNA. The results obtained were plotted relative to 100% fluorescence.  This 
procedure was employed for all liposome preparations discussed. 
 
3.2.2.4. Transmission electron microscopy  
Characterization of cationic liposome – DNA complexes was carried out as outlined in chapter 2 section 
2.2.2.3. 
 
3.2.2.5. Statistical analysis 
A comparison of the particle sizes of the different lipoplexes was analyzed using a matched 
student t-test. P-values of less than 0.05 were considered to be of statistical significance. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Gel retardation assays 
3.3.1.1. Gel retardation of:      
(a) Chol-T : DNA,  
(b) Chol-T: Gal: DNA and, 
(c) Chol-T: Glu: DNA 
The results for the agarose gel electrophoresis of these three liposome formulations can be seen in Figure 





    
 
(a)                                   (b)                      (c) 
 
Figure 3.5: Agarose Gels showing the liposome – DNA binding by the different cationic liposome 
preparations. Reaction mixtures of samples in lanes 1 – 8 consisted of varying amounts of 
liposome in 20 mM HEPES, 150 mM NaCl (pH 7.5), shown below. pBR322 DNA was 
maintained at a constant 0.5 µg.   
(a.) Chol-T, (0, 1, 1.5, 2, 2.5, 3, 3.5, 4 μg) 
(b.) Chol-T-Gal, (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg) and 
(c.) Chol-T-Glu (0, 1, 1.5, 2, 2.5, 3, 3.5, 4 μg) 
 
Table 3.2: DNA – Liposome ratios of complete and optimal binding 
Liposome 
Preparation 
Optimal Retardation conditions 
Liposome (μg) DNA: Liposome 
Ratio (w/w) 
DNA: Liposome 
Charge Ratio (-ve/+ve) 
Chol-T 2 1 : 4 1 : 1.1 
Chol-T-Gal 3 1 : 6 1 : 1.6 








3.3.1.2. Gel retardation of:      
(a) RUI-128 : DNA,  
(b) RUI-128: Gal: DNA and, 
(c) RUI-128: Glu: DNA 
Figure 3.6 below shows the results of the agarose gel retardation studies of these three liposome 
formulations. The retardation information gathered has been compiled in Table 3.3.  
 
(a)                                               (b)                                               (c) 
 
Figure 3.6: Agarose Gels showing liposome – DNA binding by the different cationic liposome 
preparations (a – c). Reaction mixtures of samples in lanes 1 – 8 consisted of varying 
amounts of liposome in 20 mM HEPES, 150 mM NaCl (pH 7.5), shown below. pBR322 
DNA was maintained at a constant 0.5 µg.   
(a) RUI-128, (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg) 
(b) RUI-128-Gal, (0, 2, 2.5, 3, 3.5, 4, 4.5, 5 μg) and 
(c) RUI-128-Glu (0, 2, 2.5, 3, 3.5, 4, 4.5, 5 μg) 
Table 3.3: DNA – Liposome ratios of complete and optimal binding 
Liposome 
Preparation 
Optimal Retardation conditions 
Liposome (μg) DNA: Liposome 
Ratio (w/w) 
DNA: Liposome 
Charge Ratio (-ve/+ve) 
RUI-128 3.5 1 : 7 1 : 1.9 
RUI-128-Gal 4 1 : 8 1 : 1.8 
RUI-128-Glu 5 1: 10 1 : 2.3 
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    3.3.1.3. Gel retardation of:      
(a) RUI-129 : DNA,  
(b) RUI-129: Gal: DNA and, 
(c) RUI-129: Glu: DNA 
Figure 3.7 shows the results of the agarose gel electrophoresis of the above samples. The charge and 
DNA binding ratios are outlined in Table 3.4. 
 
(a)                                            (b)                                              (c) 
Figure 3.7: Agarose Gels showing liposome – DNA binding by the different cationic liposome 
preparations. Reaction mixtures of samples in lanes 1 – 8 consisted of varying amounts of 
liposome in 20 mM HEPES, 150 mM NaCl (pH 7.5), shown below. pBR322 DNA was 
maintained at a constant 0.5 µg.   
(a) RUI-129, (0, 2, 2.5, 3, 3.5, 4, 4.5, 5 μg) 
(b) RUI-129-Gal, (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg)  and 
(c) RUI-129-Glu (0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 μg) 
 
Table 3.4: DNA – Liposome ratios of complete and optimal binding 
Liposome 
Preparation 
Optimal Retardation conditions 




RUI-129 3 1 : 6 1 : 1.97 
RUI-129-Gal 2 1 : 4 1 : 0.93 




From the results it is evident that all liposome formulations are capable of binding DNA successfully. For 
all gel retardation studies (Figure 3.5 – 3.7) the first lane of all gels contained the control pBR322 DNA 
alone, displaying the three conformations of undigested DNA migrating through the gel. These bands 
moving slowest to fastest were the nicked, linearised and supercoiled DNA. This plasmid DNA migrates 
freely toward the cathode of the electrophoresis apparatus. Upon introduction of liposome at varying 
amounts, less DNA is able to move through the agarose gel matrix. This inhibition of DNA migration will 
proceed to a point at which the DNA is completely bound or retarded by the liposome preparation. This is 
known as the point of electroneutrality, where as mentioned earlier all negative charges are completely 
titrated by the cationic liposome in what is termed an electroneutral complex. This is evidenced by the 
DNA retained in the wells of the agarose gel. Beyond this point the complexes possess an excess of 
positive charge and are drawn toward the anode. Aggregated complexes may also float out of wells. 
The targeted formulations of both Chol-T and RUI-128 were required at higher quantities for DNA 
binding as shown in Tables 3.2 and 3.3. This was in contrast to the targeted RUI-129 liposomes which 
were able to completely bind DNA at lower concentrations than the untargeted variety (Table 3.4).  
The Chol-T preparation (Figure 3.5.a.) showed the ability to form electroneutral complexes at a DNA 
ratio of 1:4 using 2 μg of liposome to completely neutralize the negative charges of 0.5 μg of plasmid 
pBR322 DNA.  This is in contrast to earlier studies (Singh et al., 2001) that have reported slightly higher 
ratios of DNA retardation with the Chol-T liposomes. This interaction between the cationic liposome and 
the plasmid DNA backbone is known to affect the organization of the solvent present around the lipoplex 
ultimately resulting in the restriction of the number of sites available for plasmid DNA binding (Ferrari et 
al., 2001). This could account for some preparations resulting in more or less restriction of these binding 
sites depending on their composition and interaction with the surroundings. The resulting potential 
shielding effect could be responsible for the higher amount of liposome required for optimal binding of 
the DNA by the targeted preparations. The targeting ligands in this regard may potentially adumbrate 
some of the positive charge centers. Moreover evaluation of the RUI-128 crown ether (CE) liposomes 
showed a larger concentration of the targeted preparations being employed for optimal DNA retardation. 
However, on closer evaluation of their respective charge ratios, almost all formulations whether targeted 
or not required close to 2 positive charges to neutralize 1 negative. The large cavity of the crown ether 
head may play a role in this potential masking of the positive charges. The aza-18-crown-6 employed is 
known for its ability to bind large cations, potassium in particular. Its bulky nature may play an, as yet, ill 
defined role in DNA binding. 
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In contrast the RUI-129 liposomes with their smaller crowns provide less inhibitory shielding potential. 
Remarkably the targeted formulations here were able to achieve effective DNA retardation at a ratio of 
1:4, lower than that achieved by the untargeted liposome. It may be possible that rearrangements on 
formulation has resulted in more of the cationic Chol-T cytofectin being present at the liposome surface 
leading to these preparations being able to bind DNA at lower concentrations.  
In all liposome preparations there exists an excess of the neutral lipid DOPE in contrast to the other 
components. It is thus possible that this excess could cause a greater internalization of the Chol-T during 
formulation. If this were to be the case, then this effect would lead to different consequences with respect 
to the different formulations. The targeted Chol-T-Gal and Chol-T-Glu having lower amounts of Chol-T 
in their formulation than the untargeted Chol-T liposome require more liposome to completely retard the 
pBR322 plasmid DNA. Once again the same could be said for the targeted and untargeted RUI-128 
liposomes, which showed a higher amount of positive charges required for optimal DNA binding. Finally 
on application of these suppositions to the RUI-129 CE preparations we find that despite this possible 
effect of DOPE in the formulations, the targeted liposomes were able to produce optimal DNA retardation 
using very low amounts of liposome. Therefore with respect to these particular preparations, the strong 
binding of the CE with small cations (Na+) could assist significantly in improving the interaction of the 
liposomes with the DNA through the formation of an additional cationic head. The same may occur for 
the RUI-128 liposomes; however, their crown could prove more inhibitory than advantageous as a result 
of the potential steric hindrance associated with the much larger cavity size. 
The information extracted from these agarose gel electrophoresis studies will be used to produce 
transfection complexes for transfection experiments in the HEK293 and HepG2 cell lines (Chapter 4). 
The resulting lipoplexes show sensitivity to the DNA-liposome charge ratio where low charge ratios are 
associated with poor transfection due to possible nucleic acid exposure. Although cationic liposomes are 
capable of negative charge neutralization the quantity of DNA required and the optimal ratio of DNA 
phosphate to cationic lipid for efficient transfection vary for the different cell types (Reimer et al., 1997). 
As such the reaction complexes were formulated at the optimal DNA: liposome ratio as well as at a ratio 
before (slightly negative) and one after (slightly positive). 
 
3.3.2. Nuclease Protection Assay 
The results from the serum nuclease protection studies as carried out by agarose gel electrophoresis can 




Figure 3.8:  Serum nuclease protection assay of the DNA-cationic liposome complexes containing Chol-
T, Chol-T-Gal and Chol-T-Glu, respectively.  
Lane 1:       pBR322 DNA (1 μg).  
Lane 2:       Naked pBR322 DNA (1 μg) in the presence of 10% (v/v) serum for 4 hours.  
Lanes 3-5:   DNA-cationic liposome complexes with Chol-T (3, 4 and 5 μg).  
Lanes 6-8:   DNA-cationic liposome complexes with Chol-T/ Gal (5, 6 and 7 μg).  





Figure 3.9:    Serum nuclease protection assay of the DNA-cationic liposome complexes containing RUI-
128, RUI-128-Gal and RUI-128-Glu, respectively.  
Lane 1:        pBR322 DNA (1 μg).  
Lane 2:         Naked pBR322 DNA (1 μg) in the presence of 10% (v/v) serum for 4 hours.  
Lanes 3-5:   DNA-cationic liposome complexes with RUI-128 (6, 7 and 8 μg) with serum 
10%.  
Lanes 6-8:   DNA-cationic liposome complexes with RUI-128-Gal (7, 8 and 9 μg) with 
10% foetal bovine serum.  
Lanes 9-11:  DNA-cationic liposome complexes with RUI-128-Glu (9, 10 and 11 μg) with 







Figure 3.10: Serum nuclease protection assay of the DNA-cationic liposome complexes containing RUI-
129, RUI-129-Gal and RUI-129-Glu, respectively.  
Lane 1:       pBR322 DNA (1 μg).  
Lane 2:        Naked pBR322 DNA (1 μg) in the presence of 10% (v/v) serum for 4 hours.  
Lanes 3-5:   DNA-cationic liposome complexes with RUI-129 (5, 6 and 7 μg).  
Lanes 6-8:   DNA-cationic liposome complexes with RUI-129-Gal (3, 4 and 5 μg).  
Lanes 9-11: DNA-cationic liposome complexes with RUI-129-Glu (3, 4 and 5 μg).  
 
In this analysis the different liposomes were tested for their ability to protect the integrity of the DNA to 
which they are complexed. The ratios for this were determined by the gel retardation or mobility shift 
studies in section 3.3.1. This assay provides information as to the ability of the complexes to successfully 
navigate the conditions of the in vivo system where they will be faced with different cellular barriers, 
particularly serum nucleases. 
Two controls were employed for all three agarose gels shown above, viz. pBR322 plasmid DNA alone, 
and pBR322 plasmid DNA in the presence of 10% foetal bovine serum. The reasoning behind these 
controls is to identify the extent of the serum nuclease degradation on naked DNA compared to that of 
undigested DNA. The DNA is complexed with varying amounts of liposome and incubated in 10% serum 
(Huang et al., 1998). Once liberated the DNA migrates through the agarose gel so that its integrity or 
extent of degradation may be observed. 
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From this study it is evident that the introduction of liposomes to the DNA provides complete protection 
against the effect of nucleases present in the serum (Figure 3.8 – 3.10).  All liposomes afforded the DNA 
protection at all three ratios analyzed, i.e., at, before and after electroneutrality or the optimum DNA: 
liposome ratio. Lane 2 in all gels gives a clear indication of the effect of serum on DNA, where all DNA 
has been degraded. In contrast lane 1, with no serum shows intact plasmid DNA. Since the liposomes 
were able to release the DNA in its original form we can confirm their ability to protect DNA hence 
underscoring their value as suitable transfection agents. The banding pattern observed for DNA released 
from all investigated lipoplexes shows a clearly defined third band, which may be identified as the nicked 
or open circular conformation of the DNA. High charge ratios of liposome : DNA correlate with a high 
capacity to circumvent the serum effected impediment on lipofection (Chaudhuri, 2002). A possible 
explanation for this protection could be the degree of binding and compaction involved in the formation 
of the highly organized supramolecular structure of the lipoplex and the electrostatic forces responsible 
for it. 
Nuclease digestions were conducted at 37 oC for 4 hours, the same conditions under which cells are 
exposed to lipoplexes in transfection studies in vitro. Hence it can be taken from this study that all the 
liposomes formulated show a good degree of serum stability and protection of DNA under these 
conditions and in the presence of 10% foetal bovine serum. 
 
3.3.3. Ethidium Bromide Intercalation Assay 
DNA is known to be condensed by liposomes in lipoplexes, a property that was confirmed with the 
ethidium bromide dye displacement protocol as outlined in section 3.2.2.3. The results from this study on 













Figure 3.11:  Ethidium bromide intercalation assay for cationic liposomes. The volume of incubation 
mixtures was 500 µl and contained 6 µg pBR322 and increasing amounts of liposome. (a) 














Figure 3.12:  Ethidium bromide intercalation assay for cationic liposomes. The volume of incubation 
mixtures was 500 µl and contained 6 µg pBR322 and increasing amounts of liposome. (a) 














Figure 3.13: Ethidium bromide intercalation assay for cationic liposomes. The volume of incubation 
mixtures was 500 µl and contained 6 µg pBR322 and increasing amounts of liposome. (a) 
RUI-129 (b) RUI-129-Gal and (c) RUI-129-Glu. 
 
As mentioned earlier, this assay can be used to analyze the interaction of liposomes and DNA within 
lipoplexes. In this assay the ethidium ions intercalate between the base pairs of the DNA double helix and 
emit an intense fluorescence at 600 nm when excited at 500 nm. Consequently the liposome-DNA 
association can be estimated by the relative decrease in fluorescence due to the liposome interacting with 
the DNA and displacing the ethidium dye (Hasegawa et al., 2002; Ueno et al., 2007). The decrease in the 
initial levels of fluorescence is brought about by the tight liposome/DNA interaction leading to DNA 
encapsulation restricting intercalation of the ethidium bromide stain (Hirashima et al., 2007). 
In our studies all liposome preparations were able to successfully displace the ethidium dye and bind the 
plasmid DNA. To the initial solution of plasmid DNA-ethidium bromide solution increasing amounts of 
the different liposomes were introduced which formed complexes with the DNA. This was continued 
until fluorescence decay reached a plateau or point of inflection. This point of leveling off represents the 
DNA: liposome ratio at which there is maximal DNA condensation and dye displacement.  
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All cationic liposomes prepared produced a decline in the fluorescence emitted to this point of inflection 
with the DNA: liposome ratios identified here showing relatively good correlation with those achieved in 
the gel retardation studies section 3.3.1., Tables 3.2 – 3.4. The Chol-T, Chol-T-Gal and Chol-T-Glu 
liposomes were found to maximally condense DNA at DNA: liposome ratios of 1: 4.62, 1: 1.2 and 1: 1. 
The RUI-128, RUI-128-Gal and RUI-Glu preparations produced a reduction in fluorescence emitted 
down to a plateau corresponding to the DNA: liposome ratios of 1: 8.3, 1: 6.64 and 1: 6.68. Finally the 
RUI-129, RUI-129-Gal and RUI-129-Glu liposomes showed the ability to completely complex DNA at 
ratios of 1: 6.6, 1: 4.2 and 1: 5.06. The slight differences observed between the two assays could be 
attributed to the highly sensitive nature of this assay. Alternatively it could be put down to the differences 
that exist between this assay and the agarose gel retardation assay. Although in general this may be 
considered as a corroborative study for the gel mobility shift analyses, some discrepancies do exist. In this 
regard the retardation studies are based on charge neutralization involving the complete association of the 
cationic liposome positive charges with the negative charges of the DNA backbone. In contrast this assay 
has its primary focus based on the condensation of DNA.  
In this assay the percentage of ethidium bromide displaced, as identified in Figures 3.8 – 3.10, is a 
reflection of the degree of DNA compaction. It is important to note also that the degree of compaction 
should not be too high as this is indicative of the DNA being bound too tightly and as such may limit the 
later steps of the transfection process when complex dissociation is essential. On the other hand it should 
also not be too low as this may induce early dissociation and subsequent DNA degradation. The Chol-T, 
Chol-T-Gal and Chol-T-Glu formulations showed a 40%, 25% and less than 10% decrease in 
fluorescence respectively at their points of inflection. The RUI-128, RUI-128-Gal and RUI-Glu 
preparations demonstrated an approximate 40%, 30% and 40% decrease in fluorescence respectively. The 
RUI-129, RUI-129-Gal and RUI-129-Glu CE liposomes produced a decrease in fluorescence of 
approximately 10%, 20% and 30% respectively. The RUI-129 liposome also showed a slight increase in 
fluorescence prior to displacing the ethidium bromide fluorophore. 
This increase could be due to the stain continuing to intercalate between the DNA even on addition of the 
first few micrograms of liposome. The relatively low percentage of fluorescence reduction is indicative of 
a low degree of DNA compaction. Despite the low concentration of liposome required for DNA 
complexation, the actual condensation of the DNA is not effective and may result in the early 
disengagement of the DNA from the liposome carrier, which may or may not be advantageous depending 




3.3.4. Transmission Electron Microscopy 
Transmission electron microscopy using the negative staining-vitrification protocol (outlined in Chapter 2 
section 2.2.2.4 and section 3.2.2.4) revealed cationic liposome-DNA complexes at varying sizes and 
distribution (Figures 3.14 – 3.16).  Cationic lipoplexes display a wide range in size from 50 nm to 300 nm 
in diameter.  The mean diameter sizes of the different CL-DNA complexes can be seen in Table 3.5 
below. 






Chol-T 185.70 53.01 
Chol-T-Gal 169.30 42.23 
Chol-T-Glu 50.48 12.47 
RUI-128 101.03 25.06 
RUI-128-Gal 130.55 102.6 
RUI-128-Glu 171.22 27.82 
RUI-129 228.84 34.82 
RUI-129-Gal 183.65 28.11 
RUI-129-Glu 131.61 57.04 
Note: The data are presented as a means, ±S.D. (n = 5). 
From the results tabulated above it is seen that all cationic liposome-DNA complexes were in the size 
range acceptable for application in vivo, but with the DNA being only moderately condensed by the 
different liposome preparations (Figures 3.11 – 3.13). The large size of the RUI-129 lipoplex, in 
particular, may be problematic for in vivo transfection experiments. The generally low standard deviations 
observed indicate a satisfactory size distribution of most of the lipoplex suspensions. Those lipoplexes 
displaying higher standard deviations show greater size variation within a liposome population, of these 
the RUI-128-Gal complex showed greatest size variation. 
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No significant divergence in size was observed between the Chol-T lipoplex preparation and the Chol-Gal 
targeted complexes; however, statistically significant variation did exist on comparison with complexes 
that were Chol-T-Glu targeted (p < 0.05). The same was observed for the RUI-128 lipoplexes, where 
statistically significant size differences were evident against the RUI-128-Glu complexes but not the RUI-
128-Gal. Furthermore both targeted RUI-129 formulations on statistical analysis showed p-values of less 
than 0.05 when compared to the targeted preparation. This is indicative of significant variations in the 
sizes of the lipoplexes produced by the different formulations. Lastly a statistical comparative of the 
Chol-T lipoplex and both CE liposome – DNA complexes demonstrated that the differences in lipoplex 
size was of statistical significance (p < 0.05). 
All preparations displayed what could be termed a spherical morphology, however, a large number of 
complexes were observed to have a deformed nature similar to some liposomes, however, more distinct. 
The deformity and any artifacts can be accredited to the cryo-TEM freezing protocol, rendering the 
liposomes immobilized, deflated or constricted. The carbon coating used for the evaluation of crown ether 
preparations could also account for the mottled effect that can be seen in some of the preparations. 
Although this technique provides a valuable understanding of the size and distribution of the DNA-











     
              (b)                                                                             (c) 
Figure 3.14: Transmission electron micrographs of cationic liposome – DNA complexes, (a) Chol-T – 










     
                                                (b)                           (c) 
Figure 3.13: Transmission electron micrographs of cationic liposome – DNA complexes, (a) RUI-128 – 











                        (b)                                                                              (c)                                                                                       
Figure 3.16: Transmission electron micrographs of cationic liposome – DNA complexes, (a) RUI-129 – 









4. TRANSFECTION AND GROWTH INHIBITION STUDIES IN CELL CULTURE 
4.1. INTRODUCTION 
The in vivo applicability of liposome-based formulations for drug and nucleic acid targeting necessitates 
the meticulous in vitro analysis for evaluation of loading capacity, entrapment stability under 
physiological conditions as well as the efficiency of loading (Schnyder and Huwyler, 2005). The analysis 
of transfection efficacy is an essential tool to the determination of the effectiveness of a particular gene 
therapy protocol. This is because it examines the quantity of exogenous DNA that is transported into cells 
and its subsequent expression of the gene (Safinya et al., 2006). ‘Transfection’, the introduction and 
consequent expression of genes within cells has allowed for developments in therapeutic and cellular 
biology through the exploitation of this technique for the treatment of disease (Hoekstra et al., 2007). 
‘Lipofection’ more particularly looks at the cationic liposome carrier mediated introduction of functional 
nucleic acids into cells in culture (Gao, 2006)  
In an attempt to rationally design and improve lipid based delivery systems an understanding of the 
interaction between the cationic liposome – DNA complex and the surface of the mammalian cell is 
essential (Ahmed et al., 2005). Complexes consisting of a mixture of oppositely charged DNA and 
cationic liposomes mimic natural viruses in their ability to act as synthetic carriers of extracellular DNA 
across outer cell and nuclear membranes for gene delivery (Reimer et al., 1997). The use of cationic 
liposomes may enhance transfection by providing an overall positive charge to the cationic liposome – 
DNA complex enabling attachment to the anionic cell surface (Radler et al., 1997). Besides the 
application of cationic liposomes, many condensing agents have been employed for the transport of 
relatively large DNA molecules such as polyvalent cations, polycations, and cationic polyelectrolytes. 
The use of these mediators of transfection allows for improved penetration by DNA due to compaction, 
modification of its superficial structure and hydrophobic properties as well as restricted particle size 
(Zhdanov et al., 2002). An evaluation of the DNA transport properties of different liposome and lipid 
formulations allows for better understanding of the cationic lipids and liposomes. Moreover the DNA 
internalization and expression of the transgene are influenced by the intrinsic physiochemical properties 
of lipoplexes and the cell-type specific factors (Colosimo et al., 1999).  
In the preparation of our synthetic gene transfection systems, cationic liposomes prepared with and 
without galactosyl and glucosyl ligands for cell specific targeting were mixed with plasmid DNA.  Gene 
expression plasmid systems are known to possess either the full gene or minigene cDNA coding sequence 
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as well as numerous other genetic elements. A minimal requirement for the transcription unit of the 
protein encoding therapeutic gene is the presence of a 5’enhancer or promoter and a downstream 
polyadenylation signal. Many promoters that have origins in eukaryotic viruses have achieved broad scale 
application and include the cytomegalovirus (CMV),  simian virus 40 (SV40), Moloney murine leukemia 
virus (MoMLV), and the Rous sarcoma virus (RSV) (Hattoria and Maitani, 2005). The pCMV-Luc 
plasmid DNA  was used in lipoplexes with several different ratios of cationic liposome to DNA prior to 
use in culture. This reporter plasmid is employed to allow for the detection of transient expression within 
these cell lines which normally do not exhibit luciferase activity. Consequently the presence of this 
activity post gene delivery is indicative of successful transgene expression. The pCMV-Luc plasmid 
encodes the luciferase gene under the control of the cytomegalovirus promoter-enhancer (Figure 4.1) 
(Elouahabi et al., 2003).  
 
Figure 4.1: Plasmid map of pCMV-Luc control vector with a CMV promoter from pcDNA3 (Schmeer, 
2008).  
 
The luciferase gene was isolated from the North American firefly Photinus pyralis. It is an ATP-
dependent luciferase that has been applied over a broad scale as a reporter enzyme for cell directed gene 
expression assays. This luciferase offers high sensitivity and large dynamic range of bioluminescence. 
However, as a catalytic enzyme of the bimolecular reaction between D-luciferin (Figure 4.2) and ATP 
which are small substrate molecules, inhibition by a variety of low-molecular-weight heterocyclic 
compounds is not unexpected. This enzyme as a reporter is expressed intracellularly and in contrast to 





Figure 4.2: Structure of firefly D-(-)-Luciferin. 
 
Two of the most important physiochemical factors implicated in cationic lipofection are size and lipidic 
composition. The effect of these factors and others were evaluated in both the human embryonic kidney 
(HEK293) and human hepatoblastoma (HepG2) cell lines through transfection of lipoplexes having 
different liposome/DNA molar ratios.  Cationic liposome–mediated transfection may also be influenced 
by the presence of particular cell surface molecules such as lectins which provide points of targeting for 
the vector system. The importance of achieving successful gene transfection for therapeutic purposes 
cannot be over emphasized and due to its need for improved DNA uptake and expression, specific ligands 
as well as antibodies have been introduced for cell specific targeting. 
It has often been overlooked in the past that the coupling ligand may not necessarily be a polypeptide, but 
also a sugar residue as found on glycoproteins and lipids. These sugar residues such as galactose are 
recognized by lectins present such as the asialoglycoprotein receptors present on the surface of 
hepatocytes (Nishikawa and Huang, 2001). This lectin was used in the first successful attempt at gene 
glycotargeting (Paillard, 1999). Moreover this receptor mediated hepatocyte derived cellular targeted 
delivery of therapeutic DNA is imperative for the development of gene therapy protocols for human liver 
diseases and disorders (Singh and Ariatti, 2003).  Among the receptors investigated for ligand targeting, 
the transferrin receptor has been one of the most frequently used, owing to its overexpression in a variety 
of tumour cells. The asialoglycoprotein receptor (ASGP-R), however, has shown the greatest gene 
targeting potential. Besides being abundantly expressed on the HepG2 cell line, it is also renowned for 
both a high ligand affinity and rapid rate of internalization. The ASGP-R and other carbohydrate receptors 
such as the mannose receptor found on macrophage and liver endothelial cells thus allow for the requisite 
cell specific delivery in liposome carrier systems (Qi et al., 2005).   Furthermore in addition to galactose 
other low molecular weight ligands, monoclonal antibodies, or macromolecules can be used to enhance 




Figure 4.3 : Illustration portraying the interaction between a targeted cationic lipoplex and a HepG2 cell. 
(Diagram not drawn to scale). 
 
Other cell surface molecules that may also play an important role are the polyanionic glycosaminoglycans 
(GAGs) which interact with lipoplexes thus inhibiting transgene expression. Negatively charged 
sulphated proteoglycans, also  present on the cell surface, may be responsible for mediating the 
electrostatic attraction between positively charged lipoplexes and mammalian cells (Bloomfield, 1991). In 
addition  to the quantity of cell surface heparin sulphate (HS), hyaluronan (HA) and chondroitin sulphate 
(CS), the type of cells and carrier employed also play a role in the inconsistencies of cellular uptake of the 
lipoplexes. Significant levels of variance in tansfection have been reported for the same lipoplex 
formulation within different cell lines (Bailey and Cullis, 1997; Uddin, 2007).  
Most analyses of liver directed gene regulation in human cells has been in either primary cultures of 
normal hepatocytes or a restricted class of human hepatoma cell lines. Primary cells are thought to more 
closely represent the human liver metabolism compared to the HepG2 cells in that they are more sensitive 
toward promutagens and express the phase I oxidative, reductive and hydrolytic enzymes at higher levels. 
Morphologically the two cell types differ with the primary hepatocytes displaying a cubic shape with 
often two nuclei, while the HepG2 cells display a more epithelial-like morphology containing one nucleus 
and a chromosome number ranging from 48 – 54 chromosomes per cell (Wilkening et al., 2003). Thus 
human hepatocytes may be considered an ideal system for in vitro analysis of toxicological and 
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pharmaceutical studies of the human liver. These hepatocytes are long-lived cells that undergo low rates 
of proliferation in culture and supply a stable environment for prolonged gene expression (Suda et al., 
2009).  
The HepG2 cell line which is a well differentiated human hepatoma derived cell line was originally 
isolated from liver biopsies of hepatoblastoma and hepatocellular carcinomas (Aden  et al., 1979; Morris 
et al., 1982).  Hepatoma cell lines such as HepG2 and Hep3B retain a differentiation status that is 
characteristic of the adult liver. The HepG2 cells used are typified for their expression of liver specific 
genes encoding plasma protein and detoxification enzymes. These cells have also aided in our 
understanding of complement biosynthesis at either the hepatic or extrahepatic levels. Many of these liver 
specific genes are regulated by nuclear proteins which are strongly localized in the liver as well as liver-
derived cell lines (Le Jossic et al., 1996; Morris et al., 1982). This cell line has also been recognized for 
its retention of a great number of liver-specific phenotypes and possesses neither the hepatitis B surface 
antigen or intergrated viral DNA (Lee et al., 1992). 
Due to the low to moderate transfection levels obtained in vivo using low doses of cationic liposomes the 
application of higher doses is most often required, often resulting in increased levels of toxicity. This fine 
balance between efficacy and toxicity has brought into focus the question of vehicle safety (Dass and 
Choong, 2006). The trasfection efficiency and toxicity that is produced by the gene delivery vectors 
employed, has been reported by Huang and co-workers (1998) to show dependence on the cell lines used 
for the investigation undertaken. The development of in vitro assays of cytoxicity has been propelled by 
the need to be able to evaluate the potential detrimental effect of a large number of compounds as well as 
to limit the experimental investigation in the animal model. There are three essential principles on which 
cytotoxicity investigations in vitro are based: 
i. The first looks at the measurement of metabolic activity where a reduction here could provide an early 
indication of cellular damage.  
ii. Membrane integrity is a parameter for the determination of cytotoxicity involving measurement of the 
lactate dehydrogenase in the extracellular medium. When cells are damaged they become leaky and as a 
result the extracellular presence of lactate dehydrogenase is indicative of cellular damage. 
iii. The final type of assay involves the detection of cell viability or cell number as the dead cells in 
adherent cell lines are known to detach and as such are removed from the system in the culture medium.  
It has been reported that evaluation of metabolic activity provides a significantly early warning of cellular 
injury while investigations on membrane integrity are often too late, identifying a far more serious injury 
and potentially cell death (Noabbiodiscoveries, www.noabbiodiscoveries.com). 
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The cytoxicity induced by chemicals can be evaluated through various assays of cultured cells. One such 
method is the quantitative colorimetric neutral red assay (NR) which measures the uptake of the neutral 
red dye that is known to build up within the lysosomes of unaffected cells. A far more popular technique 
employed widely is the MTT assay which is based on the uptake and reduction of the yellow soluble 
MTT tetrazolium by mitochondrial succinic dehydrogenase to form an insoluble blue MTT formazan 
product. Possibly the simplest and yet highly reproducible analyses of cytotoxicity is the crystal violet 
staining assay which employs a colorimetric determination of stained cells to measure the reduction in 
cellular growth rate.  Despite being convenient means of evaluating the cellular toxicity of chemicals they 
each have their own drawbacks to their application. Use of the neutral red assay can result in 
underestimation of the cytotoxic effect as a result of lysosomal swelling, while MTT formazan product 
formation may also be compromised by some reducing agents and respiratory chain inhibitors of 
mitochondrial MTT reduction. Results obtained using the crystal violet assay may vary if the culture is 
continued past confluence. Furthermore due to the non-specificity of the crystal violet staining assay, all 
adherent cells will be considered viable. These disadvantages make the need for test methods that employ 
a variety of different cytotoxicity markers evident (Chiba et al., 1998). 
Using the results obtained from in vitro cytotoxicity and transfection studies in the ASGP-R positive cell 
line HepG2 and the ASGP-R negative cell line HEK293, three liposome formulations were chosen for in 
vivo evaluation. It is important to note, however,  that although in vivo experimentaion is the next step 
following in vitro cell culture analysis, a correlation in transfection activity does not always exist between 












4.2 MATERIALS AND METHODS  
4.2.1. Materials  
HEK293 cells were obtained from Prof. P. Arbuthnot at the University of Witwatersrand. HepG2 cells 
together with irradiated foetal bovine serum were obtained from Highveld Biological (PTY) LTD., 
Lyndhurst, South Africa.  Minimum Essential Medium (MEM) containing Earle’s salts and L-glutamine, 
trypsin-versene and Penicillin (5000 units/ml) /Streptomycin (5000 μg/ml) were purchased from Lonza 
BioWhittaker, Walkersville, USA.  The pCMV-Luc control vector was obtained from the Plasmid 
Factory, Bielefeld, Germany. The Luciferase Assay kit was purchased from the Promega Corporation, 
Madison, USA.  The Bicinchoninic acid (BCA) assay reagents were purchased from the Sigma-Aldrich 
Co., St. Louis, USA.  All tissue culture plastic consumables were purchased from Corning Incorporated, 
New York, USA.  All other reagents were of analytical grade. 
 
4.2.2. Methods  
4.2.2.1. Preparation of culture medium  
MEM was prepared in 1 litre batches using 18 Mohm water and was supplemented with NaHCO3 (10 
mM), HEPES (20 mM), penicillin (5000 units/ml) and streptomycin (5000 μg/ml). The pH was adjusted 
to 7.3 – 7.4 before the final volume adjustment. The medium was filtered through a Millipore 0.22 μm 
bell filter unit into autoclaved 250 ml wide-neck blue cap bottles. This was carried out in a laminar flow 
hood using a Cole-Palmer Masterflex (model 7017-12) peristaltic pump to drive the medium through the 
filter. The medium was stored for 24 hours at room temperature in a laminar flow hood after filtration. 
The medium was then stored long term at 4°C. Sterile foetal bovine serum was introduced into the 
medium to a final concentration of 10% (v/v) prior to use. 
4.2.2.2. Maintenance and cell culture 
All media preparation and other cell culture work were performed in a class 1 laminar flow hood. All 
cells were visually inspected frequently. Frequent medium changing is important for maintaining the pH 
balance and for eliminating waste products. Cells were subcultured when they were in a semi-confluent / 
confluent state. In general, mammalian cells should be handled gently and not vortexed, vigorously 




4.2.2.3. Reconstitution, subculture and cryopreservation of cells 
An ampoule of cells was removed from the biofreezer and placed in a 37°C water bath to thaw. Following 
disinfection of the cryogenic vial with 70% ethanol, it was opened aseptically in the laminar flow hood. 
To pellet cells the cell suspensions were centrifuged at 1000 rpm (800 x g) for 5 minutes. The medium 
was decanted and the pellet resuspended in 1 ml of fresh medium (MEM +10% FCS). Cells were 
transferred to a new flask containing 5 ml of medium containing serum. Flasks were incubated at 37°C.   
Cells were allowed to attach to the flask before the medium was replaced every 2-3 days. A colour change 
in the medium from pink to orange was used as an immediate visual indicator of medium usage and the 
need for replacement. 
4.2.2.3. (a) Trypsinization and subculturing  
MEM and trypsin-versene were removed from the refrigerator and warmed to 37°C prior to use.  After 
the cells had reached semi- or complete confluency, spent culture medium was decanted. Cells were 
rinsed with 5 ml of PBS (phosphate buffered saline). PBS was decanted and 1 ml of trypsin- versene was 
added to just cover the cells in the flask. Trypsinization was allowed to proceed at 37°C for 1 – 5 minutes, 
until rounding off of the cells was observed with a Nikon TMS inverted light microscope (100 x 
magnification). The activity of trypsin-versene was inhibited by the addition of approximately 2 – 3 ml of 
complete medium (MEM + 10% FBS). Culture flasks were tapped against the palm to dislodge cells. 
Cells were then split according to a predetermined desired ratio into separate flasks / multiwell plates or 
alternatively cryopreserved. 
4.2.2.3. (b) Cryopreservation of cells  
Following dislodging by trypsinization as described in 4.2.2.3. (a.), cells were pelleted by centrifugation 
at 1000 rpm for 5 minutes. Pelleted cells were resuspended in 0.9 ml complete medium and 0.1 ml of a 
cryoprotective medium, typically dimethylsulphoxide (DMSO). Cells were then aliquoted into suitable 
cryogenic vials which were vacuum sealed prior to freezing. Cells were frozen at a rate of -1o C / minute 
to a temperature of -50°C using a cold probe. Vials were then stored at -80°C in a NUAIRE biofreezer.    
4.2.2.4. Amplification of pCMV control vector 
The pCMV-Luc control vector was amplified in the Department of Biochemistry, University of KwaZulu-
Natal according to a standard protocol. The DNA purity and concentration was determined 
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spectroscopically using a Thermo Electron Corporation Biomate 3 spectrophotometer.  The isolated DNA 
was analyzed on a 1% agarose gel against a control DNA sample to confirm purity.  
 
4.2.2.5. Cell viability studies 
Table 4.1:  DNA : cationic liposome ratios used for reaction complexes investigated in growth inhibition 












4.2.2.5.1. Growth inhibition studies in the HEK293 and HepG2 cell lines: 
HEK293 and HepG2 cells were trypsinized and seeded into two 48 well plates at seeding densities of 1.32 
× 104 cells/well and 2.52 × 104 cells/well respectively. These plates were incubated at 37°C for 24 hours. 
The cells were prepared by removing the growth medium and replacing it with serum-free medium. All 
liposome solutions were sonicated for 30 seconds prior to formation of reaction complexes with the 
pCMV-Luc DNA. Varying concentrations of these complexes were thereafter introduced to the prepared 
wells of the cell culture plates. The assays were carried out in triplicate. The cells were incubated at 37°C 
for 4 hours. Following the incubation period, the serum-free medium was removed and replaced with 
complete (serum-containing) medium. Cells were incubated for a further 48 hours at 37°C. Thereafter the 
LIPOSOME  
PREPARATION 
DNA : LIPOSOME RATIO 
(w/w) 
Chol-T 1 : 3 1 : 4 1 : 5 
Chol-T-Gal 1 : 5 1 : 6 1 : 7 
Chol-T-Glu 1 : 5 1 : 6 1 : 7 
RUI-128 1 : 6   1 : 7 1 : 8 
RUI-128-Gal 1 : 7 1 : 8 1 : 9 
RUI-128-Glu 1:8 1:9 1:10 
RUI-129 1 : 5 1 : 6 1 : 7 
RUI-129-Gal 1 : 3 1 : 4 1 : 5 
RUI-129-Glu 1 : 3 1 : 4 1 : 5 
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medium was removed from the wells and the cells were washed twice with PBS. Cells were stained upon 
addition of 200 µl of crystal violet solution (0.5% w/v crystal violet, 0.8% w/v sodium chloride, 5% v/v 
formaldehyde, 50% v/v ethanol) for 20 minutes. Stain was then removed and the cells washed extensively 
with water. The multiwell plates were dried for 24 hours and the stain extracted from the cells using 2-
methoxyethanol over a period of 36 hours, with gentle rocking (10 rev/min) on a Stuart Scientific Stiz 6 
platform shaker. Absorbance values for the samples were then read on a UV/visible spectrometer at 550 
nm (Biomate 3). 
 
4.2.2.6. Transfection studies 
4.2.2.6.1. Transfection of the HEK293 and HepG2 cell lines 
HEK293 and HepG2 cells were trypsinized and evenly seeded into two 48-well plates at densities of 2.1 x 
105 cells/well and 2.88 x 104 cells/well respectively.  The cells were allowed to attach to the wells and 
grow to semi-confluence.  The transfection complexes were prepared as in 4.2.2.5.1 in triplicate.  The 
cells were prepared by discarding the medium and replacing it with 0.5 ml serum free medium (MEM + 
antibiotics).  The transfection complexes were then added to the wells containing cells.  Two controls 
were set up, one with wells containing HepG2 cells only and the other having received only naked DNA 
(1 µg).   The multi-well plates were then incubated at 37ºC for 4 hours.  Thereafter the medium was 
replaced with 0.5 ml complete medium (MEM + 10% foetal bovine serum + antibiotics) and the cells 
incubated for a further 48 hours at 37ºC.  Following the incubation period, the cells were assayed for 
luciferase activity. 
 
4.2.2.6.2. Luciferase assay 
The luciferase assay was carried out using the Promega Luciferase Assay kit. In principle this assay 
involves the expression of luciferase in the cytoplasm resulting in the formation and decarboxylation of 
the luciferase.luciferyl-AMP intermediate to essentially produce oxyluciferin and light, shown in Figure 
4.17. The use of Coenzyme A, as in the Promega luciferase assay protocol allows for intense light 
emission that remains constant for several minutes.  The luciferase assay reagent (20 mM tricine, 1.1 mM 
magnesium carbonate hydroxide pentahydrate, 2.7 mM magnesium sulphate, 0.1 mM EDTA, 33.3 mM 
dithiothreitol, 270 µM coenzyme A, 470 µM luciferin, 530 µM ATP), was prepared by adding 10 ml of 
the luciferase assay buffer to one vial of lyophilized luciferase assay substrate.  The cell culture lysis 
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reagent (5x) (25 mM tris-phosphate, pH 7.8; 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane – N, N, 
N’N’- tetra-acetic acid, 10% (v/v) glycerol, 1% (v/v) triton X-100), was diluted with distilled water to 
produce a 1x stock.  Both reagents were allowed to equilibrate at room temperature. 
The cells were prepared by first removing the growth medium and carefully washing twice with PBS.  
Approximately 80 µl of 1x cell lysis reagent (Promega) was added to each well to cover cells; the plate 
was then placed on a Scientific STR 6 platform shaker for 15 minutes at 30 rev /min. Attached cells once 
dislodged from the wells were briefly centrifuged (5 seconds) in an Eppendorf microcentrifuge at 12 000 
x g to pellet the debris.  The cell free extracts (supernatant) were retained to be assayed for luciferase 
activity.  This was achieved by adding 100 µl of luciferase assay reagent (Promega) to 20 µl of cell free 
extract at room temperature, mixing immediately and placing the reaction mixture in a Lumac Biocounter 
1500 luminometer.  The light emission was measured for a period of 10 seconds.  Protein determination 
was performed on the cell free extracts using the bicinchoninic acid (BCA) assay. 
 
4.3. RESULTS AND DISCUSSION: 
4.3.1. Maintenance of HEK293 and HepG2 Cell Lines 
Cells were successfully propagated and maintained in complete MEM for the entire duration of study. 
The sucessful propagation of both cell types can be seen in the representaive cell lines shown in Figure 
4.4. The initial rate of cellular growth was slow, requiring 5 – 6 days to reach confluency. Thereafter a 
vast improvement in cell growth was evident upon further propagation. This increase  in growth is 
believed to be as a result of the growth factors secreted by the cells growing in the medium. Although 
both cell lines showed an early lag in cell growth the effect was more obvious in the HepG2 cell line 
which is known to display this particular characteristic. Moreover this initial retarded growth could also 
be attributed to the cells having been exposed to extended periods of cryopreservation prior to 
reconstitution. It could also potentially be due to prolonged exposure to trypsin-versene during the 
cryopreservation protocol or extensive tapping of the cell culture flask resulting in cellular shearing and 
death. Once growing at an appreciable rate the cells were trypsinized and subdivided  in 1 : 2 or 1 : 3 




Figure 4.4: Monolayer of cells at semi-confluence viewed under an Olympus fluorescence microscope 
(100 x) A. HepG2 cells and B. HEK293 cells  
 
4.3.2. Amplification of pCMV-Luc Control Vector 
The pCMV-Luc control vector was successfully amplified.  The concentration of the plasmid DNA was 
measured by UV absorption at 260 nm and adjusted to 0.25 μg/μl.  The plasmid DNA showed relatively 
high purity with the 260 nm/ 280 nm absorption ratio between 1.8 and 2. 
 
4.3.3. Cell Viability Studies 
In order to determine the potential risk of the therapeutic compounds or drugs in humans a number of 
toxicity studies have been carried out using animal models. These may not always accurately reflect 
toxicities in humans and consequently human cell culture models have been established and employed for 
toxicity assays (Wilkening et al., 2003).  
The effets on cell survival caused by the lipoplexes was determined by the crystal violet assay in both the 
human embryonic kidney (HEK293) and HepG2 cell lines. The results of these cytoxicity evaluations can 
















Figure 4.5: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 
cells in vitro. DNA was kept constant at 1 µg while varying amounts of liposome used are 
listed below.        
                       (a) Chol-T (0, 3, 4 and 5 µg/10 µl) 
                       (b) Chol-T-Gal (0, 5, 6 and 7 µg/10 µl) 
                       (c) Chol-T-Glu (0, 5, 6 and 7 µg/10 µl) 
Data are presented as a percentage of the control sample (no liposomes) and are represented 












Figure 4.6: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 
cells in vitro. DNA was kept constant at 1 µg. Liposomes were introduced at varying 
amounts.     
                       (a) RUI-128 (0, 6, 7 and 8 µg/10 µl) 
                       (b) RUI-128-Gal (0, 7, 8and 9 µg/10 µl) 
                       (c) RUI-128-Glu (0, 9, 10 and 11 µg/10 µl) 
Data are presented as a percentage of the control sample (no liposomes) and are represented 


















Figure 4.7: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 
cells in vitro. DNA was kept constant at 1 µg while liposomes were introduced at varying 
amounts. 
                       (a) RUI-129 (0, 5, 6 and 7 µg/10 µl) 
                       (b) RUI-129-Gal (0, 3, 4and 5 µg/10 µl) 
                       (c) RUI-129-Glu (0, 3, 4and 5 µg/10 µl) 
Data are presented as a percentage of the control sample (no liposomes) and are represented 





















Figure 4.8: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells 
in vitro. DNA was kept constant at 1 µg. Liposomes were used at increasing amounts. 
                       (a) Chol-T (0, 3, 4 and 5 µg/10 µl) 
                       (b) Chol-T-Gal 0, (5, 6 and 7 µg/10 µl) 
                       (c) Chol-T-Glu (0, 5, 6 and 7 µg/10 µl) 
Data are presented as a percentage of the control sample and are represented as means ±S.D. 

















Figure 4.9: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells 
in vitro. DNA was kept constant at 1 µg. Liposomes amounts were varied. 
                       (a) RUI-128 (0, 6, 7 and 8 µg/10 µl) 
                       (b) RUI-128-Gal (0, 7, 8and 9 µg/10 µl) 
                       (c) RUI-128-Glu (0, 9, 10 and 11 µg/10 µl) 
Data are presented as a percentage of the control sample and are represented as means ±S.D. 













Figure 4.10: Growth inhibition studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells 
in vitro. DNA was kept constant at 1 µg with liposomes used at varying amounts. 
                       (a) RUI-129 (0, 5, 6 and 7 µg/10 µl) 
                       (b) RUI-129-Gal (0, 3, 4and 5 µg/10 µl) 
                       (c) RUI-129-Glu (0, 3, 4and 5 µg/10 µl) 
Data are presented as a percentage of the control sample and are represented as means 










Cationic amphiphiles are regarded as toxic both in vitro and in vivo as they induce several cellular 
changes including cellular shrinking, a reduction in the number of mitoses and vacuolization of the 
cytoplasm. Structurally both the hydrophobic and hydrophilic regions of the cationic lipid play a 
significant role in both transfection and the level of toxicity produced (Mohr et al., 2001). 
The untargeted Chol-T formulation showed little toxicity with maximal cell death recorded at 33% and 
25% in the HEK293 and HepG2 cell lines respectively. The targeted Chol-T-Gal and Chol-T-Glu 
produced increases in percentage cell death. Chol-T-Gal produced results of 22 and 44 % cell death 
respectively in each cell line while Chol-T-Glu showed an approximate 40 – 50% cell death in each. The 
RUI-128 CE preparation upon examination displayed the greatest levels of cell mortality at 30.4% and 
43.8% in the HEK293 and HepG2 cell lines respectively. Maximal cell death produced by RUI-128-Gal 
was at 52.2% and 44.4% in the respective cell lines while the RUI-128-Glu liposome showed cell death of 
approximately 67% and 26.1% respectively. The RUI-128 (aza-18-crown-6) formulations showed the 
highest levels of cell mortality from all liposome preparations examined. This could be attibuted to the 
large cavity size of the crown ether, where increases in the cavity size have been reported to correlate to 
increases in toxicity. Finally the RUI-129 CE formulation recorded relatively high levels of toxicity with 
maximum cell death observed at 49.5% and 62.1%  respectively. In most cases it was shown that the 
targeted liposome formulations produced increased levels of cytotoxicity. The galactosyl and glucosyl 
targeted RUI-129 preparations in contrast to the other examined targeted formulations, showed 
approximately 50% cell death in the HEK293 cell line and 35% cell death in the HepG2 cell line. 
It should also be noted from the results presented in Figures 4.8.c, 4.9.c, 4.10.c that all the glucosyl 
targeted preparations at the lower DNA: liposome ratios showed cell survival that was close to if not 
greater than that obtained with the untreated control of HepG2 cells with DNA. In general the increase in 
cell mortality can be attributed to the increase in liposome concentration. A plausible explanation for this 
could lie in a potential synergism between the cationic lipid and the plasmid DNA. Their combined effect 
to produce significant levels of toxicity was evident on comparison to the effect of either the cationic lipid 
or DNA molecule alone (Dass and Choong, 2006; Ma et al., 2007). The augmentation of this effect by 
increased concentrations of the cationic lipid in the lipoplex was observed and reported by Felgner et al., 
(1994). Moreover the steroid backbone of Chol-T is considered more inhibitory to the protein kinase C 
than the straight chain analogues and consequently is believed more cytotoxic (Mohr et al., 2001). 
Despite this, tertiary amphiphiles such as Chol-T are known to be less toxic in general than the quaternary 
amines when used in liposome formulations, while cationic lipids with a single hydrophobic tail are 
regarded as more cytotoxic than their double tailed counterparts (Tang and Hughes, 1999; Lv et al., 
2006). A possible explaination for this cytotoxicity, almost always associated with cationic liposomes in 
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lipoplexes, is the induction of pro-inflammatory cytokines (TNF-α, IL-6, IL-12 and IFN-γ) in response to 
immune cell stimulation by the unmethylated CpG motifs. These CpG sequences are identified to be 
located in plasmid DNA and in the pCMV-Luc vector employed, these sequences specifically induce 
production of the tumour necrosis factor-α (TNF-α) (Niidome and Huang, 2002; Elouahabi et al., 2003; 
Kako et al., 2008). 
Finally in addition to the cationic lipid altering the membrane surface charge, activity of the ion channels, 
receptors and enzymes as well as producing membrane perturbations the organic solvent used in liposome 
formulation is also a concern (Felgner et al., 1994; Tang and Hughes, 1999). Any residual solvent present 
in the liposome would contribute to the toxicity and stability of the lipid vesicle. These solvents exert 
their cytotoxic effect either at the molecular level involving enzyme inhibition, protein denaturation and 
membrane modification, or at the phase level involving nutrient extraction, cell wall disruption, formation 
of emulsions and cell coating (Mortazavi et al., 2007). 
 
4.3.4. Transfection Studies 
Lipofection mediated by cationic liposomes has been established as a valuable method for gene transfer 
both in vitro and in vivo. This process involves the mixing of plasmid DNA in tandem with prepared 
cationic liposome vesicles for the production of lipoplexes which go on to interact with and be 
endocytosed by the targeted cells. In general the ratio of positive charge present on the cationic liposomes 
to the negative charge on the plasmid DNA is a critical determinant involved in producing optimal 
conditions for transfection (Sakurai et al., 2000).  
The results of cationic liposome mediated transfection studies in the HEK293 cell line can be seen in 


















Figure 4.11:  Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 cells in 
vitro. DNA was kept constant at 1 µg. Liposomes were introduced at varying amounts.  
                       (a) Chol-T (0, 3, 4 and 5 µg/10 µl) 
                       (b) Chol-T-Gal (0, 5, 6 and 7 µg/10 µl) 
                       (c) Chol-T-Glu (0, 5, 6 and 7 µg/10 µl) 











Figure 4.12: Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 cells in 
vitro. DNA was kept constant at 1 µg. Liposomes were varied. 
                       (a) RUI-128 (0, 6, 7 and 8 µg/10 µl) 
                       (b) RUI-128-Gal (0, 7, 8 and 9 µg/10 µl) 
                       (c) RUI-128-Glu (0, 9, 10 and 11 µg/10 µl) 


















Figure 4.13:  Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HEK293 cells in 
vitro. DNA was kept constant at 1 µg. Liposomes were used at varying concentrations. 
                       (a) RUI-129 (5, 6 and 7µg/10 µl) 
                       (b) RUI-129-Gal (3, 4 and 5µg/10 µl) 
                       (c) RUI-129-Glu (3, 4 and 5µg/10 µl) 




















Figure 4.14:  Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells in 
vitro. DNA was kept constant at 1 µg   with liposomes introduced at varying quantities. 
                       (a) Chol-T (0, 3, 4 and 5 µg/10 µl) 
                       (b) Chol-T-Gal (0, 5, 6 and 7 µg/10 µl) 
                       (c) Chol-T-Glu (0, 5, 6 and 7 µg/10 µl) 













Figure 4.15:  Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells in 
vitro. DNA was kept constant at 1 µg while liposomes were introduced at varying amounts. 
                       (a) RUI-128 (0, 6, 7 and 8 µg/10 µl) 
                       (b) RUI-128-Gal (0, 7, 8and 9 µg/10 µl) 
                       (c) RUI-128-Glu (0, 9, 10 and 11 µg/10 µl) 












Figure 4.16:  Transfection studies of cationic liposome: pCMV-Luc DNA complexes to HepG2 cells in 
vitro. DNA was kept constant at 1 µg. Liposomes were used at varying amounts. 
                       (a) RUI-129 (0, 5, 6 and 7 µg/10 µl) 
                       (b) RUI-129-Gal (0, 3, 4and 5 µg/10 µl) 
                       (c) RUI-129-Glu (0, 3, 4and 5 µg/10 µl) 











The HepG2 cell line was employed as the targeted test cell line as it expresses an abundance of 
asialoglycoprotein receptors on the extracellular surface of its plasma membrane. In theory the liposome 
formulations presenting either galactosyl or glucosyl moieties should be directed to and internalized by 
these receptors. The HEK293 cell line which is ASGP-R negative was used as a control cell population, 
against which the activity of the liposome formulations would be tested. Transient gene expression in 
both these cell lines was detected using the luciferase assay system. This is a chemiluminescent assay for 
firefly luciferase activity. In comparison with other reporter assays used, the luciferase assay has shown 
higher levels of sensitivity, speed of reading results without sacrificing the accuracy of results. The 
overall ATP dependent reaction catalyzed by the firefly luciferase is illustrated in Figure 4.17. 
 
 
Figure 4.17: Luciferase enzyme reaction (Adapted from Roche Molecular Biochemicals, 2003).  
 
The following trends were observed in the HEK293 cell line using this luciferase assay system. Of the 
targeted and untargeted Chol-T liposomes, the untargeted Chol-T and targeted Chol-T-Gal preparations 
showed comparable transfection levels producing higher luciferase enzyme activity than the Chol-T-Glu 
liposome. The Chol-T, Chol-T-Gal and Chol-T-Glu liposomes showed optimum activity at the DNA: 
liposome ratio of 1: 5 (w/w) each. A comparative examination of Figure 4.12 (a – c) revealed the RUI-
128, RUI-128-Gal and RUI-128-Glu preparations achieved optimal transgene expression at 1: 6, 1: 7 and 
1:9 respectively. The untargeted crown ether (CE) formulation showed 3 – 8 fold greater transgene 
activity than that produced by either targeted liposome. Lastly the RUI-129 untargeted and targeted RUI-
129-Gal and RUI-129-Glu CE preparations showed maximal luciferase activity at ratios 1: 6, 1: 4 and 1: 4 
(w/w) respectively. Here again the untargeted crown ether formulation promoted the highest activity from 
all three liposomes. 
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Overall it can be noted that both untargeted CE formulations achieved the best transfection with the 
highest levels of luciferase enzyme activity. Moreover it is also clear that for all liposomes investigated 
the galactosylated cationic liposomes showed greater activity than the glucosylated liposomes in the 
HEK293 cell line.  
On transfection of the HepG2 cell line it was observed that the Chol-T and Chol-T-Glu liposomes showed 
greatest luciferase activity recorded at their optimal DNA: liposome ratios of 1:4 and 1: 6 (w/w) 
respectively, as determined by gel retardation studies. The Chol-T-Gal preparation, however, produced 
this maximal activity at a higher liposome : DNA ratio of 1: 5 (w/w). Maximal transgene expression 
based on determinations of luciferase enzyme activity was observed for the RUI-128 liposome 
formulations. Both the RUI-128 and RUI-128-Glu preparations produced optimal activity at the DNA: 
liposome ratios of 1: 8 and 1: 11 respectively. In comparison the RUI-128-Gal formulation showed 
greatest effectiveness at a ratio of 1: 7 (w/w). Moreover the RUI-129 and RUI-129-Gal liposomes 
revealed their maximal luciferase enzyme activity at their optimal DNA: liposome ratios, while the RUI-
129-Glu preparation showed its best activity at a ratio of 1: 3 (w/w). 
An overview of these results revealed that of the untargeted liposome formulations the RUI-129 CE 
preparation performed the best followed closely by the Chol-T cationic liposome. The RUI-128 liposome 
also produced reasonable activity, although not to the extent of the afore mentioned preparations. It was 
also evident from the results that all the untargeted preparations were more effective at producing high 
levels of transfection than any of the galactosylated or glucosylated formulations. This was an unexpected 
result in this targeted cell line. 
With no recorded evidence for support the following can only be postulated based on the given working 
knowledge of the targeting compounds synthesized through click chemistry. The ineffective targeting 
achieved by these ligand targeted liposomes to the asialoglycoprotein receptors could be affected by the 
length of the spacer in either the RUI-90 or RUI-92 ligands (glucosyl and galactosyl respectively). 
Kawakami and colleagues (2001) reported that the success of liposome targeting systems is dependent on 
the biochemical and physiochemical properties of the glycosylating agents. In this regard it is possible 
that although linked to a cholesterol anchor, the sugar moiety may not be able to protrude sufficiently out 
of the liposome membrane to allow effective binding. A significant impediment to transfection by 
cationic liposomes and other non-viral vectors is the ineffective liberation of DNA into the cytoplasm as 




Although it was proposed by De Smedt and colleagues (2005) that complexes with low charge ratios and 
relatively large diameters produce low levels of transgene expression, in our studies of the different 
liposome formulations, all having low charge ratios, were capable of successful transfection. The 
increases in transfection observed with CE preparations could potentially be attributed to cation binding 
capabilities resulting in an additional positive head which could thus aid in the binding of the lipoplexes 
to the cell membrane and internalization. Ewert and others (2002) reported improved levels of 
transfection achieved with a higher head group charge on the multivalent lipids. Moreover the relatively 
large lipoplex size may be a further contributing factor in this elevated production of transgene expression 
identified by the levels of luciferase enzyme activity. In this regard the assistance or contribution comes 
from the larger size of the lipoplexes resulting in their rapid settling onto the surface of the cells in culture 
(Khalil et al., 2006). 
Since our experimental evaluations of transfection were carried out in the absence of serum, other factors 
such as the release of DNA from complexes as well as complex escape from the endosome prior to 
degradation could play a role in limiting the levels of transfection activity achieved. Furthermore, besides 
testing for protection against nuclease digestion, the effect of the complexes in the presence of serum is 
relatively unknown. Further testing under in vivo conditions was thus necessary to evaluate the full 














5. TRANSFECTION AND TOXICITY ANALYSES IN VIVO 
5.1. INTRODUCTION 
Over the past three decades research relating to the development of in vivo nucleic acid delivery vectors 
has been at its height. Amongst the first non-viral vectors used in this regard were cationic lipids followed 
closely by cationic polymers. More recent developments have involved the synthesis and implementation 
of nanoparticles (Rao 2010). One of the major obstacles facing the successful delivery of therapeutic 
plasmids is the safe and efficient transport to required cells in the in vivo situation in spite of advantages 
such as ease of large scale production (Lasic et al., 1997). 
Since their introduction cationic liposomes have been synthesized to introduce plasmid DNA to cells in 
culture, animals and clinical trial patients (Figure 5.1). The inherent flexibility in the application of these 
systems has allowed for the improvement of novel approaches for the treatment of human diseases 
(Clancy and Sorscher, 1999). Clinical trials involving earlier generation cationic lipids including DMRIE 
and DC-Chol revealed that the minimal beneficial effects of transgene expression observed were 
overshadowed by their toxicity. It is important to note that the observations made in cell culture studies 
should be treated with great caution as extrapolation of this may not lead to corroborative or similar 
results with the nucleic acid carrier in vivo. Factors important in the in vivo situation are the route of 
administration and the particle diameter (Li and Huang, 2000; Chapel et al., 2004; Dass and Choong, 
2006). Furthermore in contrast to the in vitro systems which make use of complexes displaying an excess 
positive charge, the in vivo applications have employed both this as well as lipoplexes that exhibit an 




Figure 5.1: Illustration of liposome structure and potential strategies of in vivo transfection (Adapted 
from Bios Scientific Publishers, www.azonano.com. 1999).  
 
The intraportal and intravenous administration of simple cationic liposomes is associated with the 
difficulty of effective hepatocyte transfection. This is due to the liposomes’ natural preference for lung 
and reticular endothelial system (RES) targeting. In the case of intravenous plasmid DNA injection, the 
first trap met by the cationic liposome carrier is the capillaries of the lung. Consequently the lung may be 
considered the point of highest gene expression. Therapeutic undertakings involving specific liver 
hepatocyte targeting by liposome systems obviates the challenge of enhancing the hepatocyte uptake of 
liposome carriers while reducing the Kupffer cell uptake (Qi et al., 2005). Systemic DNA injection has 
proved more advantageous than the largely popular method of local injection as it allows for a far more 
even distribution of administered DNA in the liver (Niidome and Huang, 2002). Moreover intranasal 
administration has been identified as a more capable pathway than the intratracheal treatment in 
producing enhanced expression (Wheeler et al., 1996). 
In attempts to overcome this so called ‘lung trap’ of hepatocyte cell targeting, the size of the carrier 
molecules can be altered and the surface charge of the complex with DNA reduced, ultimately allowing 
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improved accumulation of therapeutic material in the liver rather than the lung for effective transfection. 
Kupffer cells of the liver, mentioned earlier, are part of the RES which is known to commonly clear out 
liposomes when administered intravenously. The primary site of liposome accumulation has in general 
been found within the non–parenchymal cells, despite their desired incorporation into the liver 
parenchymal cells as required for liposomal gene therapy (Maitani et al., 2001). The liver was chosen in 
this study for liposomal targeted for gene delivery in vivo. 
Cationic liposome-DNA complex mediated transgene expression may most certainly produce antitumour 
effects (Thurston et al., 1998). The plasmid DNA employed in this study was the Psi-CHECK plasmid 
encoding the Renilla Luciferase and Firefly Luciferase reporter genes. Succcess of this system for in vivo 
gene expression is dependent on various factors including cholesterol based liposomes, high cationic 
charge, high DNA dose and the absence of the non-methylated CpGs which are known to induce 
inflammatory cytokine expression in the immune system (Morille et al., 2008).  The requirement for 
transplantation in in vivo gene therapy has made clear the need for direct transfer of genes into the target 
tissues and cell cultures. Consequently novel glycosylated derivatives have been synthesized over the 
years for use as liver targeting ligands, however, the low antitumoural efficacy of these systems for in 
vivo conditions necessitates the investigation and development of new and effective vectors (Eming et al., 
2007; Díez et al., 2009). 
The systemic method of administration offers the opportunity for non-invasive interaction with numerous 
target cells which are otherwise inaccessible for direct administration. The inability for effective cell 
transfection upon intravenous injection to systemic systems has primarily been ascribed to the interaction 
between lipoplexes and serum proteins, a barrier that may be surmounted through an increase in lipoplex 
charge ratio (Mohr et al., 2001). Many of the vectors employed today can afford protection to the carried 
nucleic acid and assist in internalization, however, these carrier systems are limited by their inability to 
overcome the endothelial barriers as well as to efficiently exit the general circulation (Hattori and 
Maitani, 2005). The premier obstacle that faces systemically administered lipoplexes is the glycocalyx 
shield consisting of glycoproteins, glycolipids, glycosaminoglycans, phospholipids, and proteoglycans 
which position themselves on the luminal side of the vesicular wall (Rao, 2010). 
An unfortunate disadvantage in the application of cationic lipid – DNA complexes is their associated 
toxicity primarily attributed to the systemic induction of inflammatory response to the CpG motifs of the 
compacted plasmid DNA (Elouahabi et al., 2003). Evaluation of potential therapeutic compound toxicity 
requires a blood sample from the experimetal animal model. For this to be successfully obtained blood 
must be drawn from the retro-orbital sinus of mice or the retro-orbital plexus of rats (Figure 5.2). When 
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performed correctly this method can provide moderate to large amounts of blood for analysis, however, 
incorrect handling or implementation of protocol can result in serious injury to the animal. Rats in 
comparison to mice have a plexus and thus the potential for tissue damage may be more significant than 
with mice. Consequently other available alternatives to retro-orbital bleeding should be kept in mind 
(Figure 5.3) (Guanzini and Barriere, 2009). 
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Efforts towards the successful development of lipid-based carriers for systemic transfection is highly 
significant and consequently unrelenting (Liu and Song, 1998). 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials 
All Chemicals utilized were of analytical grade. The NMRI mice are so called as they were transferred to 
the Naval Medical Research Institute after being inbred for 51 generations. The mice were thereafter in 
1979 introduced to the Charles River Laboratories. They were kept at a room temperature of 
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approximately 21oC on autoclaved sawdust bedding (Volstroff, 2007). The Psi-CHECK plasmid DNA 
was amplified in transformed Escherichia coli cells and purified using the Qiagen Endotoxin Free Kit. 
The purified plasmid DNA was analyzed on a Nano-drop spectrophotometer.  
 
5.2.2. Methods 
5.2.2.1. Lipoplex preparation  
The liposomes were prepared at their optimum DNA binding ratios (determined by agarose mobility shift 
analysis) with the amplified Psi-CHECK plasmid vector. The lipoplexes were made up in four replicates 
under aseptic conditions as shown in Table 5.1 below. The positive control was employed at 2.5ml to 
cause an alteration in the hydrostatic pressure of the mouse system, allowing delivery of the DNA. It 
further provides a good indication that the DNA being used is effective. A negative control of DNA – 
Sabax sodium chloride solution was not used in this study, however, un-injected mice were examined, 
representing normal conditions. All liposome preparations were made up in Sabax sodium chloride 
solution from Adcock Ingram, Johannesburg, South Africa.  
Table 5.2:   Component ratios of liposome and DNA used for transfection and cytotoxicity assays and the 











Negative Control  
(Un-injected NMRI Mice) 
- 5 - 
Positive Control 
(Hydrodynamic Injection) 
- 5 2500 
Chol-T Liposome 20 5 200 
RUI-129 Liposome 30 5 200 
RUI-129 – Gal Liposome 20 5 200 
 
5.2.2.2. Tail vein injection 
The NMRI mice were number tagged from 139 - 158 and divided into five groups A - E. The mice are 
characterized as inbred albino mice and were approximately 25 – 30 g in weight. For tail vein injection, 
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heat control bags were used to enhance the appearance of the vein so as to ensure accurate injection. 
Small plastic mice restraints were used to control mice movement.  
Lipoplexes of Chol-T, RUI-129 and RUI-129-Gal were injected into groups A, B and C respectively. 
Group D was subjected to the positive control of hydrodynamic injection, while group E, the negative 
control was left un-injected. 
5.2.2.3. Toxicology 
Three days after injection the mice were bled using the retro-orbital bleeding method. The blood samples 
were left to coagulate, i.e. clot by incubation in refrigerator for approximately 4hrs. These samples were 
then spun down by quick centrifugation and the supernatant collected and sent for analysis at the HIV 
testing unit at the University of Witwatersrand School of Medicine, Department of Molecular medicine 
and Hematology. The AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase) levels 
were examined as a basis for hepatic and heart cytotoxicity analysis. 
5.2.2.4. Luciferase reporter gene transfection  
The mice were thereafter sacrificed and the livers harvested. To 1 g of the harvested livers an equal 
volume of Sabax saline solution was introduced and the livers homogenized using the CATx120 
mechanical homogenizer having variable speed control. Thereafter 20 µl of the diluted homogenate was 
introduced into a 96 well plate together with 100 µl of luciferase reagents obtained from Promega. A 2x 
dilution was used with 2 reagents employed for analysis of the Psi-CHECK plasmid, i.e. both the 
luciferase and stop glow reagent for the Renilla luciferase encoded in the plasmid. The plate was 
thereafter analyzed in the Veritas Microplate Luminometer from Turner Biosystems. Protein 
determination was performed on the cell free extracts using the bicinchoninic acid (BCA) assay using the 
Pierce BCA kit. 
5.2.2.5. Statistical analysis 
A comparison between each of the positive and negative controls and the respective test groups was 






5.3. RESULTS AND DISCUSSION 
 
5.3.1. Lipoplex Preparation 
 
The Psi-CHECK plasmid used in this preparation was successfully amplified. The concentration of the 
DNA was measured and used as a stock of 1.1293 μg/μl. The plasmid DNA showed relatively high purity 
with the 260 nm/ 280 nm absorption ratio of 1.91. Lipoplexes were successfully and aseptically prepared 
using the sodium chloride solution. The DNA-saline solution was prepared at a volume of 2.5 ml as 
shown in Table 5.1.  Despite encoding both the Renilla and luciferase reporters, for consistency in our 




The potential for the administration of therapeutic agents or chemicals to produce a toxic or detrimental 
effect to the cell is often considered relative to the dose injected. The toxicity may be local, i.e., a local 
effect, where the harmful event takes place at the site of administration, or systemic involving the 
distribution of the detrimental factors throughout the cirulatory system resulting in the damage of other 
organs. In addition the toxic effect can be termed either acute or delayed, in relation to the time taken for 
exposure (Lv et al., 2006). 
 
Results from cytotoxicity analysis based on the levels of ALT and AST present in the blood samples 





Figure 5.3: ALT and AST levels of different blood samples inoculated with the different liposome 
preparations. Data presented as a mean ±S.D. (n = 4). 
 
 
Analysis of the ALT and AST levels conducted in this investigation allows for the determination of the 
extent of liver damage or toxicity induced by the presence of the liposome – DNA complex. In principle 
the damage of a specific selection of cells results in the release or leakage of certain enzymes into the 
blood.  These enzymes are thus utilized as indicators of cellular damage. The ALT levels show a marked 
increase in hepatitis and other acute liver damage. AST, although similar in this regard is not as liver 
specific as it is predominntly found in other tissues such as the heart and muscle. These enzyme are 
known as part of the transaminase family and are sometimes referred to as glutamate pyruvate 
transaminase (GPT) and glutamate oxaloacetate transaminase (GOT). As transaminases these enzymes 
are also known to facilitate certain intracellular reactions and may also be termed aminotransferases. 
Fundamentally, injury or inflammation of the liver can be identified by elevated ALT blood levels. 
Damage to the heart or liver will release additional AST into the blood stream. The levels of AST 
detected is thus believed to directly related to the degree of tissue damage accrued. In general the normal 
range of AST and ALT values should be below 40 – 50 (U/L) (Cholestech Corporation, 2007). 
 
From the results shown in Figure 5.3. all the liposomes investigated produced minimal cytotoxic effect in 
the liver tissue. This was extrapolated from a comparision between the aminotransferase levels produced 
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in response to the liposomes preparations and those of the uninfected mice in the negative control. The 
comparable levels of AST and ALT observed between the negative control and the test lipoplexes is 
indicative of minimal damage being effected by the presence of the different liposomes. The positive 
control, involving the hydrodynamic injection of the Psi-CHECK plasmid produced high level toxicity. 
This tissue toxicity was not unexpected due to the drastic changes induced by hydrodynamic injection of a 
large volume of DNA-saline solution into the bloodstream. Moreover the presence of CpG motifs in the 
DNA may once again prove their ability to potentiate cytotoxicity. 
An overview of these results further indicates higher quantities of AST rather than ALT in the blood 
samples of the control and test animals examined. The liver in general shows the ability to tolerate most 
potential toxic effects that may take place due to its regenerative capabilities (Suda et al., 2009). 
 
5.3.3. Luciferase Reporter Gene Transfection  
Results from the luciferase reporter gene assay in the NMRI mice can be viewed in Figure 5.4. 
 
 
Figure 5.4:  Luciferase activity recorded in the different groups of NMRI mice on incubation with the 
different liposome preparations. DNA was kept standard at 5 μg. The positive control 
involved injection of DNA in the absence of liposome, while the negative control used was 





For an analysis of the luciferase enzyme activity effected by the different liposome formulations, two 
control systems were employed. The first control used was a group of NMRI mice that were not treated so 
as to display the normal condition. The second control employed was the hydrodynamic injection of 2.5 
ml of a DNA-saline solution into the tail vein of the mice. This control was termed the positive control as 
it is renowned for the successful production of extremely high levels of transgene expression in the mouse 
liver. In addition to this elevated in vivo gene expression Niidome and Huang (2002) have reported the 
prolonged maintenance of this therapeutic level for at least 10 months. This postive control produced high 
levels of transgene expression that were shown to be statistically significant on comparison to the 
different liposomes examined (p < 0.05). Had all preparations been based on the hydrodynamic method of 
injection, it is possible that an alternative outcome would have resulted from the lipoplexes investigated in 
this mouse model. 
From an examination of the results it should be noted that all three liposome formulations were shown to 
be relatively poor at directing the plasmid DNA successfully to the liver for transgene expression. Despite 
this, the low luciferase enzyme activity found with liposome – DNA complexes compared to the 
background fluorescence in untreated, negative control liver extracts, were shown to be of statistical 
significance (p < 0.05).  
There are a great number of barriers presented to the in vivo transfection of liposome formulations that 
limit their effectiveness. The inconsistencies observed here and in earlier reports between the carrier 
activity in vitro and in vivo may potentially be attributed to poor condensation of the DNA resulting in the 
untimely liberation of the plasmid DNA into in vivo circulation. Xu and Szoka (1996) proposed that this 
premature DNA discharge could also be due to the endogenous glycosaminoglycans where the potent 
release agent heparin can interfere with the in vivo transfection. A possible way to comfirm this 
postulation, could have been through a real time examination of the mice using florescence imaging, so as 
to identify the location of the florescent DNA within the blood system. Moreover the intravenous 
introduction of the cationic liposome –DNA complexes in general ends in their rapid uptake by the first 
capillary system encountered (McCuskey, 1994 cited in Mohr et al., 2001; McCuskey, 2008). This 
capillary snare could result in poor in vivo tissue distribution and consequently poor luciferase 
transfection activity. Additionally despite the influence of mitotic activity on cationic liposome-mediated 
delivery in vitro, in vivo the low number of hepatocytes that undergo mitosis may, to an extent, be held 
accountable for the reduced frequency of transfected hepatocytes present in non-regenerating liver (Mohr 
et al., 2001). 
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The relatively large lipoplexes used in this study, having diameters of between 50 – 230 nm achieved 
successful transfection in vitro in the absence of serum. This may be attributed to their swift descent to 
the cell surface in the culture plate (Khalil et al., 2006). Lipoplex size is an important factor in the 
promotion of gene expression in the liver since the liver fenestrae have an average size of approximately 
150 nm and display negative charges (McCuskey, 2008). These larger size cationic lipoplexes may thus 
not be able to easily negotiate these fenestrae and reach the hepatocytes. Fenestrae avidity that is 
generally observed for injected liposomes can possibly be ascribed to their expression of positive charge 
at the lipoplex surface. This liposome–fenestrae association is known to occur via non-specific charge 
interactions (Thurston et al., 1998). 
Smaller particles of 100 nm or less are preferred for in vivo systems as they experience a lower rate of 
circulation clearance. They additionally offer greater potential to reach target cells by virtue of their 
relative ease in narrow capillary navigation. To further minimize macrophage clearance and achieve 
improved site targeting, the presence of a hydrophilic surface on the lipoplex is advantageous (Colosimo 
et al., 1999; Brannon-Peppas and Blanchette, 2004; Gao et al., 2007).  
 
Although the introduction of cell surface targeting ligands is thought to enhance hepatocyte specific 
delivery, our findings showed the RUI-129-galactosyl targeted and untargeted liposome formulations 
capable of comparable levels of transgene expression. A proposed explanation could be related to the 
Kupffer cells present in the liver expressing galactose specific receptors different to those present of the 
surface of the liver parenchymal cells (Kawakami et al., 2001). Kupffer cells are essentially macrophages 
anchored to the sinusoidal endothelium at the luminal surface and are thus exposed to the blood stream 
where they are believed to clear out any foreign particles from circulation. The liposomal carriers could 
thus potentially interact with the surface of these cells and its receptors resulting in removal from the 
blood stream before being allowed to deliver the therapeutic gene or drug to the hepatocytes 
(parenchymal cells) (McCuskey, 2008). 
 
The presence of the helper lipid DOPE in all liposome formulations may further contribute to the 
differences between the in vitro and in vivo transfections achieved. The lack of translation between the 
two systems on this basis may be as a result of the DOPE undergoing aggregation in the blood in response 
to hydrophobic effects (Lin et al., 2003). This poor correlation may also be attributable, in part, to the fact 
that in vitro transfection studies were conducted in the absence of serum (Rao, 2010). Of all sera 
available, that obtained from the mouse is believed to most closely resemble the human condition. Earlier 
reports have suggested that in the presence of mouse serum the cationic liposome-DNA complex will 
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become slightly anionic, experience an increase in size and eventually disintegrate. The rate of this 
disintegration is dependent on the nature of the co-lipid used in liposome synthesis. DOPE for example 
assists in rapid disintegration when incorporated in the liposome formulation (Nishikawa and Huang, 
2001).  
 
Finally Hartikka and co workers (2000) revealed that the level of DNA degradation that takes place in 
vivo can be reduced through a simple change in the injection medium from the traditional saline or 
phosphate buffered saline to a phosphate buffer. Additionally the introduction of molecules that provide 























A compound proficient in lipid mediated transfection in one application may not necessarily be suitable 
for another and consequently a great deal of experimental research is needed so as to ascertain the most 
favourable conditions for both in vitro and in vivo lipofection. It is precisely the ability of cationic 
liposomes to selectively deliver their material to target tissues of tumour endothelium, lungs and liver that 
make them highly striking commodities for cancer therapy (Dass and Choong, 2006). Delivery vehicles 
for gene therapy need to be chosen in accordance with their particular therapeutic aim; however, the 
absence of an ideal vector suitable to all safety and therapeutic needs still eludes us. An adept formulation 
for the application of therapeutic genes for cancer treatment must be capable of complete protection of 
encapsulated nucleic acids, endosomal escape and specific site targeting. For this purpose numerous 
systems have been developed and investigated for efficient therapeutic gene transfer (El-Aneed, 2004).  
Our investigations have focussed on the development of novel hepatotropic cationic liposomes prepared 
from the Chol-T cytofectin, DOPE, the crown ethers (CE’s) RUI-128 and RUI-129, and the 
glycotargeting ligands RUI-90 (galactosyl) and RUI-92 (glucosyl). Formulations of cationic liposomes 
used for the translocation of plasmid DNA have the zwitterionic molecule DOPE incorporated as it acts as 
a fusogenic lipid component and can promote an increase in the efficiency of transfection under in vivo 
conditions, although it is more effective in vitro. The presence of this neutral lipid in the cationic 
liposomes may also assist in enhancing the biodistribution at the target site in addition to potentially 
contributing to the intracellular sorting in the target cells in vivo (Han et al., 2008). These liposomes 
formed by thin film hydration and sonication were distinguished as small unilamellar vesicles with broad 
size range and distribution by cryo-TEM. The liposome preparations were shown via gel retardation and 
ethidium bromide displacement studies to form lipoplexes with plasmid DNA, which on nuclease 
digestion analysis was proven to offer effective serum protection.  
Differences found in the structure of cationic cholesterol derivatives directly affects their DNA interaction 
and is consequently reflected in variations in transfection activity. In our evaluations of lipoplexes in the 
HepG2 and control HEK293 cell lines, low cell growth inhibition was observed for the Chol-T liposomes, 
however, the addition of  the glycotargeting ligands and crown ether compounds led to distinct increases 
in the levels of cell cytotoxicity. Luciferase analysis of transfection of the pCMV-Luc control vector 
revealed the untargeted Chol-T, RUI-128 and RUI-129 liposomes directed to the HepG2 cell line 
produced approximtely 10, 3 and 20 times greater levels of transgene activity than their glycosylated 
counterparts. Of all the liposomes the RUI-129 cationic liposome preparation was able to achieve 
maximal transgene expression in both cell lines, showing that the introduction of the aza-15-crown-5 
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crown ether could enhance cationic liposome driven transfection. Although the RUI- 128 liposome was 
capable of cellular transfection its effect was not of the same magnitude as the afore-mentioned 
preparation, showing that the CE cavity size may play a significant role in determining transfection 
activity. The Chol-T preparation also showed high transfection levels based on luciferase enzyme activity. 
From these studies it is evident that the indroduction of the crown ether functionalities was most 
beneficial to the effectiveness of the cationic liposomes investigated in this study. 
Three of the most promising formulations that produced high level transfection results in vitro were 
selected for further evaluation in vivo. Chol-T, RUI-129 and RUI-129-Gal liposomes were thus assessed 
in the NMRI mouse model where they showed low, but mearsurable transfection activity in the liver. 
All cationic liposomes tested in the NMRI mouse model showed low levels of therapeutic nucleic acid 
delivery in vivo. However, a significant increase in luciferase reporter gene expression was observable on 
comparison with control untreated mice. From these studies it was also evident that the introduction of 
plasmid DNA to the liver was most effectively achieved through hydrodynamic injection. This method, 
however, was also responsible for far higher levels of tissue toxicity than that obsevered with the cationic 
liposomes. To address this difficulty, much research has focused on improving the cell specificity of 
cationic liposome –DNA complexes through engineered surface proteins or targeting ligands such as the 
asialoglycoproteins, transferrin, the epidermal growth factor, lactose and antibodies (Zheng et al., 2009). 
The ligands, RUI-90 and RUI-92 intended for hepatotargeting, however, proved to be ineffective in the 
present study in vitro.  
In vivo transfection activity of cationic liposomes may be improved through the introduction of certain 
molecular modifications. The introduction of polyethylene glycol to the liposomal formulation is one 
such modification that can improve the in vivo activity of cationic liposomes by extending the half life of 
liposomes in circulation. Ligand attachment for receptor targeted delivery may also be achieved through 
either the direct coupling of the ligand to the phospholipid or by means of fusion with the distal end of the 
PEG-lipid which proves advantageous as the ligand is more accessible for receptor interaction (Rao, 
2010). Reports by Xu and co-workers (1999) that the transfection activities of distinct  lipoplexes are 
more resistant to serum effects than those complexes which are aggregated is a promising observation for 
in vivo gene therapies and provides an alternate approach to transfection using cationic lipoplexes which 
are subsequently more stable in the presence of serum. 
Nucleic acids differ from smaller drugs due to their polycationic nature which renders them more 
dependent on the nature of their carrier systems if their application in gene therapy is to be successful. 
The use of RNAi and RNA decoys for regulatory protein coupling and modulation of gene expression, in 
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addition to work carried out with DNA provides an exciting potential for the future. Non-viral gene 
delivery systems remain at an early stage of their development, with improvement in these systems 
showing continuous dependence on an improved knowledge of the cellular and in vivo barriers to gene 
transfer. In spite of the multitude of advantages and applications of non-viral vector systems in 
transfection, many of them are unable to completely replace viral vectors for high expression in gene 
therapy protocols. Cationic liposomes have, however, even in the face of ongoing criticism, persisted and 
have yet to be overtaken by other gene delivery methods or other liposome types. Adaptation and 
enhancement is required, but we now know that the task is no longer an insurmountable one, when the 
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Chemical and spectral data of the crown ether and deacetylated sugar moieties employed, 
obtained from Islam, R.U. (unpublished research). 
Compound RUI-128: 
Molecular Formula: (M + H)+ C40H70NO7 
Infrared spectra: 2934, 2866, 1738, 1697, 1466 cm-1 
Melting Point: 58-600C 
1H NMR (300 MHz, CDCl3): 0.67(s, 3H, -CH3), 0.85-0.87(d, 6H, J = 6 Hz, -CH3), 0.90-0.92 
(d, 3H, J = 6 Hz, -CH3), 1.00 (s, 3H, -CH3), 1.04-1.60( m, 21H, Cholesteryl H), 1.69-1.95(m, 
5H), 2.17-2.33 (m, 2H), 3.44-3.61(m, 4H), 3.80-3.83(m, 20H), 4.38-4.48(m, 1H), 5.30(s, 1H) 
 13C (75 MHz, CDCl3):  11.8, 18.7, 19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 27.9, 28.2, 28.2, 31.8, 
35.7, 36.1, 36.5, 37.0, 38.6, 39.4, 39.5, 39.7, 42.3, 50.0, 56.1, 56.6, 70.0, 70.4, 70.6, 70.6, 70.8, 
74.7, 76.6, 122.4, 139.8, 155.8 
Mass: 698 (100%), 654 (20) 
Molecular Weight: 676.51500 
 
Compound RUI-129: 
Molecular Formula: (M + H)+ C38H66NO6 
Infrared Spectra: 2939, 2866, 1738, 1698, 1462 cm-1 
Melting Point: 68-700C 
1H NMR (300 MHz, CDCl3): 0.67(s, 3H, -CH3), 0.85-0.87(d, 6H, J = 6 Hz, -CH3), 0.90-0.92 
(d, 3H, J = 6 Hz, -CH3), 1.01 (s, 3H, -CH3), 1.05-1.63( m, 21H, Cholesteryl H), 1.63-1.98(m, 
5H), 2.24-2.38 (m, 2H), 3.37-3.50(m, 4H), 3.63-3.72(m, 16H), 4.45-4.55(m, 1H), 5.35-5.37(d, 
1H, J = 4.8 Hz) 
 13C (75 MHz, CDCl3):  11.8, 18.7, 19.3, 21.0, 22.5, 22.8, 23.8, 24.2, 27.9, 28.2, 28.2, 31.8, 
35.7, 36.1, 36.5, 37.0, 38.6, 39.5, 39.7, 42.3, 49.3, 50.0, 56.1, 56.6, 69.7, 70.2, 70.2, 71.0, 71.2, 
74.7, 76.6, 122.3, 139.9, 155.8 
Mass: 1286 (15%), 632 (100) 




Molecular Formula: (M + H)+ C37H61N4O7 
Infrared Spectra: 3381, 3130, 2941, 2358, 1740, 1682, 1460 cm-1 
Melting Point: 188-1900C 
1H NMR (300 MHz, CDCl3): 0.64(s, 3H, -CH3), 0.83-0.85(d, 6H, J = 6 Hz, -CH3), 0.90-0.92 
(d, 3H, J = 6 Hz, -CH3), 0.98 (s, 3H, -CH3), 1.03-1.52(m, 23H), 1.79-1.97(m, 5H), 2.20-2.30(m, 
2H), 2.49-2.50(t, 2H, J = 4.2 Hz), 3.45-3.54(m, 3H), 3.67-3.70(t, 1H, J = 4.2 Hz), 3.75(d, 1H, J 
= 1.8 Hz ….), 3.97-4.01(t, 1H, J = 6.9 Hz), 4.22(s, 2H), 4.30-4.38(m, 1H), 4.63-4.69(m, 1H), 
5.33-5.43(m, 1H), 5.43-5.45(d, 1H, J = 6.9 Hz), 7.99(s, 1H)  
13C (75 MHz, CDCl3): 11.4, 18.3, 18.8, 20.3, 22.1, 22.4, 23.0, 23.6, 27.2, 27.5, 27.6, 31.1, 31.2, 
35.0, 35.4, 35.8, 36.4, 38.1, 38.7, 49.3, 55.4, 55.9, 60.1, 68.1, 69.1, 73.0, 73.4, 78.7, 78.9, 79.0, 
87.8, 121.1, 121.6, 139.5, 145.2, 155.5 
Mass: EI = 673 (100%) 
Molecular Weight: 673.45312 
 
Compound RUI-92: 
Infrared Spectra: 3379, 2939, 2359, 1737, 1680, 1457 cm-1 
Melting Point: 145-1470C 
1H NMR (300 MHz, CDCl3): 0.64(s, 3H, -CH3), 0.83-0.85(d, 6H, J = 6 Hz, -CH3), 0.90-0.92 
(d, 3H, J = 6 Hz, -CH3), 1.04 (s, 3H, -CH3), 1.08-1.51(m, 22H), 1.79-1.97(m, 5H), 2.20-2.30(m, 
2H), 2.49-2.50(s, 2H), 3.67-3.76(m, 2H), 4.21-4.32(m, 3H), 4.30-4.38(m, 1H), 4.34(s, 1H), 
5.24(s, 3H), 5.32-5.34(d, 1H, J = 4.8 Hz), 5.47-5.50( d, 1H, J = 9Hz), 8.02(s, 1H)  
13C (75 MHz, CDCl3): 11.5, 18.4, 18.8, 20.4, 22.2, 22.5, 23.1, 23.7, 27.2, 27.6, 27.7, 31.2, 31.2, 
35.0, 35.5, 35.6, 35.9, 36.4, 38.1, 39.9, 41.7, 49.3, 55.4, 56.0, 60.5, 69.4, 71.8, 73.0, 76.8, 79.7, 
87.2, 121.6, 139.5, 145.1, 155.6 
Mass:  ESI(+) = 673.41(M+), 674.45(M+1) 













Animal experimentation was carried out using protocols approved by the University of 
Witwatersrand Animal Ethics Screening Committee. 
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